{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:39:20Z","timestamp":1792463960068,"version":"4.5.0"},"reference-count":744,"publisher":"Innovative Healthcare Institute","issue":"4","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,29]]},"abstract":"ABSTRACT<\/jats:title>\n Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, yet their clinical impact is limited by immune-related adverse events (irAEs), therapeutic resistance, and the lack of reliable predictive biomarkers, contributing to a shift from early promise to a therapeutic plateau. irAEs affect multiple organ systems and may lead to treatment interruption and significant morbidity. Emerging strategies emphasize phenotype-driven and steroid-sparing approaches to control toxicity while preserving antitumor efficacy. Concurrently, primary and acquired resistance remain major challenges, driven by tumor-intrinsic mechanisms, immune microenvironment alterations, and host factors. Furthermore, current biomarkers, including programmed cell death ligand 1 (PD-L1) expression and tumor mutation burden, demonstrate inconsistent predictive performance across tumor types. Advances in immune profiling, genomics, and microbiome research are enabling more precise patient stratification and informing novel therapeutic strategies, including rational combinations and targeted immunomodulation. This position article synthesizes key barriers in ICI therapy while highlighting emerging opportunities to refine patient selection, improve safety, and enhance therapeutic durability. Together, these advances position the field to move beyond the current plateau toward a more precise, effective, and patient-centered era of immuno-oncology.<\/jats:p>\n \n Graphical Abstract<\/jats:title>\n \n \n <\/jats:p>\n <\/jats:sec>","DOI":"10.36401\/jipo-26-12","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T07:42:21Z","timestamp":1790667741000},"page":"153-245","source":"Crossref","is-referenced-by-count":0,"title":["The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact"],"prefix":"10.36401","volume":"9","author":[{"given":"Joud","family":"Hajjar","sequence":"first","affiliation":[{"name":"Department of Adult Allergy and Immunology, Baylor College of Medicine and Texas Children\u2019s Hospital, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettzy","family":"Stephen","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley E.","family":"Aaroe","sequence":"additional","affiliation":[{"name":"Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen M.","family":"Aiche","sequence":"additional","affiliation":[{"name":"Division of Pulmonary, Critical Care and Sleep Medicine, McGovern Medical School at UTHealth, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagham","family":"Al-Zubidi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Ameri","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Baylor College of Medicine, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5717-558X","authenticated-orcid":true,"given":"Kaitlyn E.","family":"Aragon","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan Darin","family":"Carabenciov","sequence":"additional","affiliation":[{"name":"Department of Neurology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Chambers","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina Lateef","family":"Chaudhry","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean M.","family":"Connors","sequence":"additional","affiliation":[{"name":"Division of Cancer Hematology, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Davies","sequence":"additional","affiliation":[{"name":"Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"},{"name":"Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kala Chand","family":"Debnath","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"},{"name":"Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saadia A.","family":"Faiz","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifton D.","family":"Fuller","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan P.","family":"Goepfert","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan S.","family":"Gombos","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Gupta","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Department of Medicine, Mass General Brigham, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, MA, USA"},{"name":"Adult Survivorship Program, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Hadfield","sequence":"additional","affiliation":[{"name":"Division of Hematology Oncology, Department of Medicine, The Warren Alpert Medical School of Brown University, Brown University Health, Providence, RI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Hutcheson","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shajedul","family":"Islam","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"},{"name":"Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Jalal","sequence":"additional","affiliation":[{"name":"Division of Renal Medicine, Department of Medicine, Mass General Brigham, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, MA, USA"},{"name":"Adult Survivorship Program, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Migara","family":"Jayasekera","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, The University of Texas Medical Branch Health, Galveston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khalid A.","family":"Jazieh","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aye","family":"Khine","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, The University of California San Francisco, San Francisco, CA, USA"},{"name":"Diabetes Center, The University of California San Francisco, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Y.","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Leo","family":"Lei","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanteng Jeff","family":"Li","sequence":"additional","affiliation":[{"name":"Sectionof Rheumatology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetomir N.","family":"Markovic","sequence":"additional","affiliation":[{"name":"Department of Oncology, Mayo Clinic, Rochester, MN, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"McMillan","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy C.","family":"Moreno","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorinda","family":"Muhaj","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc-Elie","family":"Nader","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adegbenga","family":"Otun","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Pacha","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas L.","family":"Palaskas","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisha B.","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nimisha","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Quandt","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology and Metabolism, Department of Medicine, The University of California San Francisco, San Francisco, CA, USA"},{"name":"Diabetes Center, The University of California San Francisco, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oded","family":"Sagiv","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Sharon","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, MA, USA"},{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malek","family":"Shatila","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Wayne State University, Detroit, MI, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Sheshadri","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Suarez-Almazor","sequence":"additional","affiliation":[{"name":"Department of Health Services Research-Clinical, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anusha Shirwaikar","family":"Thomas","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology & Hepatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghong","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology & Hepatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Won","sequence":"additional","affiliation":[{"name":"Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao Chi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology & Hepatology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4803-8513","authenticated-orcid":true,"given":"Aung","family":"Naing","sequence":"additional","affiliation":[{"name":"Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"22027","reference":[{"key":"i2590-017X-9-4-153-b01","series-title":"Nat Rev Drug Discov","first-page":"509","article-title":"The foundations of immune checkpoint blockade and the ipilimumab approval decennial","volume":"21","author":"Korman","year":"2022","unstructured":"Korman AJ,Garrett-Thomson SC,Lonberg N. The foundations of immune checkpoint blockade and the ipilimumab approval decennial. Nat Rev Drug Discov. 2022;21:509\u2013528. DOI: 10.1038\/s41573-021-00345-8"},{"key":"i2590-017X-9-4-153-b02","series-title":"J Hematol Oncol","first-page":"107","article-title":"Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000\u20132025)","volume":"18","author":"Huang","year":"2025","unstructured":"Huang L,Zhu H,Shi Y. Immune checkpoint inhibitors for the treatment of solid tumors and lymphoma in the past 26 years (2000\u20132025). J Hematol Oncol. 2025;18:107. DOI: 10.1186\/s13045-025-01734-x"},{"key":"i2590-017X-9-4-153-b03","series-title":"J Immunother Cancer","first-page":"e012457","article-title":"Why has immune \u201ccheckpoint\u201d therapy failed in most clinical trials","volume":"13","author":"Yang","year":"2025","unstructured":"Yang X,Chen L. Why has immune \u201ccheckpoint\u201d therapy failed in most clinical trials? J Immunother Cancer. 2025;13:e012457. DOI: 10.1136\/jitc-2025-012457"},{"key":"i2590-017X-9-4-153-b04","series-title":"Eur J Cancer","first-page":"115605","article-title":"Approaches to overcome the current treatment plateau in immunotherapy","volume":"226","author":"Di Giacomo","year":"2025","unstructured":"Di Giacomo AM,Canetta R,Connolly J, et al. Approaches to overcome the current treatment plateau in immunotherapy. Eur J Cancer. 2025;226:115605. DOI: 10.1016\/j.ejca.2025.115605"},{"key":"i2590-017X-9-4-153-b05","series-title":"Nat Commun","first-page":"3801","article-title":"A decade of immune-checkpoint inhibitors in cancer therapy","volume":"11","author":"Robert","year":"2020","unstructured":"Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11:3801. DOI: 10.1038\/s41467-020-17670-y"},{"key":"i2590-017X-9-4-153-b06","series-title":"N Engl J Med","first-page":"158","article-title":"Immune-related adverse events associated with immune checkpoint blockade","volume":"378","author":"Postow","year":"2018","unstructured":"Postow MA,Sidlow R,Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378:158\u2013168. DOI: 10.1056\/NEJMra170348129320654"},{"key":"i2590-017X-9-4-153-b07","series-title":"JOP","first-page":"247","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline summary","volume":"14","author":"Brahmer","year":"2018","unstructured":"Brahmer JR,Lacchetti C,Thompson JA. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline summary. JOP. 2018;14:247\u2013249. DOI: 10.1200\/JOP.18.00005"},{"key":"i2590-017X-9-4-153-b08","series-title":"JOP","first-page":"e825","article-title":"Immune-related adverse events requiring hospitalization: spectrum of toxicity, treatment, and outcomes","volume":"15","author":"Balaji","year":"2019","unstructured":"Balaji A,Zhang J,Wills B, et al. Immune-related adverse events requiring hospitalization: spectrum of toxicity, treatment, and outcomes. JOP. 2019;15:e825\u2013e34. DOI: 10.1200\/JOP.18.00703"},{"key":"i2590-017X-9-4-153-b09","series-title":"Front Pharmacol","first-page":"1671","article-title":"Organ-specific immune-related adverse events associated with immune checkpoint inhibitor monotherapy versus combination therapy in cancer: a meta-analysis of randomized controlled trials","volume":"10","author":"Da","year":"2020","unstructured":"Da L,Teng Y,Wang N, et al. Organ-specific immune-related adverse events associated with immune checkpoint inhibitor monotherapy versus combination therapy in cancer: a meta-analysis of randomized controlled trials. Front Pharmacol. 2020;10:1671. DOI: 10.3389\/fphar.2019.01671"},{"key":"i2590-017X-9-4-153-b10","series-title":"Cancers","first-page":"340","article-title":"Incidence of cutaneous immune-related adverse events and outcomes in immune checkpoint inhibitor-containing regimens: a systematic review and meta-analysis","volume":"16","author":"Curkovic","year":"2024","unstructured":"Curkovic NB,Bai K,Ye F,Johnson DB. Incidence of cutaneous immune-related adverse events and outcomes in immune checkpoint inhibitor-containing regimens: a systematic review and meta-analysis. Cancers. 2024;16:340. DOI: 10.3390\/cancers16020340"},{"key":"i2590-017X-9-4-153-b11","series-title":"JAMA Dermatol","first-page":"1093","article-title":"Cutaneous adverse events and cancer survival prognosis with immune checkpoint inhibitor treatment: a systematic review and meta-analysis","volume":"159","author":"Du","year":"2023","unstructured":"Du Y,Wu W,Chen M,Dong Z,Wang F. Cutaneous adverse events and cancer survival prognosis with immune checkpoint inhibitor treatment: a systematic review and meta-analysis. JAMA Dermatol. 2023;159:1093\u20131101. DOI: 10.1001\/jamadermatol.2023.3003"},{"key":"i2590-017X-9-4-153-b12","series-title":"Front Oncol","first-page":"1417175","article-title":"Early discontinuation of immune checkpoint inhibitor therapy prior to disease progression in patients with metastatic non-small cell lung cancer: a survival analysis","volume":"14","author":"McKinley","year":"2024","unstructured":"McKinley BJ,Pai TS,Wolf EB, et al. Early discontinuation of immune checkpoint inhibitor therapy prior to disease progression in patients with metastatic non-small cell lung cancer: a survival analysis. Front Oncol. 2024;14:1417175. DOI: 10.3389\/fonc.2024.1417175"},{"key":"i2590-017X-9-4-153-b13","series-title":"JCO","first-page":"2872","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","unstructured":"Arbour KC,Mezquita L,Long N, et al. Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer. JCO. 2018;36:2872\u20132878. DOI: 10.1200\/JCO.2018.79.0006"},{"key":"i2590-017X-9-4-153-b14","series-title":"JCO","first-page":"3713","article-title":"Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials","volume":"42","author":"Verheijden","year":"2024","unstructured":"Verheijden RJ,de Groot JS,Fabriek BO, et al. Corticosteroids for immune-related adverse events and checkpoint inhibitor efficacy: analysis of six clinical trials. JCO. 2024;42:3713\u20133724. DOI: 10.1200\/JCO.24.00191"},{"key":"i2590-017X-9-4-153-b15","series-title":"JCO Oncol Pract","first-page":"431","article-title":"Management of the top 10 most common immune-related adverse events in patients treated with immune checkpoint inhibitor therapy","volume":"18","author":"Schneider","year":"2022","unstructured":"Schneider BJ,Lacchetti C,Bollin K. Management of the top 10 most common immune-related adverse events in patients treated with immune checkpoint inhibitor therapy. JCO Oncol Pract. 2022;18:431\u2013444. DOI: 10.1200\/OP.21.00776"},{"key":"i2590-017X-9-4-153-b16","series-title":"JCO","first-page":"4073","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","unstructured":"Schneider BJ,Naidoo J,Santomasso BD, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. JCO. 2021;39:4073\u20134126. DOI: 10.1200\/JCO.21.01440"},{"key":"i2590-017X-9-4-153-b17","series-title":"J Immunother Cancer","first-page":"95","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","unstructured":"Puzanov I,Diab A,Abdallah K, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) toxicity management working group. J Immunother Cancer. 2017;5:95. DOI: 10.1186\/s40425-017-0300-z"},{"key":"i2590-017X-9-4-153-b18","series-title":"J Natl Compr Cancer Netw","first-page":"582","article-title":"NCCN Guidelines(R) insights: management of immunotherapy-related toxicities, version 2.2024","volume":"22","author":"Thompson","year":"2024","unstructured":"Thompson JA,Schneider BJ,Brahmer J, et al. NCCN Guidelines(R) insights: management of immunotherapy-related toxicities, version 2.2024. J Natl Compr Cancer Netw. 2024;22:582\u2013592. DOI: 10.6004\/jnccn.2024.0057"},{"key":"i2590-017X-9-4-153-b19","series-title":"Am J Clin Dermatol","first-page":"345","article-title":"Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy","volume":"19","author":"Sibaud","year":"2018","unstructured":"Sibaud V. Dermatologic reactions to immune checkpoint inhibitors: skin toxicities and immunotherapy. Am J Clin Dermatol. 2018;19:345\u2013361. DOI: 10.1007\/s40257-017-0336-3"},{"key":"i2590-017X-9-4-153-b20","series-title":"J Am Acad Dermatol","first-page":"1255","article-title":"Immune checkpoint inhibitor-related dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","unstructured":"Geisler AN,Phillips GS,Barrios DM, et al. Immune checkpoint inhibitor-related dermatologic adverse events. J Am Acad Dermatol. 2020;83:1255\u20131268. DOI: 10.1016\/j.jaad.2020.03.132"},{"key":"i2590-017X-9-4-153-b21","series-title":"Front Immunol","first-page":"1071983","article-title":"Cutaneous manifestations associated with immune checkpoint inhibitors","volume":"14","author":"Watanabe","year":"2023","unstructured":"Watanabe T,Yamaguchi Y. Cutaneous manifestations associated with immune checkpoint inhibitors. Front Immunol. 2023;14:1071983. DOI: 10.3389\/fimmu.2023.1071983"},{"key":"i2590-017X-9-4-153-b22","series-title":"JAMA Netw Open","first-page":"e252668","article-title":"Late-onset immune-related adverse events after immune checkpoint inhibitor therapy","volume":"8","author":"Durbin","year":"2025","unstructured":"Durbin SM,Zubiri L,Perlman K, et al. Late-onset immune-related adverse events after immune checkpoint inhibitor therapy. JAMA Netw Open. 2025;8:e252668. DOI: 10.1001\/jamanetworkopen.2025.2668"},{"key":"i2590-017X-9-4-153-b23","series-title":"Acad Dermatol Venereol","first-page":"332","article-title":"European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'dermatology for cancer patients' position statement","volume":"36","author":"Apalla","year":"2022","unstructured":"Apalla Z,Nikolaou V,Fattore D, et al. European recommendations for management of immune checkpoint inhibitors-derived dermatologic adverse events. The EADV task force 'dermatology for cancer patients' position statement. Acad Dermatol Venereol. 2022;36:332\u2013350. DOI: 10.1111\/jdv.17855"},{"key":"i2590-017X-9-4-153-b24","article-title":"Evaluation and management of suspected immune-mediated dermatologic toxicities [the algorithms that received approval from the clinical effectiveness office have been made available for public access on an external website]","author":"The University of Texas MD Anderson Cancer Center","year":"Sep 17, 2024","unstructured":"The University of Texas MD Anderson Cancer Center. Evaluation and management of suspected immune-mediated dermatologic toxicities [the algorithms that received approval from the clinical effectiveness office have been made available for public access on an external website]. Sep 17, 2024. www.mdanderson.org\/content\/dam\/mdanderson\/documents\/for-physicians\/algorithms\/clinical-management\/clin-management-dermatologic-toxicities-web-algorithm.pdf"},{"key":"i2590-017X-9-4-153-b25","series-title":"J Immunother Cancer","first-page":"e007324","article-title":"Management of immune-related cutaneous adverse events with dupilumab","volume":"11","author":"Kuo","year":"2023","unstructured":"Kuo AM-S,Gu S,Stoll J, et al. Management of immune-related cutaneous adverse events with dupilumab. J Immunother Cancer. 2023;11:e007324. DOI: 10.1136\/jitc-2023-007324"},{"key":"i2590-017X-9-4-153-b26","series-title":"Clin Cancer Res","first-page":"2822","article-title":"Immunologic profiling of immune-related cutaneous adverse events with checkpoint inhibitors reveals polarized actionable pathways","volume":"30","author":"Lacouture","year":"2024","unstructured":"Lacouture ME,Goleva E,Shah N, et al. Immunologic profiling of immune-related cutaneous adverse events with checkpoint inhibitors reveals polarized actionable pathways. Clin Cancer Res. 2024;30:2822\u20132834. DOI: 10.1158\/1078-0432.CCR-23-3431"},{"key":"i2590-017X-9-4-153-b27","series-title":"Eur J Cancer","first-page":"8","article-title":"Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors","volume":"107","author":"Hasan Ali","year":"2019","unstructured":"Hasan Ali O,Berner F,Bomze D, et al. Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors. Eur J Cancer. 2019;107:8\u201314. DOI: 10.1016\/j.ejca.2018.11.009"},{"key":"i2590-017X-9-4-153-b28","series-title":"Oncologist","first-page":"oyaf208","article-title":"Dupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series","volume":"30","author":"Nykaza","year":"2025","unstructured":"Nykaza I,Moy A,Dusza SW, et al. Dupilumab for bullous pemphigoid related to immune checkpoint inhibitors: a retrospective case series. Oncologist. 2025;30:oyaf208. DOI: 10.1093\/oncolo\/oyaf208"},{"key":"i2590-017X-9-4-153-b29","series-title":"J Am Acad Dermatol","first-page":"1130","article-title":"Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features","volume":"83","author":"Ellis","year":"2020","unstructured":"Ellis SR,Vierra AT,Millsop JW,Lacouture ME,Kiuru M. Dermatologic toxicities to immune checkpoint inhibitor therapy: a review of histopathologic features. J Am Acad Dermatol. 2020;83:1130\u20131143. DOI: 10.1016\/j.jaad.2020.04.105"},{"key":"i2590-017X-9-4-153-b30","series-title":"Curr Oncol","first-page":"2871","article-title":"Cutaneous adverse events associated with immune checkpoint inhibitors: a review article","volume":"29","author":"Chen","year":"2022","unstructured":"Chen CH,Yu HS,Yu S. Cutaneous adverse events associated with immune checkpoint inhibitors: a review article. Curr Oncol. 2022;29:2871\u20132886. DOI: 10.3390\/curroncol29040234"},{"key":"i2590-017X-9-4-153-b31","series-title":"J Am Acad Dermatol","first-page":"1475","article-title":"Generalized bullous mucocutaneous eruption mimicking Stevens-Johnson syndrome in the setting of immune checkpoint inhibition: a multicenter case series","volume":"83","author":"Molina","year":"2020","unstructured":"Molina GE,Yu Z,Foreman RK,Reynolds KL,Chen ST. Generalized bullous mucocutaneous eruption mimicking Stevens-Johnson syndrome in the setting of immune checkpoint inhibition: a multicenter case series. J Am Acad Dermatol. 2020;83:1475\u20131477. DOI: 10.1016\/j.jaad.2020.03.029"},{"key":"i2590-017X-9-4-153-b32","series-title":"Int J Dermatology","first-page":"1292","article-title":"Successful rechallenge with pembrolizumab after case of progressive immunotherapy-related mucocutaneous eruption (PIRME), a Stevens-Johnson syndrome-like reaction","volume":"62","author":"Shi","year":"2023","unstructured":"Shi CR,Shaughnessy M,Sehgal K, et al. Successful rechallenge with pembrolizumab after case of progressive immunotherapy-related mucocutaneous eruption (PIRME), a Stevens-Johnson syndrome-like reaction. Int J Dermatology. 2023;62:1292\u20131294. DOI: 10.1111\/ijd.16572"},{"key":"i2590-017X-9-4-153-b33","series-title":"Am J Dermatopathol","first-page":"750","article-title":"Progressive immunotherapy-related mucocutaneous eruption: a mimicker of SJS-TEN","volume":"47","author":"Sangani","year":"2025","unstructured":"Sangani KA,Lee V,Schroedl L, et al. Progressive immunotherapy-related mucocutaneous eruption: a mimicker of SJS-TEN. Am J Dermatopathol. 2025;47:750\u2013753. DOI: 10.1097\/DAD.0000000000003083"},{"key":"i2590-017X-9-4-153-b34","series-title":"JAAD Case Rep","first-page":"27","article-title":"A case of pembrolizumab-induced toxic epidermal necrolysis with a delayed developmental timeline","volume":"53","author":"Driscoll","year":"2024","unstructured":"Driscoll W,Yale K,Smith J. A case of pembrolizumab-induced toxic epidermal necrolysis with a delayed developmental timeline. JAAD Case Rep. 2024;53:27\u201329. DOI: 10.1016\/j.jdcr.2024.08.011"},{"key":"i2590-017X-9-4-153-b35","series-title":"Front Med","first-page":"1213889","article-title":"Updates in SJS\/TEN: collaboration, innovation, and community","volume":"10","author":"Marks","year":"2023","unstructured":"Marks ME,Botta RK,Abe R, et al. Updates in SJS\/TEN: collaboration, innovation, and community. Front Med. 2023;10:1213889. DOI: 10.3389\/fmed.2023.1213889"},{"key":"i2590-017X-9-4-153-b36","series-title":"JAMA Dermatol","first-page":"555","article-title":"Characterizing chronic cutaneous immune-related adverse events following immune checkpoint inhibitors","volume":"161","author":"Fletcher","year":"2025","unstructured":"Fletcher KA,Goodman RS,Lawless A, et al. Characterizing chronic cutaneous immune-related adverse events following immune checkpoint inhibitors. JAMA Dermatol. 2025;161:555\u2013557. DOI: 10.1001\/jamadermatol.2025.0025"},{"key":"i2590-017X-9-4-153-b37","series-title":"Am J Clin Dermatol","first-page":"707","article-title":"Challenging dermatologic considerations associated with immune checkpoint inhibitors","volume":"23","author":"Park","year":"2022","unstructured":"Park BC,Jung S,Chen ST,Dewan AK,Johnson DB. Challenging dermatologic considerations associated with immune checkpoint inhibitors. Am J Clin Dermatol. 2022;23:707\u2013717. DOI: 10.1007\/s40257-022-00706-y"},{"key":"i2590-017X-9-4-153-b38","series-title":"JAMA Oncol","first-page":"865","article-title":"Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer","volume":"6","author":"Dolladille","year":"2020","unstructured":"Dolladille C,Ederhy S,Sassier M, et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol. 2020;6:865\u2013871. DOI: 10.1001\/jamaoncol.2020.0726"},{"key":"i2590-017X-9-4-153-b39","series-title":"J Immunother Cancer","first-page":"e000604","article-title":"Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy","volume":"8","author":"Haanen","year":"2020","unstructured":"Haanen J,Ernstoff M,Wang Y, et al. Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategy. J Immunother Cancer. 2020;8:e000604. DOI: 10.1136\/jitc-2020-000604"},{"key":"i2590-017X-9-4-153-b40","series-title":"J Immunother Cancer","first-page":"e002627","article-title":"Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR","volume":"9","author":"Bayless","year":"2021","unstructured":"Bayless NL,Bluestone JA,Bucktrout S, et al. Development of preclinical and clinical models for immune-related adverse events following checkpoint immunotherapy: a perspective from SITC and AACR. J Immunother Cancer. 2021;9:e002627. DOI: 10.1136\/jitc-2021-002627"},{"key":"i2590-017X-9-4-153-b41","series-title":"Cancers (Basel)","first-page":"1845","article-title":"Interleukin-4 and -13 gene expression profiles in immune-related bullous pemphigoid indicate efficacy of IL-4\/IL-13 inhibitors","volume":"17","author":"Arnold","year":"2025","unstructured":"Arnold L,Morak M,Kramer N, et al. Interleukin-4 and -13 gene expression profiles in immune-related bullous pemphigoid indicate efficacy of IL-4\/IL-13 inhibitors. Cancers (Basel). 2025;17:1845. DOI: 10.3390\/cancers17111845"},{"key":"i2590-017X-9-4-153-b42","series-title":"Cancer","article-title":"Retrospective analysis of cutaneous immune-related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA-B*51:01 allele","volume":"132","author":"DiLeo","year":"2026","unstructured":"DiLeo M,Oglesby S,Leung CH, et al. Retrospective analysis of cutaneous immune-related adverse events following checkpoint inhibitor therapy in melanoma patients reveals increased risk associated with the HLA-B*51:01 allele. Cancer. 2026;132. DOI: 10.1002\/cncr.70262"},{"key":"i2590-017X-9-4-153-b43","article-title":"Dupilumab_metastatic NSCLC","year":"2025","unstructured":"Dupilumab_metastatic NSCLC. 2025. Accessed Jan 7, 2026. clinicaltrials.gov\/study\/NCT05013450"},{"key":"i2590-017X-9-4-153-b44","series-title":"J Immunother Cancer","first-page":"e011401","article-title":"Histologic and immune characterization of cutaneous immune-related adverse events induced by immune checkpoint inhibitors","volume":"13","author":"Pacha","year":"2025","unstructured":"Pacha O,Patel AB,Curry JL, et al. Histologic and immune characterization of cutaneous immune-related adverse events induced by immune checkpoint inhibitors. J Immunother Cancer. 2025;13:e011401. DOI: 10.1136\/jitc-2024-011401"},{"key":"i2590-017X-9-4-153-b45","series-title":"Front Allergy","first-page":"1147513","article-title":"Mucocutaneous adverse events to immune checkpoint inhibitors","volume":"4","author":"Muhaj","year":"2023","unstructured":"Muhaj F,Karri PV,Moody W,Brown A,Patel AB. Mucocutaneous adverse events to immune checkpoint inhibitors. Front Allergy. 2023;4:1147513. DOI: 10.3389\/falgy.2023.1147513"},{"key":"i2590-017X-9-4-153-b46","series-title":"Support Care Cancer","first-page":"989","article-title":"Biologic therapies for checkpoint inhibitor-induced cutaneous toxicities: a single-institution study of 17 consecutively treated patients","volume":"30","author":"Lo","year":"2022","unstructured":"Lo JJ,Heberton MM,Pacha O,Huen AO,Patel AB. Biologic therapies for checkpoint inhibitor-induced cutaneous toxicities: a single-institution study of 17 consecutively treated patients. Support Care Cancer. 2022;30:989\u2013994. DOI: 10.1007\/s00520-021-06548-434519869"},{"key":"i2590-017X-9-4-153-b47","series-title":"Dermatitis","first-page":"201","article-title":"Systemic treatment of cutaneous adverse events after immune checkpoint inhibitor therapy: a review","volume":"34","author":"Brown","year":"2023","unstructured":"Brown AM,Masterson W,Lo J,Patel AB. Systemic treatment of cutaneous adverse events after immune checkpoint inhibitor therapy: a review. Dermatitis. 2023;34:201\u2013208. DOI: 10.1097\/DER.0000000000000776"},{"key":"i2590-017X-9-4-153-b48","series-title":"Cancer","first-page":"975","article-title":"Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: incidence, management, and clinical benefit","volume":"128","author":"Patel","year":"2022","unstructured":"Patel AB,Farooq S,Welborn M, et al. Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: incidence, management, and clinical benefit. Cancer. 2022;128:975\u2013983. DOI: 10.1002\/cncr.34004"},{"key":"i2590-017X-9-4-153-b49","series-title":"Ann Oncol","first-page":"1217","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","unstructured":"Haanen J,Obeid M,Spain L, et al. Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33:1217\u20131238. DOI: 10.1016\/j.annonc.2022.10.001"},{"key":"i2590-017X-9-4-153-b50","series-title":"J Immunother Cancer","first-page":"e011865","article-title":"Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors","volume":"13","author":"Zhu","year":"2025","unstructured":"Zhu L,Cheung Y-MM,Chiang C, et al. Consensus-based disease definitions for endocrine immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. 2025;13:e011865. DOI: 10.1136\/jitc-2025-01186541093625"},{"key":"i2590-017X-9-4-153-b51","series-title":"Annu Rev Med","first-page":"313","article-title":"Autoimmune endocrinopathies: an emerging complication of immune checkpoint inhibitors","volume":"72","author":"Quandt","year":"2021","unstructured":"Quandt Z,Young A,Perdigoto AL,Herold KC,Anderson MS. Autoimmune endocrinopathies: an emerging complication of immune checkpoint inhibitors. Annu Rev Med. 2021;72:313\u2013330. DOI: 10.1146\/annurev-med-050219-034237"},{"key":"i2590-017X-9-4-153-b52","series-title":"JAMA Oncol","first-page":"173","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","unstructured":"Barroso-Sousa R,Barry WT,Garrido-Castro AC, et al. Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis. JAMA Oncol. 2018;4:173\u2013182. DOI: 10.1001\/jamaoncol.2017.3064"},{"key":"i2590-017X-9-4-153-b53","series-title":"Diabetes","first-page":"1471","article-title":"Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors","volume":"67","author":"Stamatouli","year":"2018","unstructured":"Stamatouli AM,Quandt Z,Perdigoto AL, et al. Collateral damage: insulin-dependent diabetes induced with checkpoint inhibitors. Diabetes. 2018;67:1471\u20131480. DOI: 10.2337\/dbi18-0002"},{"key":"i2590-017X-9-4-153-b54","series-title":"JAMA Oncol","first-page":"194","article-title":"Immune checkpoint inhibitor-induced diabetes across National Cancer Institute Trials that included PD-1 or PD-L1 agents","volume":"12","author":"Quandt","year":"2026","unstructured":"Quandt ZE,Finnigan S,Hill V, et al. Immune checkpoint inhibitor-induced diabetes across National Cancer Institute Trials that included PD-1 or PD-L1 agents. JAMA Oncol. 2026;12:194. DOI: 10.1001\/jamaoncol.2025.5594"},{"key":"i2590-017X-9-4-153-b55","series-title":"J Clin Endocrinol Metab","first-page":"5499","article-title":"Checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes","volume":"104","author":"Tsang","year":"2019","unstructured":"Tsang VHM,McGrath RT,Clifton-Bligh RJ, et al. Checkpoint inhibitor-associated autoimmune diabetes is distinct from type 1 diabetes. J Clin Endocrinol Metab. 2019;104:5499\u20135506. DOI: 10.1210\/jc.2019-00423"},{"key":"i2590-017X-9-4-153-b56","series-title":"Clin Exp Immunol","first-page":"131","article-title":"Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes","volume":"200","author":"Quandt","year":"2020","unstructured":"Quandt Z,Young A,Anderson M. Immune checkpoint inhibitor diabetes mellitus: a novel form of autoimmune diabetes. Clin Exp Immunol. 2020;200:131\u2013140. DOI: 10.1111\/cei.13424"},{"key":"i2590-017X-9-4-153-b57","series-title":"AACE Clin Case Rep","first-page":"232","article-title":"Primary adrenal insufficiency from immune checkpoint inhibitors","volume":"4","author":"Shariff","year":"2018","unstructured":"Shariff AI,D\u2019Alessio DA. Primary adrenal insufficiency from immune checkpoint inhibitors. AACE Clin Case Rep. 2018;4:232\u2013234. DOI: 10.4158\/ACCR-2017-0133"},{"key":"i2590-017X-9-4-153-b58","series-title":"AACE Endocrinol Diabetes","first-page":"97","article-title":"Durvalumab-induced hypoparathyroidism","volume":"12","author":"Chan","year":"2025","unstructured":"Chan C,Manoharan V,Manoharan M. Durvalumab-induced hypoparathyroidism. AACE Endocrinol Diabetes. 2025;12:97\u2013100. DOI: 10.1016\/j.aed.2025.04.005"},{"key":"i2590-017X-9-4-153-b59","series-title":"Mayo Clin Proc Innov Qual Outcomes","first-page":"821","article-title":"Hypoparathyroidism: an uncommon complication associated with immune checkpoint inhibitor therapy","volume":"4","author":"El Kawkgi","year":"2020","unstructured":"El Kawkgi OM,Li D,Kotwal A,Wermers RA. Hypoparathyroidism: an uncommon complication associated with immune checkpoint inhibitor therapy. Mayo Clin Proc Innov Qual Outcomes. 2020;4:821\u2013825. DOI: 10.1016\/j.mayocpiqo.2020.07.006"},{"key":"i2590-017X-9-4-153-b60","series-title":"Melanoma Res","first-page":"109","article-title":"Pembrolizumab-induced acquired lipodystrophy: a case report and review of the literature","volume":"35","author":"Marsiglio","year":"2025","unstructured":"Marsiglio J,McPherson J,Wahl M,Hu-Lieskovan S. Pembrolizumab-induced acquired lipodystrophy: a case report and review of the literature. Melanoma Res. 2025;35:109\u2013114. DOI: 10.1097\/CMR.0000000000000998"},{"key":"i2590-017X-9-4-153-b61","series-title":"Nat Commun","first-page":"3355","article-title":"Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade","volume":"12","author":"Khan","year":"2021","unstructured":"Khan Z,Hammer C,Carroll J, et al. Genetic variation associated with thyroid autoimmunity shapes the systemic immune response to PD-1 checkpoint blockade. Nat Commun. 2021;12:3355. DOI: 10.1038\/s41467-021-23661-4"},{"key":"i2590-017X-9-4-153-b62","series-title":"J Clin Endocrinol Metab","first-page":"e1056","article-title":"Risk of thyroid dysfunction in PD-1 blockade is stratified by the pattern of TgAb and TPOAb positivity at baseline","volume":"108","author":"Zhou","year":"2023","unstructured":"Zhou X,Iwama S,Kobayashi T,Ando M,Arima H. Risk of thyroid dysfunction in PD-1 blockade is stratified by the pattern of TgAb and TPOAb positivity at baseline. J Clin Endocrinol Metab. 2023;108:e1056\u2013e1062. DOI: 10.1210\/clinem\/dgad231"},{"key":"i2590-017X-9-4-153-b63","series-title":"Eur J Endocrinol","first-page":"211","article-title":"Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis","volume":"181","author":"Faje","year":"2019","unstructured":"Faje A,Reynolds K,Zubiri L, et al. Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis. Eur J Endocrinol. 2019;181:211\u2013219. DOI: 10.1530\/EJE-19-0238"},{"key":"i2590-017X-9-4-153-b64","series-title":"J Endocr Soc","article-title":"Spectrum of clinical presentations, imaging findings, and HLA types in immune checkpoint inhibitor-induced hypophysitis","volume":"7","author":"Quandt","year":"2023","unstructured":"Quandt Z,Kim S,Villanueva-Meyer J, et al. Spectrum of clinical presentations, imaging findings, and HLA types in immune checkpoint inhibitor-induced hypophysitis. J Endocr Soc. 2023;7. DOI:10.1210\/jendso\/bvad012"},{"key":"i2590-017X-9-4-153-b65","series-title":"NPJ Breast Cancer","article-title":"Multi-institutional analysis of incidence and risks for late-onset immune toxicity in breast cancer","volume":"11","author":"Jacob","year":"2025","unstructured":"Jacob S,Fisch S,Face C, et al. Multi-institutional analysis of incidence and risks for late-onset immune toxicity in breast cancer. NPJ Breast Cancer. 2025;11. DOI:10.1038\/s41523-025-00849-1"},{"key":"i2590-017X-9-4-153-b66","series-title":"Thyroid","first-page":"1243","article-title":"Immune-related thyroiditis with immune checkpoint inhibitors","volume":"28","author":"Iyer","year":"2018","unstructured":"Iyer PC,Cabanillas ME,Waguespack SG, et al. Immune-related thyroiditis with immune checkpoint inhibitors. Thyroid. 2018;28:1243\u20131251. DOI: 10.1089\/thy.2018.0116"},{"key":"i2590-017X-9-4-153-b67","series-title":"J Clin Oncol","first-page":"e14571","article-title":"The incidence of occult endocrinopathies in patients with cancer undergoing immunotherapy in community practice","volume":"39","author":"Abdalla","year":"2021","unstructured":"Abdalla A,Singh A,Gharib H, et al. The incidence of occult endocrinopathies in patients with cancer undergoing immunotherapy in community practice. J Clin Oncol. 2021;39:e14571. DOI: 10.1200\/JCO.2021.39.15_suppl.e14571"},{"key":"i2590-017X-9-4-153-b68","series-title":"J Immunother Cancer","first-page":"e011545","article-title":"Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study","volume":"13","author":"Quandt","year":"2025","unstructured":"Quandt Z,Lucas A,Liang SI, et al. Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study. J Immunother Cancer. 2025;13:e011545. DOI: 10.1136\/jitc-2025-011545"},{"key":"i2590-017X-9-4-153-b69","series-title":"Immunotherapy","first-page":"417","article-title":"Clinical outcomes of immune checkpoint inhibitor diabetes mellitus at a comprehensive cancer center","volume":"15","author":"Jeun","year":"2023","unstructured":"Jeun R,Iyer PC,Best C, et al. Clinical outcomes of immune checkpoint inhibitor diabetes mellitus at a comprehensive cancer center. Immunotherapy. 2023;15:417\u2013428. DOI: 10.2217\/imt-2021-0316"},{"key":"i2590-017X-9-4-153-b70","series-title":"Oncoimmunology","article-title":"Immune-related hepatitis and hypophysitis are associated with superior survival in melanoma patients treated with combined ipilimumab and nivolumab","volume":"14","author":"Al Remawi","year":"2025","unstructured":"Al Remawi H,Lind\u00e9n M,Zhao Z, et al. Immune-related hepatitis and hypophysitis are associated with superior survival in melanoma patients treated with combined ipilimumab and nivolumab. Oncoimmunology. 2025;14. DOI:10.1080\/2162402X.2025.2543510"},{"key":"i2590-017X-9-4-153-b71","series-title":"J Natl Compr Canc Ne","first-page":"281","article-title":"Hypophysitis and secondary adrenal insufficiency from immune checkpoint inhibitors: diagnostic challenges and link with survival","volume":"21","author":"Johnson","year":"2023","unstructured":"Johnson J,Goldner W,Abdallah D, et al. Hypophysitis and secondary adrenal insufficiency from immune checkpoint inhibitors: diagnostic challenges and link with survival. J Natl Compr Canc Ne. 2023;21:281\u2013287. DOI: 10.6004\/jnccn.2022.7098"},{"key":"i2590-017X-9-4-153-b72","series-title":"J Invest Med","first-page":"939","article-title":"Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort","volume":"70","author":"Kotwal","year":"2022","unstructured":"Kotwal A,Rouleau SG,Dasari S, et al. Immune checkpoint inhibitor-induced hypophysitis: lessons learnt from a large cancer cohort. J Invest Med. 2022;70:939\u2013946. DOI: 10.1136\/jim-2021-002099"},{"key":"i2590-017X-9-4-153-b73","series-title":"Cancer","first-page":"3706","article-title":"High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma","volume":"124","author":"Faje","year":"2018","unstructured":"Faje AT,Lawrence D,Flaherty K, et al. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma. Cancer. 2018;124:3706\u20133714. DOI: 10.1002\/cncr.31629"},{"key":"i2590-017X-9-4-153-b74","article-title":"NCCN Clinical Practice Guidelines in Oncology: management of immune checkpoint inhibitor-related toxicities Version 1","author":"National Comprehensive Cancer Network","year":"2026","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: management of immune checkpoint inhibitor-related toxicities Version 1. 2026. Accessed Jan 7, 2026. www.nccn.org\/guidelines\/guidelines-detail?category=3&id=1548"},{"key":"i2590-017X-9-4-153-b75","series-title":"J Immunother Cancer","first-page":"e002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","unstructured":"Brahmer JR,Abu-Sbeih H,Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9:e002435. DOI: 10.1136\/jitc-2021-002435"},{"key":"i2590-017X-9-4-153-b76","series-title":"JCI Insight","article-title":"Immune cells and their inflammatory mediators modify beta cells and cause checkpoint inhibitor-induced diabetes","volume":"7","author":"Perdigoto","year":"2022","unstructured":"Perdigoto AL,Deng S,Du KC, et al. Immune cells and their inflammatory mediators modify beta cells and cause checkpoint inhibitor-induced diabetes. JCI Insight. 2022;7. DOI: 10.1172\/jci.insight.156330"},{"key":"i2590-017X-9-4-153-b77","series-title":"JCI Insight","article-title":"Polyfunctional T follicular helper cells drive checkpoint-inhibitor diabetes and are targeted by JAK inhibitor therapy","volume":"10","author":"Huang","year":"2025","unstructured":"Huang NL,Ortega JG,Kimbrell K, et al. Polyfunctional T follicular helper cells drive checkpoint-inhibitor diabetes and are targeted by JAK inhibitor therapy. JCI Insight. 2025;10. DOI: 10.1172\/jci.insight.188843"},{"key":"i2590-017X-9-4-153-b78","series-title":"Clin Trans Imm","first-page":"e1425","article-title":"Diabetes induced by checkpoint inhibition in nonobese diabetic mice can be prevented or reversed by a JAK1\/JAK2 inhibitor","volume":"11","author":"Ge","year":"2022","unstructured":"Ge T,Phung A,Jhala G, et al. Diabetes induced by checkpoint inhibition in nonobese diabetic mice can be prevented or reversed by a JAK1\/JAK2 inhibitor. Clin Trans Imm. 2022;11:e1425. DOI: 10.1002\/cti2.1425"},{"key":"i2590-017X-9-4-153-b79","series-title":"Thyroid","first-page":"496","article-title":"Optimal thyroid hormone replacement dose in immune checkpoint inhibitor-associated hypothyroidism is distinct from Hashimoto's thyroiditis","volume":"32","author":"Mosaferi","year":"2022","unstructured":"Mosaferi T,Tsai K,Sovich S, et al. Optimal thyroid hormone replacement dose in immune checkpoint inhibitor-associated hypothyroidism is distinct from Hashimoto's thyroiditis. Thyroid. 2022;32:496\u2013504. DOI: 10.1089\/thy.2021.0685"},{"key":"i2590-017X-9-4-153-b80","series-title":"J. Clin Endocrinol Metab","first-page":"3342","article-title":"Optimal levothyroxine dosing strategy for immune checkpoint inhibitor-related hypothyroidism: a retrospective study","volume":"110","author":"Gao","year":"2025","unstructured":"Gao Y,Du C,Xu Y, et al. Optimal levothyroxine dosing strategy for immune checkpoint inhibitor-related hypothyroidism: a retrospective study. J. Clin Endocrinol Metab. 2025;110:3342\u20133353. DOI: 10.1210\/clinem\/dgaf260"},{"key":"i2590-017X-9-4-153-b81","series-title":"Clinical Cancer Research","first-page":"5131","article-title":"Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with PD-1 blockade in non-small cell lung cancer","volume":"27","author":"Luo","year":"2021","unstructured":"Luo J,Martucci VL,Quandt Z, et al. Immunotherapy-mediated thyroid dysfunction: genetic risk and impact on outcomes with PD-1 blockade in non-small cell lung cancer. Clinical Cancer Research. 2021;27:5131\u20135140. DOI: 10.1158\/1078-0432.CCR-21-0921"},{"key":"i2590-017X-9-4-153-b82","series-title":"Endocr J","first-page":"987","article-title":"Prediction-based prompt levothyroxine replacement to prevent a hypothyroid state after immune-related adverse events involving the thyroid gland","volume":"70","author":"Yamauchi","year":"2023","unstructured":"Yamauchi I,Hakata T,Sugawa T, et al. Prediction-based prompt levothyroxine replacement to prevent a hypothyroid state after immune-related adverse events involving the thyroid gland. Endocr J. 2023;70:987\u2013998. DOI: 10.1507\/endocrj.EJ23-0262"},{"key":"i2590-017X-9-4-153-b83","series-title":"J Immunother Cancer","first-page":"e011273","article-title":"Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events","volume":"13","author":"Middha","year":"2025","unstructured":"Middha P,Thummalapalli R,Quandt Z, et al. Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events. J Immunother Cancer. 2025;13:e011273. DOI: 10.1136\/jitc-2024-011273"},{"key":"i2590-017X-9-4-153-b84","article-title":"Prediction of cancer immunotherapy-precipitated autoimmune diabetes","author":"Quandt","year":"2025","unstructured":"Quandt Z. Prediction of cancer immunotherapy-precipitated autoimmune diabetes. Breakthrough T1D; 2025. Accessed Aug 27, 2026. www.breakthrought1d.org\/grants\/united-states\/california\/prediction-of-cancer-immunotherapy-precipitated-autoimmune-diabetes\/"},{"key":"i2590-017X-9-4-153-b85","series-title":"Cancer","first-page":"367","article-title":"Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course","volume":"129","author":"Haryal","year":"2023","unstructured":"Haryal A,Townsend MJ,Baskaran V, et al. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course. Cancer. 2023;129:367\u2013375. DOI: 10.1002\/cncr.34543"},{"key":"i2590-017X-9-4-153-b86","series-title":"J Natl Compr Canc Netw","first-page":"896","article-title":"Clinicopathologic features, treatment response, and outcomes of immune checkpoint inhibitor-related esophagitis","volume":"19","author":"Panneerselvam","year":"2021","unstructured":"Panneerselvam K,Amin RN,Wei D, et al. Clinicopathologic features, treatment response, and outcomes of immune checkpoint inhibitor-related esophagitis. J Natl Compr Canc Netw. 2021;19:896\u2013904. DOI: 10.6004\/jnccn.2020.7675"},{"key":"i2590-017X-9-4-153-b87","series-title":"Cancer Treat Rev","first-page":"102440","article-title":"Immune checkpoint inhibitor-induced diarrhea and colitis: incidence and management. A systematic review and meta-analysis","volume":"109","author":"Nielsen","year":"2022","unstructured":"Nielsen DL,Juhl CB,Chen IM,Kellermann L,Nielsen OH. Immune checkpoint inhibitor-induced diarrhea and colitis: incidence and management. A systematic review and meta-analysis. Cancer Treat Rev. 2022;109:102440. DOI: 10.1016\/j.ctrv.2022.102440"},{"key":"i2590-017X-9-4-153-b88","series-title":"Oncoimmunology","first-page":"e1344805","article-title":"Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis","volume":"6","author":"Wang","year":"2017","unstructured":"Wang DY,Ye F,Zhao S,Johnson DB. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis. Oncoimmunology. 2017;6:e1344805. DOI: 10.1080\/2162402X.2017.1344805"},{"key":"i2590-017X-9-4-153-b89","series-title":"J Immunother","first-page":"325","article-title":"Immune checkpoint inhibitor-associated diarrhea and colitis: a systematic review and meta-analysis of observational studies","volume":"44","author":"Tran","year":"2021","unstructured":"Tran AN,Wang M,Hundt M, et al. Immune checkpoint inhibitor-associated diarrhea and colitis: a systematic review and meta-analysis of observational studies. J Immunother. 2021;44:325\u2013334. DOI: 10.1097\/CJI.0000000000000383"},{"key":"i2590-017X-9-4-153-b90","series-title":"Gastroenterology","first-page":"1195","article-title":"Insights from pharmacovigilance: gastrointestinal-related immune checkpoint inhibitor adverse events","volume":"159","author":"Reese","year":"2020","unstructured":"Reese SW,Marchese M,McNabb-Baltar J. Insights from pharmacovigilance: gastrointestinal-related immune checkpoint inhibitor adverse events. Gastroenterology. 2020;159:1195\u20131200.e1. DOI: 10.1053\/j.gastro.2020.06.093"},{"key":"i2590-017X-9-4-153-b91","series-title":"Front Immunol","first-page":"1508512","article-title":"Predictors of severity and onset timing of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a retrospective analysis","volume":"16","author":"Fang","year":"2025","unstructured":"Fang Q,Qian Y,Xie Z, et al. Predictors of severity and onset timing of immune-related adverse events in cancer patients receiving immune checkpoint inhibitors: a retrospective analysis. Front Immunol. 2025;16:1508512. DOI: 10.3389\/fimmu.2025.1508512"},{"key":"i2590-017X-9-4-153-b92","series-title":"Cancers (Basel)","first-page":"2329","article-title":"Obesity measured via body mass index may be associated with increased incidence but not worse outcomes of immune-mediated diarrhea and colitis","volume":"15","author":"Kono","year":"2023","unstructured":"Kono M,Shatila M,Xu G, et al. Obesity measured via body mass index may be associated with increased incidence but not worse outcomes of immune-mediated diarrhea and colitis. Cancers (Basel). 2023;15:2329. DOI: 10.3390\/cancers15082329"},{"key":"i2590-017X-9-4-153-b93","series-title":"ECCOJC","first-page":"395","article-title":"Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease","volume":"10","author":"Marthey","year":"2016","unstructured":"Marthey L,Mateus C,Mussini C, et al. Cancer immunotherapy with anti-CTLA-4 monoclonal antibodies induces an inflammatory bowel disease. ECCOJC. 2016;10:395\u2013401. DOI: 10.1093\/ecco-jcc\/jjv227"},{"key":"i2590-017X-9-4-153-b94","series-title":"Clin Genitourin Cancer","first-page":"260","article-title":"Chronic use of proton pump inhibitors is associated with an increased risk of immune checkpoint inhibitor colitis in renal cell carcinoma","volume":"20","author":"Yin","year":"2022","unstructured":"Yin J,Elias R,Peng L, et al. Chronic use of proton pump inhibitors is associated with an increased risk of immune checkpoint inhibitor colitis in renal cell carcinoma. Clin Genitourin Cancer. 2022;20:260\u2013269. DOI: 10.1016\/j.clgc.2022.01.017"},{"key":"i2590-017X-9-4-153-b95","series-title":"J Immunother Cancer","first-page":"e002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","unstructured":"Brahmer JR,Abu-Sbeih H,Ascierto PA, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. J Immunother Cancer. 2021;9:e002435. DOI: 10.1136\/jitc-2021-002435"},{"key":"i2590-017X-9-4-153-b96","series-title":"J Natl Compr Canc Netw","first-page":"582","article-title":"NCCN guidelines\u00ae insights: management of Immunotherapy-related toxicities, version 2.2024","volume":"22","author":"Thompson","year":"2024","unstructured":"Thompson JA,Schneider BJ,Brahmer J, et al. NCCN guidelines\u00ae insights: management of Immunotherapy-related toxicities, version 2.2024. J Natl Compr Canc Netw. 2024;22:582\u2013592. DOI: 10.6004\/jnccn.2024.0057"},{"key":"i2590-017X-9-4-153-b97","series-title":"Gastroenterology","first-page":"1384","article-title":"AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review","volume":"160","author":"Dougan","year":"2021","unstructured":"Dougan M,Wang Y,Rubio-Tapia A,Lim JK. AGA clinical practice update on diagnosis and management of immune checkpoint inhibitor colitis and hepatitis: expert review. Gastroenterology. 2021;160:1384\u20131393. DOI: 10.1053\/j.gastro.2020.08.063"},{"key":"i2590-017X-9-4-153-b98","series-title":"Lancet Gastroenterol Hepatol","first-page":"679","article-title":"British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis","volume":"5","author":"Powell","year":"2020","unstructured":"Powell N,Ibraheim H,Raine T, et al. British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. Lancet Gastroenterol Hepatol. 2020;5:679\u2013697. DOI: 10.1016\/S2468-1253(20)30014-5"},{"key":"i2590-017X-9-4-153-b99","series-title":"ESMO Open","first-page":"e000278","article-title":"Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management","volume":"3","author":"Geukes Foppen","year":"2018","unstructured":"Geukes Foppen MH,Rozeman EA,van Wilpe S, et al. Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. ESMO Open. 2018;3:e000278. DOI: 10.1136\/esmoopen-2017-000278"},{"key":"i2590-017X-9-4-153-b100","series-title":"J Immunother Cancer","first-page":"e000451","article-title":"Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis","volume":"8","author":"Mooradian","year":"2020","unstructured":"Mooradian MJ,Wang DY,Coromilas A, et al. Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis. J Immunother Cancer. 2020;8:e000451. DOI: 10.1136\/jitc-2019-000451"},{"key":"i2590-017X-9-4-153-b101","series-title":"J Immunotherapy Cancer","first-page":"292","article-title":"Budesonide treatment for microscopic colitis from immune checkpoint inhibitors","volume":"7","author":"Hughes","year":"2019","unstructured":"Hughes MS,Molina GE,Chen ST, et al. Budesonide treatment for microscopic colitis from immune checkpoint inhibitors. J Immunotherapy Cancer. 2019;7:292. DOI: 10.1186\/s40425-019-0756-0"},{"key":"i2590-017X-9-4-153-b102","series-title":"Inflamm Bowel Dis","first-page":"1695","article-title":"Endoscopic and histologic features of immune checkpoint inhibitor-related colitis","volume":"24","author":"Wang","year":"2018","unstructured":"Wang Y,Abu-Sbeih H,Mao E, et al. Endoscopic and histologic features of immune checkpoint inhibitor-related colitis. Inflamm Bowel Dis. 2018;24:1695\u20131705. DOI: 10.1093\/ibd\/izy104"},{"key":"i2590-017X-9-4-153-b103","series-title":"Gastrointest Endosc","first-page":"273","article-title":"Novel endoscopic scoring system for immune mediated colitis: a multicenter retrospective study of 674 patients","volume":"100","author":"Wang","year":"2024","unstructured":"Wang Y,Abu-Sbeih H,Tang T, et al. Novel endoscopic scoring system for immune mediated colitis: a multicenter retrospective study of 674 patients. Gastrointest Endosc. 2024;100:273\u2013282.e4. DOI: 10.1016\/j.gie.2024.01.024"},{"key":"i2590-017X-9-4-153-b104","series-title":"iGIE","first-page":"136","article-title":"Validation of the immune-mediated colitis endoscopic score using a retrospective cohort of patients with immune-mediated colitis","volume":"5","author":"Shatila","year":"2026","unstructured":"Shatila M,Cruz CC,Varatharajalu K, et al. Validation of the immune-mediated colitis endoscopic score using a retrospective cohort of patients with immune-mediated colitis. iGIE. 2026;5:136\u2013144.e5. DOI: 10.1016\/j.igie.2025.09.002"},{"key":"i2590-017X-9-4-153-b105","series-title":"J Natl Compr Canc Netw","first-page":"e257046","article-title":"Disease outcomes in immune-mediated colitis: a study describing initial endoscopic and histologic presentations and treatment options","volume":"23","author":"Shatila","year":"2025","unstructured":"Shatila M,Cruz CC,Takigawa K, et al. Disease outcomes in immune-mediated colitis: a study describing initial endoscopic and histologic presentations and treatment options. J Natl Compr Canc Netw. 2025;23:e257046. DOI: 10.6004\/jnccn.2025.704640930146"},{"key":"i2590-017X-9-4-153-b106","series-title":"Gastroenterology","first-page":"S-541","article-title":"Sa1826: the prognostic value of fecal calprotectin in predicting need for aggressive treatment and future disease remission among patients with immune checkpoint inhibitor colitis","volume":"169","author":"Shatila","year":"2025","unstructured":"Shatila M,Lu L,Gupta T, et al. Sa1826: the prognostic value of fecal calprotectin in predicting need for aggressive treatment and future disease remission among patients with immune checkpoint inhibitor colitis. Gastroenterology. 2025;169:S-541. DOI: 10.1016\/S0016-5085(25)02188-2"},{"key":"i2590-017X-9-4-153-b107","series-title":"J Immunotherapy Cancer","first-page":"93","article-title":"Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis","volume":"7","author":"Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih H,Ali FS,Wang X, et al. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunotherapy Cancer. 2019;7:93. DOI: 10.1186\/s40425-019-0577-1"},{"key":"i2590-017X-9-4-153-b108","series-title":"J Immunother Cancer","first-page":"e001329","article-title":"Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis","volume":"8","author":"Durbin","year":"2020","unstructured":"Durbin SM,Mooradian MJ,Fintelmann FJ, et al. Diagnostic utility of CT for suspected immune checkpoint inhibitor enterocolitis. J Immunother Cancer. 2020;8:e001329. DOI: 10.1136\/jitc-2020-001329"},{"key":"i2590-017X-9-4-153-b109","series-title":"J Immunother Precis Oncol","first-page":"32","article-title":"Role of abdominal and pelvic CT scans in diagnosis of patients with immunotherapy-induced colitis","volume":"5","author":"Ibarra Rovira","year":"2022","unstructured":"Ibarra Rovira J,Thirumurthi S,Taggart M, et al. Role of abdominal and pelvic CT scans in diagnosis of patients with immunotherapy-induced colitis. J Immunother Precis Oncol. 2022;5:32\u201336. DOI: 10.36401\/JIPO-21-21"},{"key":"i2590-017X-9-4-153-b110","series-title":"Clin Gastroenterol Hepatol","first-page":"1790","article-title":"AGA Clinical Practice Update on the role of intestinal ultrasound in inflammatory bowel disease: commentary","volume":"22","author":"Chavannes","year":"2024","unstructured":"Chavannes M,Dolinger MT,Cohen-Mekelburg S,Abraham B. AGA Clinical Practice Update on the role of intestinal ultrasound in inflammatory bowel disease: commentary. Clin Gastroenterol Hepatol. 2024;22:1790\u20131795.e1. DOI: 10.1016\/j.cgh.2024.04.039"},{"key":"i2590-017X-9-4-153-b111","series-title":"Intest Res","first-page":"126","article-title":"Characteristics and usefulness of transabdominal ultrasonography in immune-mediated colitis","volume":"21","author":"Sakurai","year":"2023","unstructured":"Sakurai K,Katsurada T,Nishida M, et al. Characteristics and usefulness of transabdominal ultrasonography in immune-mediated colitis. Intest Res. 2023;21:126\u2013136. DOI: 10.5217\/ir.2021.00166"},{"key":"i2590-017X-9-4-153-b112","series-title":"Inflamm Bowel Dis","first-page":"1182","article-title":"Symptomatic and sonographic improvement of immune checkpoint inhibitor enterocolitis with risankizumab","volume":"31","author":"Mei","year":"2025","unstructured":"Mei R,Pepe E,Oh DY, et al. Symptomatic and sonographic improvement of immune checkpoint inhibitor enterocolitis with risankizumab. Inflamm Bowel Dis. 2025;31:1182\u20131183. DOI: 10.1093\/ibd\/izae259"},{"key":"i2590-017X-9-4-153-b113","series-title":"SN Compr Clin Med","first-page":"215","article-title":"Immune checkpoint inhibitor-induced colitis successfully followed up by ultrasonography","volume":"2","author":"Omotehara","year":"2020","unstructured":"Omotehara S,Nishida M,Nagashima K, et al. Immune checkpoint inhibitor-induced colitis successfully followed up by ultrasonography. SN Compr Clin Med. 2020;2:215\u2013221. DOI: 10.1007\/s42399-019-00211-0"},{"key":"i2590-017X-9-4-153-b114","series-title":"Gastroenterology","first-page":"S-152","article-title":"Randomized clinical trial of infliximab versus vedolizumab for immune checkpoint inhibitor related colitis","volume":"169","author":"Wang","year":"2025","unstructured":"Wang Y,Varatharajalu K,Cruz CC, et al. Randomized clinical trial of infliximab versus vedolizumab for immune checkpoint inhibitor related colitis. Gastroenterology. 2025;169:S-152. DOI: 10.1016\/S0016-5085(25)01294-6"},{"key":"i2590-017X-9-4-153-b115","series-title":"J Immunother Cancer","first-page":"e003277","article-title":"Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study","volume":"9","author":"Zou","year":"2021","unstructured":"Zou F,Faleck D,Thomas A, et al. Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study. J Immunother Cancer. 2021;9:e003277. DOI: 10.1136\/jitc-2021-003277"},{"key":"i2590-017X-9-4-153-b116","series-title":"Am J Gastroenterol","first-page":"1679","article-title":"IL12\/23 blockade for refractory immune-mediated colitis: 2-center experience","volume":"118","author":"Shirwaikar Thomas","year":"2023","unstructured":"Shirwaikar Thomas A,Lee SE,Shatila M, et al. IL12\/23 blockade for refractory immune-mediated colitis: 2-center experience. Am J Gastroenterol. 2023;118:1679\u20131683. DOI: 10.14309\/ajg.0000000000002332"},{"key":"i2590-017X-9-4-153-b117","series-title":"N Engl J Med","first-page":"2374","article-title":"Tofacitinib for refractory immune-related colitis from PD-1 therapy","volume":"382","author":"Esfahani","year":"2020","unstructured":"Esfahani K,Hudson M,Batist G. Tofacitinib for refractory immune-related colitis from PD-1 therapy. N Engl J Med. 2020;382:2374\u20132375. DOI: 10.1056\/NEJMc2002527"},{"key":"i2590-017X-9-4-153-b118","series-title":"Gastroenterology","first-page":"932","article-title":"Efficacy and outcome of tofacitinib in immune checkpoint inhibitor colitis","volume":"160","author":"Bishu","year":"2021","unstructured":"Bishu S,Melia J,Sharfman W, et al. Efficacy and outcome of tofacitinib in immune checkpoint inhibitor colitis. Gastroenterology. 2021;160:932\u2013934.e3. DOI: 10.1053\/j.gastro.2020.10.029"},{"key":"i2590-017X-9-4-153-b119","series-title":"Gastroenterology","first-page":"1229","article-title":"Interferon-gamma-producing CD8","volume":"161","author":"Sasson","year":"2021","unstructured":"Sasson SC,Slevin SM,Cheung VTF, et al. Interferon-gamma-producing CD8. Gastroenterology. 2021;161:1229\u20131244.e9. DOI: 10.1053\/j.gastro.2021.06.025"},{"key":"i2590-017X-9-4-153-b120","series-title":"BMJ Open Gastroenterol","first-page":"e000989","article-title":"Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report","volume":"9","author":"Holmstroem","year":"2022","unstructured":"Holmstroem RB,Dahl EK,Helms M, et al. Tofacitinib and faecal microbiota transplantation in treating checkpoint inhibitor-induced enterocolitis: case report. BMJ Open Gastroenterol. 2022;9:e000989. DOI: 10.1136\/bmjgast-2022-000989"},{"key":"i2590-017X-9-4-153-b121","series-title":"Clin J Gastroenterol","first-page":"680","article-title":"Mirroring UC care pathways in refractory immune checkpoint inhibitor (ICI)-mediated colitis: distinct features and common pathways","volume":"16","author":"Sleiman","year":"2023","unstructured":"Sleiman J,Brand RM,Pai R, et al. Mirroring UC care pathways in refractory immune checkpoint inhibitor (ICI)-mediated colitis: distinct features and common pathways. Clin J Gastroenterol. 2023;16:680\u2013684. DOI: 10.1007\/s12328-023-01826-6"},{"key":"i2590-017X-9-4-153-b122","series-title":"Front Immunol","first-page":"1212432","article-title":"Case report: a severe case of immunosuppressant-refractory immune checkpoint inhibitor-mediated colitis rescued by tofacitinib","volume":"14","author":"Sweep","year":"2023","unstructured":"Sweep MWD,Tjan MJH,Gorris MAJ,Bol KF,Westdorp H. Case report: a severe case of immunosuppressant-refractory immune checkpoint inhibitor-mediated colitis rescued by tofacitinib. Front Immunol. 2023;14:1212432. DOI: 10.3389\/fimmu.2023.1212432"},{"key":"i2590-017X-9-4-153-b123","series-title":"J Immunother Cancer","first-page":"e008232","article-title":"Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series","volume":"12","author":"Harvey","year":"2024","unstructured":"Harvey C,Nahar KJ,McKeown J, et al. Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series. J Immunother Cancer. 2024;12:e008232. DOI: 10.1136\/jitc-2023-008232"},{"key":"i2590-017X-9-4-153-b124","series-title":"Melanoma Res","first-page":"102","article-title":"Mycophenolate mofetil alongside high-dose corticosteroids: optimizing the management of combination immune checkpoint inhibitor-induced colitis","volume":"29","author":"Mir","year":"2019","unstructured":"Mir R,Shaw HM,Nathan PD. Mycophenolate mofetil alongside high-dose corticosteroids: optimizing the management of combination immune checkpoint inhibitor-induced colitis. Melanoma Res. 2019;29:102\u2013106. DOI: 10.1097\/CMR.0000000000000543"},{"key":"i2590-017X-9-4-153-b125","series-title":"J Immunother Cancer","first-page":"e005111","article-title":"COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis","volume":"10","author":"Holmstroem","year":"2022","unstructured":"Holmstroem RB,Nielsen OH,Jacobsen S, et al. COLAR: open-label clinical study of IL-6 blockade with tocilizumab for the treatment of immune checkpoint inhibitor-induced colitis and arthritis. J Immunother Cancer. 2022;10:e005111. DOI: 10.1136\/jitc-2022-005111"},{"key":"i2590-017X-9-4-153-b126","series-title":"N Engl J Med","first-page":"294","article-title":"Extracorporeal photopheresis for colitis induced by Checkpoint-Inhibitor therapy","volume":"382","author":"Apostolova","year":"2020","unstructured":"Apostolova P,Unger S,von Bubnoff D, et al. Extracorporeal photopheresis for colitis induced by Checkpoint-Inhibitor therapy. N Engl J Med. 2020;382:294\u2013296. DOI: 10.1056\/NEJMc1912274"},{"key":"i2590-017X-9-4-153-b127","series-title":"Acad Dermatol Venereol","first-page":"e342","article-title":"Extracorporeal photophoresis in treatment of corticosteroid refractory colitis induced by combined immunotherapy for metastatic melanoma","volume":"39","author":"P\u00e1sek","year":"2025","unstructured":"P\u00e1sek M,Kopeck\u00fd J,Tretera V,Arenberger P,Arenbergerov\u00e1 M. Extracorporeal photophoresis in treatment of corticosteroid refractory colitis induced by combined immunotherapy for metastatic melanoma. Acad Dermatol Venereol. 2025;39:e342\u2013e343. DOI: 10.1111\/jdv.20331"},{"key":"i2590-017X-9-4-153-b128","series-title":"J Immunother","first-page":"227","article-title":"Extracorporeal photopheresis as a treatment option for immune-related adverse events: two case reports and a prospective study","volume":"47","author":"Ruf","year":"2024","unstructured":"Ruf T,Rahimi F,Anz D, et al. Extracorporeal photopheresis as a treatment option for immune-related adverse events: two case reports and a prospective study. J Immunother. 2024;47:227\u2013231. DOI: 10.1097\/CJI.0000000000000510"},{"key":"i2590-017X-9-4-153-b129","series-title":"Gastroenterology","first-page":"S-1486","article-title":"Tu1778: fecal transplantation improved patients\u2019 reported outcome after immune checkpoint inhibitor colitis","volume":"169","author":"Wang","year":"2025","unstructured":"Wang Y,Varatharajalu K,Shatila M, et al. Tu1778: fecal transplantation improved patients\u2019 reported outcome after immune checkpoint inhibitor colitis. Gastroenterology. 2025;169:S-1486\u2013S-1487. DOI: 10.1016\/S0016-5085(25)04307-0"},{"key":"i2590-017X-9-4-153-b130","series-title":"Eur J Cancer","first-page":"106","article-title":"Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors","volume":"106","author":"de Malet","year":"2019","unstructured":"de Malet A,Antoni G,Collins M, et al. Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors. Eur J Cancer. 2019;106:106\u2013114. DOI: 10.1016\/j.ejca.2018.10.006"},{"key":"i2590-017X-9-4-153-b131","series-title":"J Clin Oncol","first-page":"2738","article-title":"Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis","volume":"37","author":"Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih H,Ali FS,Naqash AR, et al. Resumption of immune checkpoint inhibitor therapy after immune-mediated colitis. J Clin Oncol. 2019;37:2738\u20132745. DOI: 10.1200\/JCO.19.00320"},{"key":"i2590-017X-9-4-153-b132","series-title":"J Immunother Cancer","first-page":"e007195","article-title":"Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis","volume":"11","author":"Badran","year":"2023","unstructured":"Badran YR,Zou F,Durbin SM, et al. Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis. J Immunother Cancer. 2023;11:e007195. DOI: 10.1136\/jitc-2023-007195"},{"key":"i2590-017X-9-4-153-b133","series-title":"ESMO Open","first-page":"e000945","article-title":"Lower risk of severe checkpoint inhibitor toxicity in more advanced disease","volume":"5","author":"Verheijden","year":"2020","unstructured":"Verheijden RJ,May AM,Blank CU, et al. Lower risk of severe checkpoint inhibitor toxicity in more advanced disease. ESMO Open. 2020;5:e000945. DOI: 10.1136\/esmoopen-2020-000945"},{"key":"i2590-017X-9-4-153-b134","series-title":"J Cancer","first-page":"2686","article-title":"Colon adenoma after diagnosis of immune checkpoint inhibitor-mediated colitis","volume":"14","author":"Machado","year":"2023","unstructured":"Machado AP,Shatila M,De Toni EN, et al. Colon adenoma after diagnosis of immune checkpoint inhibitor-mediated colitis. J Cancer. 2023;14:2686\u20132693. DOI: 10.7150\/jca.86635"},{"key":"i2590-017X-9-4-153-b135","series-title":"JAMA Netw Open","first-page":"e2352302","article-title":"Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors","volume":"7","author":"Cook","year":"2024","unstructured":"Cook S,Samuel V,Meyers DE, et al. Immune-related adverse events and survival among patients with metastatic NSCLC treated with immune checkpoint inhibitors. JAMA Netw Open. 2024;7:e2352302. DOI: 10.1001\/jamanetworkopen.2023.52302"},{"key":"i2590-017X-9-4-153-b136","series-title":"Cancer","first-page":"4565","article-title":"Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors","volume":"127","author":"Foster","year":"2021","unstructured":"Foster CC,Couey MA,Kochanny SE, et al. Immune-related adverse events are associated with improved response, progression-free survival, and overall survival for patients with head and neck cancer receiving immune checkpoint inhibitors. Cancer. 2021;127:4565\u20134573. DOI: 10.1002\/cncr.33780"},{"key":"i2590-017X-9-4-153-b137","series-title":"Clin Cancer Res","first-page":"2268","article-title":"Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1-treated patients in the Dutch melanoma treatment registry","volume":"26","author":"Verheijden","year":"2020","unstructured":"Verheijden RJ,May AM,Blank CU, et al. Association of anti-TNF with decreased survival in steroid refractory ipilimumab and anti-PD1-treated patients in the Dutch melanoma treatment registry. Clin Cancer Res. 2020;26:2268\u20132274. DOI: 10.1158\/1078-0432.CCR-19-3322"},{"key":"i2590-017X-9-4-153-b138","series-title":"NPJ Precis Onc","first-page":"41","article-title":"Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance","volume":"7","author":"Verheijden","year":"2023","unstructured":"Verheijden RJ,van Eijs MJM,May AM,van Wijk F,Suijkerbuijk KPM. Immunosuppression for immune-related adverse events during checkpoint inhibition: an intricate balance. NPJ Precis Onc. 2023;7:41. DOI: 10.1038\/s41698-023-00380-1"},{"key":"i2590-017X-9-4-153-b139","series-title":"Aliment Pharmacol Ther","first-page":"1370","article-title":"Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor-induced colitis","volume":"56","author":"Dahl","year":"2022","unstructured":"Dahl EK,Abed OK,Kjeldsen J, et al. Safety and efficacy of infliximab and corticosteroid therapy in checkpoint inhibitor-induced colitis. Aliment Pharmacol Ther. 2022;56:1370\u20131382. DOI: 10.1111\/apt.17201"},{"key":"i2590-017X-9-4-153-b140","series-title":"J Cancer Res Clin Oncol","first-page":"7793","article-title":"Effects of immunosuppressive treatment on patient outcomes after immune checkpoint inhibitor-related gastrointestinal toxicity","volume":"149","author":"Shatila","year":"2023","unstructured":"Shatila M,Ma W,Cui Y, et al. Effects of immunosuppressive treatment on patient outcomes after immune checkpoint inhibitor-related gastrointestinal toxicity. J Cancer Res Clin Oncol. 2023;149:7793\u20137803. DOI: 10.1007\/s00432-023-04736-9"},{"key":"i2590-017X-9-4-153-b141","series-title":"Cancer Immunol Res","first-page":"1053","article-title":"Deep immune phenotyping reveals distinct immunopathogenesis in checkpoint inhibitor-induced colitis compared with ulcerative colitis","volume":"13","author":"Pesch","year":"2025","unstructured":"Pesch G,Piseddu I,Gaertig J, et al. Deep immune phenotyping reveals distinct immunopathogenesis in checkpoint inhibitor-induced colitis compared with ulcerative colitis. Cancer Immunol Res. 2025;13:1053\u20131069. DOI: 10.1158\/2326-6066.CIR-24-0387"},{"key":"i2590-017X-9-4-153-b142","series-title":"Sig Transduct Target Ther","first-page":"110","article-title":"Adiponectin to the rescue: extracorporeal photopheresis for managing immune checkpoint inhibitor-induced toxicities","volume":"10","author":"Reschke","year":"2025","unstructured":"Reschke R,Enk AH,Hassel JC. Adiponectin to the rescue: extracorporeal photopheresis for managing immune checkpoint inhibitor-induced toxicities. Sig Transduct Target Ther. 2025;10:110. DOI: 10.1038\/s41392-025-02205-y"},{"key":"i2590-017X-9-4-153-b143","series-title":"Guide of China Medicine","first-page":"1","article-title":"The effect of Babao Dan on immune checkpoint inhibitors related colitis in mice","volume":"23","author":"Shu","year":"2025","unstructured":"Shu L,Jinhong L,Peizhi J,Yun L,Jiumao L. The effect of Babao Dan on immune checkpoint inhibitors related colitis in mice. Guide of China Medicine. 2025;23:1\u20135. DOI: 10.15912\/j.issn.1671-8194.2025.12.001"},{"key":"i2590-017X-9-4-153-b144","series-title":"Nat Commun","first-page":"6719","article-title":"Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and is dependent on an IL23\/IFN\u03b3 axis","volume":"14","author":"Lo","year":"2023","unstructured":"Lo JW,Cozzetto D,Alexander JL, et al. Immune checkpoint inhibitor-induced colitis is mediated by polyfunctional lymphocytes and is dependent on an IL23\/IFN\u03b3 axis. Nat Commun. 2023;14:6719. DOI: 10.1038\/s41467-023-41798-2"},{"key":"i2590-017X-9-4-153-b145","series-title":"Ann Oncol","first-page":"2012","article-title":"Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab","volume":"30","author":"Chaput","year":"2019","unstructured":"Chaput N,Lepage P,Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab. Ann Oncol. 2019;30:2012. DOI: 10.1093\/annonc\/mdz224"},{"key":"i2590-017X-9-4-153-b146","series-title":"Nat Commun","first-page":"10391","article-title":"Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis","volume":"7","author":"Dubin","year":"2016","unstructured":"Dubin K,Callahan MK,Ren B, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint-blockade-induced colitis. Nat Commun. 2016;7:10391. DOI: 10.1038\/ncomms10391"},{"key":"i2590-017X-9-4-153-b147","series-title":"Sci Transl Med","first-page":"eabq4006","article-title":"Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis","volume":"15","author":"Halsey","year":"2023","unstructured":"Halsey TM,Thomas AS,Hayase T, et al. Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor-induced colitis. Sci Transl Med. 2023;15:eabq4006. DOI: 10.1126\/scitranslmed.abq4006"},{"key":"i2590-017X-9-4-153-b148","series-title":"J Immunother Cancer","first-page":"e011959","article-title":"Single-cell multiomics reveals macrophage-derived IL-23 and CXCL9\/10 drive pathogenic IFNG","volume":"13","author":"Tang","year":"2025","unstructured":"Tang Z,Shi J,Xu S, et al. Single-cell multiomics reveals macrophage-derived IL-23 and CXCL9\/10 drive pathogenic IFNG. J Immunother Cancer. 2025;13:e011959. DOI: 10.1136\/jitc-2025-011959"},{"key":"i2590-017X-9-4-153-b149","series-title":"J Immunother Cancer","first-page":"e009345","article-title":"Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy","volume":"12","author":"Ju","year":"2024","unstructured":"Ju M,Zhang J,Deng Z, et al. Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy. J Immunother Cancer. 2024;12:e009345. DOI: 10.1136\/jitc-2024-009345"},{"key":"i2590-017X-9-4-153-b150","series-title":"N Engl J Med","first-page":"213","article-title":"Risankizumab versus ustekinumab for moderate-to-severe Crohn's disease","volume":"391","author":"Peyrin-Biroulet","year":"2024","unstructured":"Peyrin-Biroulet L,Chapman JC,Colombel J-F, et al. Risankizumab versus ustekinumab for moderate-to-severe Crohn's disease. N Engl J Med. 2024;391:213\u2013223. DOI: 10.1056\/NEJMoa2314585"},{"key":"i2590-017X-9-4-153-b151","series-title":"JHEP Rep","first-page":"100719","article-title":"Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort","volume":"5","author":"Hountondji","year":"2023","unstructured":"Hountondji L,Ferreira De Matos C,Leboss\u00e9 F, et al. Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort. JHEP Rep. 2023;5:100719. DOI: 10.1016\/j.jhepr.2023.100719"},{"key":"i2590-017X-9-4-153-b152","series-title":"JHEP Rep","first-page":"100851","article-title":"Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: a 10-year real-world retrospective cohort study","volume":"5","author":"Atallah","year":"2023","unstructured":"Atallah E,Welsh SJ,O\u2019Carrigan B, et al. Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: a 10-year real-world retrospective cohort study. JHEP Rep. 2023;5:100851. DOI: 10.1016\/j.jhepr.2023.100851"},{"key":"i2590-017X-9-4-153-b153","series-title":"Hepatology","first-page":"315","article-title":"Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation","volume":"72","author":"Peeraphatdit","year":"2020","unstructured":"Peeraphatdit TB,Wang J,Odenwald MA, et al. Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation. Hepatology. 2020;72:315\u2013329. DOI: 10.1002\/hep.31227"},{"key":"i2590-017X-9-4-153-b154","series-title":"Liver Int","first-page":"e16198","article-title":"Immune-mediated liver injury from checkpoint inhibitor: an evolving frontier with emerging challenges","volume":"45","author":"Dara","year":"2025","unstructured":"Dara L,Martin DE. Immune-mediated liver injury from checkpoint inhibitor: an evolving frontier with emerging challenges. Liver Int. 2025;45:e16198. DOI: 10.1111\/liv.16198"},{"key":"i2590-017X-9-4-153-b155","series-title":"Cancers (Basel)","first-page":"795","article-title":"The ABC of immune-mediated hepatitis during immunotherapy in patients with cancer: from pathogenesis to multidisciplinary management","volume":"16","author":"Lasagna","year":"2024","unstructured":"Lasagna A,Sacchi P. The ABC of immune-mediated hepatitis during immunotherapy in patients with cancer: from pathogenesis to multidisciplinary management. Cancers (Basel). 2024;16:795. DOI: 10.3390\/cancers16040795"},{"key":"i2590-017X-9-4-153-b156","series-title":"Melanoma Res","first-page":"47","article-title":"Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma","volume":"23","author":"Bernardo","year":"2013","unstructured":"Bernardo SG,Moskalenko M,Pan M, et al. Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma. Melanoma Res. 2013;23:47\u201354. DOI: 10.1097\/CMR.0b013e32835c7e68"},{"key":"i2590-017X-9-4-153-b157","series-title":"J Clin Oncol","first-page":"1020","article-title":"Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab","volume":"32","author":"Topalian","year":"2014","unstructured":"Topalian SL,Sznol M,McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020\u20131030. DOI: 10.1200\/JCO.2013.53.0105"},{"key":"i2590-017X-9-4-153-b158","series-title":"N Engl J Med","first-page":"23","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","unstructured":"Larkin J,Chiarion-Sileni V,Gonzalez R, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:23\u201334. DOI: 10.1056\/NEJMoa1504030"},{"key":"i2590-017X-9-4-153-b159","series-title":"Am J Gastroenterol","first-page":"251","article-title":"Clinical characteristics and adverse impact of hepatotoxicity due to immune checkpoint inhibitors","volume":"115","author":"Miller","year":"2020","unstructured":"Miller ED,Abu-Sbeih H,Styskel B, et al. Clinical characteristics and adverse impact of hepatotoxicity due to immune checkpoint inhibitors. Am J Gastroenterol. 2020;115:251\u2013261. DOI: 10.14309\/ajg.0000000000000398"},{"key":"i2590-017X-9-4-153-b160","series-title":"J Hepatol","first-page":"1403","article-title":"IL-6 pathway in the liver: from physiopathology to therapy","volume":"64","author":"Schmidt-Arras","year":"2016","unstructured":"Schmidt-Arras D,Rose-John S. IL-6 pathway in the liver: from physiopathology to therapy. J Hepatol. 2016;64:1403\u20131415. DOI: 10.1016\/j.jhep.2016.02.004"},{"key":"i2590-017X-9-4-153-b161","series-title":"J Immunol Res","first-page":"9437043","article-title":"Autoimmune hepatitis-immunologically triggered liver pathogenesis-diagnostic and therapeutic strategies","author":"Sucher","year":"2019","unstructured":"Sucher E,Sucher R,Gradistanac T, et al. Autoimmune hepatitis-immunologically triggered liver pathogenesis-diagnostic and therapeutic strategies. J Immunol Res. 2019:9437043. DOI: 10.1155\/2019\/943704331886312"},{"key":"i2590-017X-9-4-153-b162","series-title":"Front Immunol","first-page":"334","article-title":"Clinical potential of regulatory T cell therapy in liver diseases: an overview and current perspectives","volume":"7","author":"Jeffery","year":"2016","unstructured":"Jeffery HC,Braitch MK,Brown S,Oo YH. Clinical potential of regulatory T cell therapy in liver diseases: an overview and current perspectives. Front Immunol. 2016;7:334. DOI: 10.3389\/fimmu.2016.00334"},{"key":"i2590-017X-9-4-153-b163","series-title":"J Hepatol","first-page":"1181","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","unstructured":"De Martin E,Michot J-M,Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 2018;68:1181\u20131190. DOI: 10.1016\/j.jhep.2018.01.033"},{"key":"i2590-017X-9-4-153-b164","series-title":"WJH","first-page":"1269","article-title":"Checkpoint inhibitor-induced hepatotoxicity: role of liver biopsy and management approach","volume":"14","author":"Bessone","year":"2022","unstructured":"Bessone F,Bjornsson ES. Checkpoint inhibitor-induced hepatotoxicity: role of liver biopsy and management approach. WJH. 2022;14:1269\u20131276. DOI: 10.4254\/wjh.v14.i7.1269"},{"key":"i2590-017X-9-4-153-b165","series-title":"Am J Surg Pathol","first-page":"1075","article-title":"Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases","volume":"39","author":"Johncilla","year":"2015","unstructured":"Johncilla M,Misdraji J,Pratt DS, et al. Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases. Am J Surg Pathol. 2015;39:1075\u20131084. DOI: 10.1097\/PAS.0000000000000453"},{"key":"i2590-017X-9-4-153-b166","series-title":"Dig Dis Sci","first-page":"2233","article-title":"Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma","volume":"57","author":"Kleiner","year":"2012","unstructured":"Kleiner DE,Berman D. Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma. Dig Dis Sci. 2012;57:2233\u20132240. DOI: 10.1007\/s10620-012-2140-5"},{"key":"i2590-017X-9-4-153-b167","series-title":"Mod Pathol","first-page":"965","article-title":"Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury","volume":"31","author":"Zen","year":"2018","unstructured":"Zen Y,Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol. 2018;31:965\u2013973. DOI: 10.1038\/s41379-018-0013-y"},{"key":"i2590-017X-9-4-153-b168","series-title":"ESMO Open","first-page":"e000268","article-title":"Severe steroid-resistant anti-PD1 T cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury","volume":"2","author":"Doherty","year":"2017","unstructured":"Doherty GJ,Duckworth AM,Davies SE, et al. Severe steroid-resistant anti-PD1 T cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. ESMO Open. 2017;2:e000268. DOI: 10.1136\/esmoopen-2017-000268"},{"key":"i2590-017X-9-4-153-b169","series-title":"JGLD","first-page":"171","article-title":"Hepatic sinusoidal obstruction syndrome associated with nivolumab: an uncommon adverse event related to immune checkpoint inhibitors","volume":"30","author":"Riveiro-Barciela","year":"2021","unstructured":"Riveiro-Barciela M,Gonz\u00e1lez-Sans D,Marmolejo D,Salcedo M-T,Mu\u00f1oz-Couselo E. Hepatic sinusoidal obstruction syndrome associated with nivolumab: an uncommon adverse event related to immune checkpoint inhibitors. JGLD. 2021;30:171\u2013172. DOI: 10.15403\/jgld-3207"},{"key":"i2590-017X-9-4-153-b170","series-title":"J Immunotherapy Cancer","first-page":"118","article-title":"Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment","volume":"7","author":"Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih H,Tran CN,Ge PS, et al. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment. J Immunotherapy Cancer. 2019;7:118. DOI: 10.1186\/s40425-019-0604-2"},{"key":"i2590-017X-9-4-153-b171","series-title":"Can J Urol","first-page":"10339","article-title":"Vanishing bile duct syndrome associated with pazopanib after progression on pembrolizumab","volume":"27","author":"Zhong","year":"2020","unstructured":"Zhong YY,McLean L,Buckle A,Siva S,Tran B. Vanishing bile duct syndrome associated with pazopanib after progression on pembrolizumab. Can J Urol. 2020;27:10339\u201310341."},{"key":"i2590-017X-9-4-153-b172","series-title":"J Clin Oncol","first-page":"1714","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","unstructured":"Brahmer JR,Lacchetti C,Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36:1714\u20131768. DOI: 10.1200\/JCO.2017.77.6385"},{"key":"i2590-017X-9-4-153-b173","series-title":"SITC's Guide to Managing Immunotherapy Toxicity","author":"Ernstoff","year":"2019","unstructured":"Ernstoff MS,Puzanov I,Robert C,Diab A,Hersey P. SITC's Guide to Managing Immunotherapy Toxicity. Springer Publishing Company, 2019."},{"key":"i2590-017X-9-4-153-b174","series-title":"J Natl Compr Canc Netw","first-page":"387","article-title":"Management of immunotherapy-related toxicities, version 1.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Thompson","year":"2022","unstructured":"Thompson JA,Schneider BJ,Brahmer J, et al. Management of immunotherapy-related toxicities, version 1.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022;20:387\u2013405. DOI: 10.6004\/jnccn.2022.0020"},{"key":"i2590-017X-9-4-153-b175","series-title":"Hepatology","first-page":"2193","article-title":"Diagnosis and management of autoimmune hepatitis","volume":"51","author":"Manns","year":"2010","unstructured":"Manns MP,Czaja AJ,Gorham JD, et al. Diagnosis and management of autoimmune hepatitis. Hepatology. 2010;51:2193\u20132213. DOI: 10.1002\/hep.23584"},{"key":"i2590-017X-9-4-153-b176","series-title":"J Natl Compr Canc Netw","first-page":"230","article-title":"NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020","volume":"18","author":"Thompson","year":"2020","unstructured":"Thompson JA,Schneider BJ,Brahmer J, et al. NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020. J Natl Compr Canc Netw. 2020;18:230\u2013241. DOI: 10.6004\/jnccn.2020.0012"},{"key":"i2590-017X-9-4-153-b177","series-title":"JAMA Oncol","first-page":"1711","article-title":"Utility of liver biopsy in diagnosis and management of high-grade immune checkpoint inhibitor hepatitis in patients with cancer","volume":"7","author":"Li","year":"2021","unstructured":"Li M,Sack JS,Bell P, et al. Utility of liver biopsy in diagnosis and management of high-grade immune checkpoint inhibitor hepatitis in patients with cancer. JAMA Oncol. 2021;7:1711. DOI: 10.1001\/jamaoncol.2021.4342"},{"key":"i2590-017X-9-4-153-b178","article-title":"Predicting steroid-refractory immune checkpoint inhibitor hepatitis: development and external validation of the novel sunlit model and identifying a cutoff for biochemical nonresponse after steroid treatment","author":"Li","year":"2023","unstructured":"Li M,Sack JS,Vogel AS, et al.. Predicting steroid-refractory immune checkpoint inhibitor hepatitis: development and external validation of the novel sunlit model and identifying a cutoff for biochemical nonresponse after steroid treatment. Presented at AASLD: The Liver Meeting 2023, Nov 2023."},{"key":"i2590-017X-9-4-153-b179","series-title":"(Abstract 0115) American Association for the Study of Liver Diseases: 2020","article-title":"Predictors and outcomes of steroid-refractory immune checkpoint inhibitor hepatitis","author":"Li","year":"Feb 18, 2021","unstructured":"Li M,Sack J,Rahma OE,Grover S,Zucker SD. Predictors and outcomes of steroid-refractory immune checkpoint inhibitor hepatitis. (Abstract 0115) American Association for the Study of Liver Diseases: 2020. Feb 18, 2021."},{"key":"i2590-017X-9-4-153-b180","series-title":"J Natl Compr Canc Netw","first-page":"617","article-title":"Early liver specialist consultation is associated with faster biochemical resolution of severe immune checkpoint inhibitor-induced hepatitis","volume":"21","author":"Li","year":"2023","unstructured":"Li M,Wong D,Sack JS, et al. Early liver specialist consultation is associated with faster biochemical resolution of severe immune checkpoint inhibitor-induced hepatitis. J Natl Compr Canc Netw. 2023;21:617\u2013626 e3. DOI: 10.6004\/jnccn.2023.7013"},{"key":"i2590-017X-9-4-153-b181","series-title":"Eur J Intern Med","first-page":"87","article-title":"Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series","volume":"93","author":"Campochiaro","year":"2021","unstructured":"Campochiaro C,Farina N,Tomelleri A, et al. Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series. Eur J Intern Med. 2021;93:87\u201394. DOI: 10.1016\/j.ejim.2021.07.016"},{"key":"i2590-017X-9-4-153-b182","series-title":"J Immunother Cancer","first-page":"e006814","article-title":"Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events","volume":"11","author":"Fa'ak","year":"2023","unstructured":"Fa'ak F,Buni M,Falohun A, et al. Selective immune suppression using interleukin-6 receptor inhibitors for management of immune-related adverse events. J Immunother Cancer. 2023;11:e006814. DOI: 10.1136\/jitc-2023-006814"},{"key":"i2590-017X-9-4-153-b183","series-title":"J Clin Oncol","first-page":"TPS9589","article-title":"Ipilimumab, nivolumab and tocilizumab as first-line therapy for advanced melanoma","volume":"39","author":"Mehmi","year":"2021","unstructured":"Mehmi I,Hamid O,Hodi FS, et al. Ipilimumab, nivolumab and tocilizumab as first-line therapy for advanced melanoma. J Clin Oncol. 2021;39:TPS9589. DOI: 10.1200\/JCO.2021.39.15_suppl.TPS9589"},{"key":"i2590-017X-9-4-153-b184","series-title":"J Thorac Oncol","first-page":"318","article-title":"Personalized cytokine-directed therapy with tocilizumab for refractory immune checkpoint inhibitor-related cholangiohepatitis","volume":"16","author":"Moi","year":"2021","unstructured":"Moi L,Bouchaab H,Mederos N, et al. Personalized cytokine-directed therapy with tocilizumab for refractory immune checkpoint inhibitor-related cholangiohepatitis. J Thorac Oncol. 2021;16:318\u2013326. DOI: 10.1016\/j.jtho.2020.09.00732956849"},{"key":"i2590-017X-9-4-153-b185","series-title":"Melanoma Res","first-page":"335","article-title":"Tocilizumab in the treatment of steroid refractory immune-related hepatotoxicity: a case series and review of the literature","volume":"34","author":"Ozluk","year":"2024","unstructured":"Ozluk AA,Gunenc D,Yildirim SS,Karaca B. Tocilizumab in the treatment of steroid refractory immune-related hepatotoxicity: a case series and review of the literature. Melanoma Res. 2024;34:335\u2013342. DOI: 10.1097\/CMR.0000000000000969"},{"key":"i2590-017X-9-4-153-b186","series-title":"Immunotherapy","first-page":"1527","article-title":"Nivolumab-induced large-duct cholangiopathy treated with ursodeoxycholic acid and tocilizumab","volume":"11","author":"Reddy","year":"2019","unstructured":"Reddy CA,Schneider BJ,Brackett LM,Tai AW. Nivolumab-induced large-duct cholangiopathy treated with ursodeoxycholic acid and tocilizumab. Immunotherapy. 2019;11:1527\u20131531. DOI: 10.2217\/imt-2019-0121"},{"key":"i2590-017X-9-4-153-b187","series-title":"J Immunother Cancer","first-page":"e002855","article-title":"Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report","volume":"9","author":"Sackstein","year":"2021","unstructured":"Sackstein P,Zaemes J,Kim C. Pembrolizumab-induced cytokine release syndrome in a patient with metastatic lung adenocarcinoma: a case report. J Immunother Cancer. 2021;9:e002855. DOI: 10.1136\/jitc-2021-002855"},{"key":"i2590-017X-9-4-153-b188","series-title":"J Oncol Pharm Pract","first-page":"551","article-title":"Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade","volume":"25","author":"Stroud","year":"2019","unstructured":"Stroud CRG,Hegde A,Cherry C, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract. 2019;25:551\u2013557. DOI: 10.1177\/1078155217745144"},{"key":"i2590-017X-9-4-153-b189","series-title":"J Clin Oncol","first-page":"e21712","article-title":"Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade","volume":"35","author":"Stroud","year":"2017","unstructured":"Stroud CRG,Cherry CR,Naqash AR, et al. Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Clin Oncol. 2017;35:e21712. DOI: 10.1200\/JCO.2017.35.15_suppl.e21712"},{"key":"i2590-017X-9-4-153-b190","series-title":"AASLD: The Liver Meeting 2021","article-title":"Tocilizumab as an alternative treatment strategy for immunotherapy-mediated hepatobiliary toxicity: addressing an urgent unmet need","author":"Zhang","year":"Nov 2021","unstructured":"Zhang HC,Eyada M,Miller E,Wang L. Tocilizumab as an alternative treatment strategy for immunotherapy-mediated hepatobiliary toxicity: addressing an urgent unmet need. AASLD: The Liver Meeting 2021. Nov 2021."},{"key":"i2590-017X-9-4-153-b191","series-title":"ACG 2021 Annual Scientific Meeting Abstracts","article-title":"Clinical presentation, treatment strategies, and chronic sequelae of immune checkpoint inhibitor-mediated cholangiopathy: a case study [abstract ID: 1073348]","author":"Zhang","year":"Oct 25, 2021","unstructured":"Zhang HC,Eyada M,Taggart M, et al. Clinical presentation, treatment strategies, and chronic sequelae of immune checkpoint inhibitor-mediated cholangiopathy: a case study [abstract ID: 1073348]. ACG 2021 Annual Scientific Meeting Abstracts. American College of Gastroenterology, Las Vegas, Nevada, Oct 25, 2021."},{"key":"i2590-017X-9-4-153-b192","series-title":"ACG 2021 Annual Scientific Meeting Abstracts","article-title":"Extrahepatic biliary sequelae in immune checkpoint inhibitor-mediated cholangiohepatitis: urgent unmet need for early effective treatment (P1868) [abstract ID: 1073546]","author":"Zhang","year":"Oct 25, 2021","unstructured":"Zhang HC,Taggart M,Miller E,Fossella F,Wang L. Extrahepatic biliary sequelae in immune checkpoint inhibitor-mediated cholangiohepatitis: urgent unmet need for early effective treatment (P1868) [abstract ID: 1073546]. ACG 2021 Annual Scientific Meeting Abstracts. American College of Gastroenterology, Las Vegas, Nevada, Oct 25, 2021."},{"key":"i2590-017X-9-4-153-b193","series-title":"ACG Case Rep J","first-page":"e01162","article-title":"A potential new use for tocilizumab: refractory checkpoint inhibitor hepatitis","volume":"10","author":"Lyles","year":"2023","unstructured":"Lyles L,Farmer R,Abougergi M. A potential new use for tocilizumab: refractory checkpoint inhibitor hepatitis. ACG Case Rep J. 2023;10:e01162. DOI: 10.14309\/crj.0000000000001162"},{"key":"i2590-017X-9-4-153-b194","series-title":"J Clin Oncol","first-page":"e237","article-title":"Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy","volume":"29","author":"Chmiel","year":"2011","unstructured":"Chmiel KD,Suan D,Liddle C, et al. Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy. J Clin Oncol. 2011;29:e237\u2013e240. DOI: 10.1200\/JCO.2010.32.2206"},{"key":"i2590-017X-9-4-153-b195","series-title":"BMJ Case Rep","first-page":"bcr2014208102","article-title":"Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy","volume":"2015","author":"Ahmed","year":"2015","unstructured":"Ahmed T,Pandey R,Shah B,Black J. Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy. BMJ Case Rep. 2015;2015:bcr2014208102. DOI: 10.1136\/bcr-2014-208102"},{"key":"i2590-017X-9-4-153-b196","series-title":"Cancer Immunol Immunother","first-page":"563","article-title":"Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report","volume":"67","author":"McGuire","year":"2018","unstructured":"McGuire HM,Shklovskaya E,Edwards J, et al. Anti-PD-1-induced high-grade hepatitis associated with corticosteroid-resistant T cells: a case report. Cancer Immunol Immunother. 2018;67:563\u2013573. DOI: 10.1007\/s00262-017-2107-7"},{"key":"i2590-017X-9-4-153-b197","series-title":"Hepatology","first-page":"2235","article-title":"Severe refractory checkpoint inhibitor-related hepatitis reversed with anti-thymocyte globulin and N-acetylcysteine","volume":"72","author":"Motomura","year":"2020","unstructured":"Motomura D,Baetz T,Grin A,Flemming JA. Severe refractory checkpoint inhibitor-related hepatitis reversed with anti-thymocyte globulin and N-acetylcysteine. Hepatology. 2020;72:2235\u20132238. DOI: 10.1002\/hep.3139632484945"},{"key":"i2590-017X-9-4-153-b198","series-title":"Eur J Cancer","first-page":"203","article-title":"Severe hepatitis under combined immunotherapy: resolution under corticosteroids plus anti-thymocyte immunoglobulins","volume":"81","author":"Spankuch","year":"2017","unstructured":"Spankuch I,Gassenmaier M,Tampouri I, et al. Severe hepatitis under combined immunotherapy: resolution under corticosteroids plus anti-thymocyte immunoglobulins. Eur J Cancer. 2017;81:203\u2013205. DOI: 10.1016\/j.ejca.2017.05.018"},{"key":"i2590-017X-9-4-153-b199","series-title":"Eur J Cancer","first-page":"221","article-title":"Corrigendum to \u201csevere hepatitis under combined immunotherapy: resolution under corticosteroids plus anti-thymocyte immunoglobulins\u201d [Eur J Cancer 81 (August 2017) 203\u2013205]","volume":"87","author":"Spankuch","year":"2017","unstructured":"Spankuch I,Gassenmaier M,Tampouri I, et al. Corrigendum to \u201csevere hepatitis under combined immunotherapy: resolution under corticosteroids plus anti-thymocyte immunoglobulins\u201d [Eur J Cancer 81 (August 2017) 203\u2013205]. Eur J Cancer. 2017;87:221. DOI: 10.1016\/j.ejca.2017.09.01228986136"},{"key":"i2590-017X-9-4-153-b200","series-title":"J Hepatol","first-page":"564","article-title":"Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: new settings call for new treatment strategies","volume":"70","author":"Riveiro-Barciela","year":"2019","unstructured":"Riveiro-Barciela M,Munoz-Couselo E,Fernandez-Sojo J, et al. Acute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: new settings call for new treatment strategies? J Hepatol. 2019;70:564\u2013566. DOI: 10.1016\/j.jhep.2018.10.020"},{"key":"i2590-017X-9-4-153-b201","series-title":"J Hepatol","first-page":"566","article-title":"Reply to: \u201cacute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: new settings call for new treatment strategies","volume":"70","author":"De Martin","year":"2019","unstructured":"De Martin E,Michot J-M,Papouin B, et al. Reply to: \u201cacute liver failure due to immune-mediated hepatitis successfully managed with plasma exchange: new settings call for new treatment strategies? J Hepatol. 2019;70:566\u2013567. DOI: 10.1016\/j.jhep.2018.11.016"},{"key":"i2590-017X-9-4-153-b202","series-title":"Case Reports Hepatol","first-page":"5908411","article-title":"Plasmapheresis for pembrolizumab-induced hepatitis in a patient with squamous cell carcinoma and prior orthotopic liver transplantation","volume":"2022","author":"Al-Nattah","year":"2022","unstructured":"Al-Nattah S,Lata Sharma K,Caldis M, et al. Plasmapheresis for pembrolizumab-induced hepatitis in a patient with squamous cell carcinoma and prior orthotopic liver transplantation. Case Reports Hepatol. 2022;2022:5908411. DOI: 10.1155\/2022\/5908411"},{"key":"i2590-017X-9-4-153-b203","series-title":"Am J Gastroenterol","first-page":"S2481","article-title":"S3887 recognition of delayed-onset immune checkpoint inhibitor-mediated hepatotoxicity treated with budesonide: a case study factoring in pharmacokinetics of immunotherapies","volume":"118","author":"Chopra","year":"2023","unstructured":"Chopra M,Zhang HC. S3887 recognition of delayed-onset immune checkpoint inhibitor-mediated hepatotoxicity treated with budesonide: a case study factoring in pharmacokinetics of immunotherapies. Am J Gastroenterol. 2023;118:S2481\u2013S2482. DOI: 10.14309\/01.ajg.0000965188.32051.39"},{"key":"i2590-017X-9-4-153-b204","series-title":"J Immunotherapy Cancer","first-page":"165","article-title":"Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance","volume":"7","author":"Couey","year":"2019","unstructured":"Couey MA,Bell RB,Patel AA, et al. Delayed immune-related events (DIRE) after discontinuation of immunotherapy: diagnostic hazard of autoimmunity at a distance. J Immunotherapy Cancer. 2019;7:165. DOI: 10.1186\/s40425-019-0645-6"},{"key":"i2590-017X-9-4-153-b205","series-title":"Frontline Gastroenterol","first-page":"364","article-title":"Immunotherapy-related hepatitis: real-world experience from a tertiary Centre","volume":"10","author":"Cheung","year":"2019","unstructured":"Cheung V,Gupta T,Payne M, et al. Immunotherapy-related hepatitis: real-world experience from a tertiary Centre. Frontline Gastroenterol. 2019;10:364\u2013371. DOI: 10.1136\/flgastro-2018-101146"},{"key":"i2590-017X-9-4-153-b206","series-title":"Aliment Pharmacol Ther","first-page":"865","article-title":"An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor-induced liver injury","volume":"59","author":"Riveiro\u2010Barciela","year":"2024","unstructured":"Riveiro\u2010Barciela M,Barreira\u2010D\u00edaz A,Salcedo M, et al. An algorithm based on immunotherapy discontinuation and liver biopsy spares corticosteroids in two thirds of cases of severe checkpoint inhibitor-induced liver injury. Aliment Pharmacol Ther. 2024;59:865\u2013876. DOI: 10.1111\/apt.17898"},{"key":"i2590-017X-9-4-153-b207","series-title":"Digestive Disease Week","article-title":"Moderate dose steroid treatment for immune checkpoint inhibitor-mediated hepatotoxicity (Su327)","author":"Wang","year":"May 23, 2021","unstructured":"Wang LS,Miller ED,Zhang HC. Moderate dose steroid treatment for immune checkpoint inhibitor-mediated hepatotoxicity (Su327). Digestive Disease Week. May 23, 2021."},{"key":"i2590-017X-9-4-153-b208","series-title":"Hepatology","first-page":"508","article-title":"Corticosteroids for high-grade immune checkpoint inhibitor-mediated hepatitis: Is less more","volume":"75","author":"Pan","year":"2022","unstructured":"Pan JJ,Razumilava N. Corticosteroids for high-grade immune checkpoint inhibitor-mediated hepatitis: Is less more? Hepatology. 2022;75:508\u2013510. DOI: 10.1002\/hep.32330"},{"key":"i2590-017X-9-4-153-b209","series-title":"J Hepatol","first-page":"548","article-title":"Immune-related hepatitis with immunotherapy: Are corticosteroids always needed","volume":"69","author":"Gauci","year":"2018","unstructured":"Gauci M-L,Baroudjian B,Zeboulon C, et al. Immune-related hepatitis with immunotherapy: Are corticosteroids always needed? J Hepatol. 2018;69:548\u2013550. DOI: 10.1016\/j.jhep.2018.03.034"},{"key":"i2590-017X-9-4-153-b210","series-title":"Oncoimmunology","first-page":"1875639","article-title":"A multicenter characterization of hepatitis associated with immune checkpoint inhibitors","volume":"10","author":"Patrinely","year":"2021","unstructured":"Patrinely JR Jr,McGuigan B,Chandra S, et al. A multicenter characterization of hepatitis associated with immune checkpoint inhibitors. Oncoimmunology. 2021;10:1875639. DOI: 10.1080\/2162402X.2021.1875639"},{"key":"i2590-017X-9-4-153-b211","series-title":"Hepatology","first-page":"671","article-title":"Diagnosis and management of autoimmune hepatitis in adults and children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases","volume":"72","author":"Mack","year":"2020","unstructured":"Mack CL,Adams D,Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 Practice Guidance and Guidelines From the American Association for the Study of Liver Diseases. Hepatology. 2020;72:671\u2013722. DOI: 10.1002\/hep.31065"},{"key":"i2590-017X-9-4-153-b212","series-title":"Gastroenterology","first-page":"1198","article-title":"Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis","volume":"139","author":"Manns","year":"2010","unstructured":"Manns MP,Woynarowski M,Kreisel W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis. Gastroenterology. 2010;139:1198\u20131206. DOI: 10.1053\/j.gastro.2010.06.046"},{"key":"i2590-017X-9-4-153-b213","series-title":"J Hepatol","first-page":"657","article-title":"Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids","volume":"66","author":"Ziemer","year":"2017","unstructured":"Ziemer M,Koukoulioti E,Beyer S,Simon JC,Berg T. Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. J Hepatol. 2017;66:657\u2013659. DOI: 10.1016\/j.jhep.2016.11.015"},{"key":"i2590-017X-9-4-153-b214","series-title":"J Clin Oncol","first-page":"3073","article-title":"Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids","volume":"35","author":"Ziemer","year":"2017","unstructured":"Ziemer M,Koukoulioti E,Simon J-C,Berg T. Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids. J Clin Oncol. 2017;35:3073. DOI: 10.1200\/JCO.2017.35.15_suppl.3073"},{"key":"i2590-017X-9-4-153-b215","series-title":"Am J Gastroenterol","first-page":"S1139","article-title":"S2722 budesonide as an alternative steroid agent, in combination with adjunctive agents, for the treatment of immune checkpoint inhibitor-mediated cholangiohepatitis: a case study","volume":"116","author":"Zhang","year":"2021","unstructured":"Zhang HC,Wang L,Wang Y,Miller E. S2722 budesonide as an alternative steroid agent, in combination with adjunctive agents, for the treatment of immune checkpoint inhibitor-mediated cholangiohepatitis: a case study. Am J Gastroenterol. 2021;116:S1139. DOI: 10.14309\/01.ajg.0000784420.59476.c6"},{"key":"i2590-017X-9-4-153-b216","series-title":"Am J Gastroenterol","first-page":"S2919","article-title":"S4601 a case of successful treatment of high-grade immune-mediated hepatobiliary toxicity with oral budesonide: shifting the paradigm away from systemic steroids","volume":"119","author":"Zhang","year":"2024","unstructured":"Zhang HC,Miller E,Wang L. S4601 a case of successful treatment of high-grade immune-mediated hepatobiliary toxicity with oral budesonide: shifting the paradigm away from systemic steroids. Am J Gastroenterol. 2024;119:S2919\u2013S2920. DOI: 10.14309\/01.ajg.0001047772.57280.7d"},{"key":"i2590-017X-9-4-153-b217","series-title":"Oncologist","first-page":"oyae361","article-title":"Steroid-refractory immune mediated hepatitis managed with budesonide in patients with metastatic melanoma: proof of concept and literature review","volume":"30","author":"Kankaria","year":"2025","unstructured":"Kankaria RA,Johnson DB. Steroid-refractory immune mediated hepatitis managed with budesonide in patients with metastatic melanoma: proof of concept and literature review. Oncologist. 2025;30:oyae361. DOI: 10.1093\/oncolo\/oyae361"},{"key":"i2590-017X-9-4-153-b218","series-title":"Medicine (Baltimore)","first-page":"e29473","article-title":"Immune-checkpoint inhibitor-associated grade 3 hepatotoxicity managed with enteric-coated budesonide monotherapy: a case report","volume":"101","author":"Eleftheriotis","year":"2022","unstructured":"Eleftheriotis G,Skopelitis E. Immune-checkpoint inhibitor-associated grade 3 hepatotoxicity managed with enteric-coated budesonide monotherapy: a case report. Medicine (Baltimore). 2022;101:e29473. DOI: 10.1097\/MD.0000000000029473"},{"key":"i2590-017X-9-4-153-b219","series-title":"Gastroenterology","article-title":"Oral budesonide as an effective alternative treatment of immune-mediated hepatobiliary toxicities associated with immune checkpoint inhibitors: a case series","volume":"169","author":"Pizuorno Machado","year":"2025","unstructured":"Pizuorno Machado A,Caskey KN,Shaikh AS, et al. Oral budesonide as an effective alternative treatment of immune-mediated hepatobiliary toxicities associated with immune checkpoint inhibitors: a case series. Gastroenterology. 2025;169."},{"key":"i2590-017X-9-4-153-b220","series-title":"World J Gastroenterol","first-page":"353","article-title":"Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review","volume":"26","author":"Onoyama","year":"2020","unstructured":"Onoyama T,Takeda Y,Yamashita T, et al. Programmed cell death-1 inhibitor-related sclerosing cholangitis: a systematic review. World J Gastroenterol. 2020;26:353\u2013365. DOI: 10.3748\/wjg.v26.i3.353"},{"key":"i2590-017X-9-4-153-b221","series-title":"Endoscopy","first-page":"E402","article-title":"Peroral cholangioscopy of programmed cell death-1 inhibitor-related sclerosing cholangitis: three case reports","volume":"51","author":"Onoyama","year":"2019","unstructured":"Onoyama T,Takeda Y,Kato M, et al. Peroral cholangioscopy of programmed cell death-1 inhibitor-related sclerosing cholangitis: three case reports. Endoscopy. 2019;51:E402\u2013E403. DOI: 10.1055\/a-0948-1271"},{"issue":"Suppl 1","key":"i2590-017X-9-4-153-b222","series-title":"Eur J Gastroenterol Hepatol","first-page":"e858","article-title":"Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management","volume":"33(","author":"Pi","year":"2021","unstructured":"Pi B,Wang J,Tong Y, et al. Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management. Eur J Gastroenterol Hepatol. 2021;33(Suppl 1):e858\u2013e867. DOI: 10.1097\/MEG.0000000000002280"},{"key":"i2590-017X-9-4-153-b223","series-title":"Mol Clin Onc","first-page":"439","article-title":"Nivolumab-induced cholangitis in patients with non-small cell lung cancer: case series and a review of literature","volume":"11","author":"Izumi","year":"2019","unstructured":"Izumi H,Kodani M,Kurai J, et al. Nivolumab-induced cholangitis in patients with non-small cell lung cancer: case series and a review of literature. Mol Clin Onc. 2019;11:439\u2013446. DOI: 10.3892\/mco.2019.1923"},{"key":"i2590-017X-9-4-153-b224","series-title":"Liver Int","first-page":"e70073","article-title":"Ursodeoxycholic acid alone is effective and safe to treat cholestatic checkpoint inhibitor-induced liver injury","volume":"45","author":"Hountondji","year":"2025","unstructured":"Hountondji L,Faure S,Palassin P, et al. Ursodeoxycholic acid alone is effective and safe to treat cholestatic checkpoint inhibitor-induced liver injury. Liver Int. 2025;45:e70073. DOI: 10.1111\/liv.7007340198079"},{"key":"i2590-017X-9-4-153-b225","series-title":"Jpn J Clin Oncol","first-page":"887","article-title":"Immune-related adverse event-associated sclerosing cholangitis due to immune checkpoint inhibitors: imaging findings and treatments","volume":"54","author":"Okamoto","year":"2024","unstructured":"Okamoto K,Hijioka S,Nagashio Y, et al. Immune-related adverse event-associated sclerosing cholangitis due to immune checkpoint inhibitors: imaging findings and treatments. Jpn J Clin Oncol. 2024;54:887\u2013894. DOI: 10.1093\/jjco\/hyae060"},{"key":"i2590-017X-9-4-153-b226","series-title":"Clin Gastroenterol Hepatol","first-page":"1539","article-title":"Tofacitinib is effective in treating refractory immune checkpoint inhibitor hepatitis","volume":"22","author":"Wang","year":"2024","unstructured":"Wang M,Reynolds KL,Montazeri K, et al. Tofacitinib is effective in treating refractory immune checkpoint inhibitor hepatitis. Clin Gastroenterol Hepatol. 2024;22:1539\u20131541e2. DOI: 10.1016\/j.cgh.2023.12.011"},{"key":"i2590-017X-9-4-153-b227","series-title":"J Immunother Cancer","first-page":"e008074","article-title":"Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids","volume":"12","author":"Burri","year":"2024","unstructured":"Burri E,Mangana J,Cheng PF, et al. Infliximab in steroid-refractory immune-related hepatitis does not demonstrate hepatotoxicity and may shorten time on steroids. J Immunother Cancer. 2024;12:e008074. DOI: 10.1136\/jitc-2023-008074"},{"key":"i2590-017X-9-4-153-b228","series-title":"Front Immunol","first-page":"1156746","article-title":"Successful treatment of severe immune checkpoint inhibitor associated autoimmune hepatitis with basiliximab: a case report","volume":"14","author":"Zarrabi","year":"2023","unstructured":"Zarrabi M,Hamilton C,French SW,Federman N,Nowicki TS. Successful treatment of severe immune checkpoint inhibitor associated autoimmune hepatitis with basiliximab: a case report. Front Immunol. 2023;14:1156746. DOI: 10.3389\/fimmu.2023.1156746"},{"key":"i2590-017X-9-4-153-b229","series-title":"Front Immunol","first-page":"1727312","article-title":"Extracorporeal photopheresis as a therapeutic approach for treatment resistant immune-related adverse events in anti-PD-1-treated melanoma patients","volume":"16","author":"Thielmann","year":"2025","unstructured":"Thielmann CM,Seier JA,Schielke L, et al. Extracorporeal photopheresis as a therapeutic approach for treatment resistant immune-related adverse events in anti-PD-1-treated melanoma patients. Front Immunol. 2025;16:1727312. DOI: 10.3389\/fimmu.2025.1727312"},{"key":"i2590-017X-9-4-153-b230","series-title":"Jeadv Clin Pract","first-page":"317","article-title":"Successful treatment of refractory checkpoint inhibitor-induced hepatitis with quadruple therapy including extracorporeal photopheresis and infliximab","volume":"3","author":"Hansen","year":"2024","unstructured":"Hansen I,K\u00f6tt J,Heidenreich S, et al. Successful treatment of refractory checkpoint inhibitor-induced hepatitis with quadruple therapy including extracorporeal photopheresis and infliximab. Jeadv Clin Pract. 2024;3:317\u2013320. DOI: 10.1002\/jvc2.288"},{"key":"i2590-017X-9-4-153-b231","series-title":"Cancer","first-page":"5088","article-title":"Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis","volume":"126","author":"Li","year":"2020","unstructured":"Li M,Sack JS,Rahma OE, et al. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis. Cancer. 2020;126:5088\u20135097. DOI: 10.1002\/cncr.33165"},{"key":"i2590-017X-9-4-153-b232","series-title":"Clin Gastroenterol Hepatol","first-page":"732","article-title":"Retreatment with immune checkpoint inhibitors after a severe immune-related hepatitis: results from a prospective multicenter study","volume":"21","author":"Riveiro-Barciela","year":"2023","unstructured":"Riveiro-Barciela M,Barreira-D\u00edaz A,Callejo-P\u00e9rez A, et al. Retreatment with immune checkpoint inhibitors after a severe immune-related hepatitis: results from a prospective multicenter study. Clin Gastroenterol Hepatol. 2023;21:732\u2013740. DOI: 10.1016\/j.cgh.2022.03.05035487453"},{"key":"i2590-017X-9-4-153-b233","series-title":"Front Pharmacol","first-page":"1426847","article-title":"Immune checkpoint inhibitors-induced pancreatitis: a systematic review and real-world pharmacovigilance analysis","volume":"16","author":"Fang","year":"2025","unstructured":"Fang W,Wang H,Zhang X, et al. Immune checkpoint inhibitors-induced pancreatitis: a systematic review and real-world pharmacovigilance analysis. Front Pharmacol. 2025;16:1426847. DOI: 10.3389\/fphar.2025.1426847"},{"key":"i2590-017X-9-4-153-b234","series-title":"Targ Oncol","first-page":"867","article-title":"Pancreatitis in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"19","author":"Koseki","year":"2024","unstructured":"Koseki M,Nishimura Y,Elias E, et al. Pancreatitis in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis. Targ Oncol. 2024;19:867\u2013877. DOI: 10.1007\/s11523-024-01098-1"},{"key":"i2590-017X-9-4-153-b235","series-title":"Cancers (Basel)","first-page":"1080","article-title":"Immune checkpoint inhibitor-induced pancreatic injury (ICI-PI) in adult cancer patients: a systematic review and meta-analysis","volume":"17","author":"Lee","year":"2025","unstructured":"Lee CL,Riya IJ,Piya IJ, et al. Immune checkpoint inhibitor-induced pancreatic injury (ICI-PI) in adult cancer patients: a systematic review and meta-analysis. Cancers (Basel). 2025;17:1080. DOI: 10.3390\/cancers17071080"},{"key":"i2590-017X-9-4-153-b236","series-title":"Curr Gastroenterol Rep","first-page":"255","article-title":"Immune checkpoint inhibitor-induced (type 3) autoimmune pancreatitis","volume":"25","author":"Shirwaikar Thomas","year":"2023","unstructured":"Shirwaikar Thomas A,Chari ST. Immune checkpoint inhibitor-induced (type 3) autoimmune pancreatitis. Curr Gastroenterol Rep. 2023;25:255\u2013259. DOI: 10.1007\/s11894-023-00885-6"},{"key":"i2590-017X-9-4-153-b237","series-title":"Targ Oncol","first-page":"25","article-title":"Immune checkpoint inhibitor-induced pancreatic injury: imaging findings and literature review","volume":"15","author":"Porcu","year":"2020","unstructured":"Porcu M,Solinas C,Migali C, et al. Immune checkpoint inhibitor-induced pancreatic injury: imaging findings and literature review. Targ Oncol. 2020;15:25\u201335. DOI: 10.1007\/s11523-019-00694-w"},{"key":"i2590-017X-9-4-153-b238","series-title":"J Gastroenterol","first-page":"424","article-title":"Pancreatic injury in patients treated with immune checkpoint inhibitors: a retrospective multicenter study","volume":"59","author":"Nagao","year":"2024","unstructured":"Nagao K,Sakai A,Tsumura H, et al. Pancreatic injury in patients treated with immune checkpoint inhibitors: a retrospective multicenter study. J Gastroenterol. 2024;59:424\u2013433. DOI: 10.1007\/s00535-024-02083-1"},{"key":"i2590-017X-9-4-153-b239","series-title":"Front Immunol","first-page":"1166299","article-title":"Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis","volume":"14","author":"Zhao","year":"2023","unstructured":"Zhao Z,Zhang W,Pang L, et al. Pancreatic adverse events of immune checkpoint inhibitors therapy for solid cancer patients: a systematic review and meta-analysis. Front Immunol. 2023;14:1166299. DOI: 10.3389\/fimmu.2023.1166299"},{"key":"i2590-017X-9-4-153-b240","series-title":"Am J Gastroenterol","first-page":"e3","article-title":"S4 Autoimmune pancreatitis secondary to immune checkpoint inhibitor therapy (type 3 AIP): insights into a new disease from clinical review and serial pancreatic imaging","volume":"117","author":"Thomas","year":"2022","unstructured":"Thomas AS,Abreo M,Ahmed AS, et al. S4 Autoimmune pancreatitis secondary to immune checkpoint inhibitor therapy (type 3 AIP): insights into a new disease from clinical review and serial pancreatic imaging. Am J Gastroenterol. 2022;117:e3\u2013e4. DOI: 10.14309\/01.ajg.0000856656.76875.b0"},{"key":"i2590-017X-9-4-153-b241","series-title":"Acad Dermatol Venereol","first-page":"1656","article-title":"Immune checkpoint inhibitor-induced pancreatic enzyme elevation in melanoma patients: incidence, management and therapy-A multicentre analysis","volume":"39","author":"Brandlmaier","year":"2025","unstructured":"Brandlmaier M,Hoellwerth M,Silly T, et al. Immune checkpoint inhibitor-induced pancreatic enzyme elevation in melanoma patients: incidence, management and therapy-A multicentre analysis. Acad Dermatol Venereol. 2025;39:1656\u20131665. DOI: 10.1111\/jdv.20384"},{"key":"i2590-017X-9-4-153-b242","series-title":"J Clin Med","first-page":"3076","article-title":"Autoimmune pancreatitis: a review","volume":"14","author":"Vemulapalli","year":"2025","unstructured":"Vemulapalli V,Natha C,Shirwaikar Thomas A. Autoimmune pancreatitis: a review. J Clin Med. 2025;14:3076. DOI: 10.3390\/jcm14093076"},{"key":"i2590-017X-9-4-153-b243","series-title":"Front Pharmacol","first-page":"817662","article-title":"Pancreatic adverse events associated with immune checkpoint inhibitors: a large-scale pharmacovigilance analysis","volume":"13","author":"Zhang","year":"2022","unstructured":"Zhang Y,Fang Y,Wu J, et al. Pancreatic adverse events associated with immune checkpoint inhibitors: a large-scale pharmacovigilance analysis. Front Pharmacol. 2022;13:817662. DOI: 10.3389\/fphar.2022.817662"},{"key":"i2590-017X-9-4-153-b244","series-title":"Am J Gastroenterol","first-page":"S1548","article-title":"Endoscopic ultrasound with fine needle biopsy confirming a diagnosis of immune checkpoint inhibitor-related type III autoimmune pancreatitis","volume":"118","author":"Ley","year":"2023","unstructured":"Ley D,Walayat S,Sharma K, et al. Endoscopic ultrasound with fine needle biopsy confirming a diagnosis of immune checkpoint inhibitor-related type III autoimmune pancreatitis. Am J Gastroenterol. 2023;118:S1548\u2013S1549. DOI: 10.14309\/01.ajg.0000958212.46527.33"},{"key":"i2590-017X-9-4-153-b245","series-title":"J Natl Compr Canc Netw","first-page":"831","article-title":"Pancreatitis and hyperlipasemia in the setting of immune checkpoint inhibitor therapy","volume":"21","author":"Townsend","year":"2023","unstructured":"Townsend MJ,Liu M,Giobbie-Hurder A, et al. Pancreatitis and hyperlipasemia in the setting of immune checkpoint inhibitor therapy. J Natl Compr Canc Netw. 2023;21:831\u2013840.e3. DOI: 10.6004\/jnccn.2023.7034"},{"key":"i2590-017X-9-4-153-b246","series-title":"J Immunotherapy Cancer","first-page":"31","article-title":"Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury","volume":"7","author":"Abu-Sbeih","year":"2019","unstructured":"Abu-Sbeih H,Tang T,Lu Y, et al. Clinical characteristics and outcomes of immune checkpoint inhibitor-induced pancreatic injury. J Immunotherapy Cancer. 2019;7:31. DOI: 10.1186\/s40425-019-0502-7"},{"key":"i2590-017X-9-4-153-b247","series-title":"Oncologist","first-page":"105","article-title":"Workup and management of immune-mediated hepatobiliary pancreatic toxicities that develop during immune checkpoint inhibitor treatment","volume":"25","author":"Hsu","year":"2020","unstructured":"Hsu C,Marshall JL,He AR. Workup and management of immune-mediated hepatobiliary pancreatic toxicities that develop during immune checkpoint inhibitor treatment. Oncologist. 2020;25:105\u2013111. DOI: 10.1634\/theoncologist.2018-0162"},{"key":"i2590-017X-9-4-153-b248","series-title":"Front Pharmacol","first-page":"955701","article-title":"Pancreatic injury following immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"13","author":"Zhang","year":"2022","unstructured":"Zhang T,Wang Y,Shi CH, et al. Pancreatic injury following immune checkpoint inhibitors: a systematic review and meta-analysis. Front Pharmacol. 2022;13:955701. DOI: 10.3389\/fphar.2022.955701"},{"key":"i2590-017X-9-4-153-b249","series-title":"Cancer Research","first-page":"5096","article-title":"Clinical feature of immune checkpoint inhibitor-induced pancreatic injury","volume":"84","author":"Itani","year":"2024","unstructured":"Itani J,Ishikawa T,Doi T, et al. Clinical feature of immune checkpoint inhibitor-induced pancreatic injury. Cancer Research. 2024;84:5096. DOI: 10.1158\/1538-7445.AM2024-5096"},{"key":"i2590-017X-9-4-153-b250","series-title":"J Clin Oncol","first-page":"709","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","unstructured":"Naidoo J,Wang X,Woo KM, et al. Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy. J Clin Oncol. 2017;35:709\u2013717. DOI: 10.1200\/JCO.2016.68.2005"},{"key":"i2590-017X-9-4-153-b251","series-title":"Oncologist","first-page":"e1065","article-title":"Incidence and risk factors for pneumonitis associated with checkpoint inhibitors in advanced non-small cell lung cancer: a single center experience","volume":"28","author":"Altan","year":"2023","unstructured":"Altan M,Soto F,Zhong LL, et al. Incidence and risk factors for pneumonitis associated with checkpoint inhibitors in advanced non-small cell lung cancer: a single center experience. Oncologist. 2023;28:e1065\u2013e1074. DOI: 10.1093\/oncolo\/oyad118"},{"key":"i2590-017X-9-4-153-b252","series-title":"J Thorac Oncol","first-page":"1930","article-title":"Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors","volume":"13","author":"Suresh","year":"2018","unstructured":"Suresh K,Voong KR,Shankar B, et al. Pneumonitis in non-small cell lung cancer patients receiving immune checkpoint immunotherapy: incidence and risk factors. J Thorac Oncol. 2018;13:1930\u20131939. DOI: 10.1016\/j.jtho.2018.08.2035"},{"key":"i2590-017X-9-4-153-b253","series-title":"Clin Lung Cancer","first-page":"624","article-title":"Long-term clinical, radiological, and mortality outcomes following pneumonitis in non-small cell lung cancer patients receiving immune checkpoint inhibitors: a retrospective analysis","volume":"25","author":"Soto-Lanza","year":"2024","unstructured":"Soto-Lanza F,Glick L,Chan C, et al. Long-term clinical, radiological, and mortality outcomes following pneumonitis in non-small cell lung cancer patients receiving immune checkpoint inhibitors: a retrospective analysis. Clin Lung Cancer. 2024;25:624\u2013633 e2. DOI: 10.1016\/j.cllc.2024.07.017"},{"key":"i2590-017X-9-4-153-b254","series-title":"JAMA Oncol","first-page":"1607","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","unstructured":"Nishino M,Giobbie-Hurder A,Hatabu H,Ramaiya NH,Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2:1607\u20131616. DOI: 10.1001\/jamaoncol.2016.2453"},{"key":"i2590-017X-9-4-153-b255","series-title":"Sci Rep","first-page":"44173","article-title":"PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis","volume":"7","author":"Wu","year":"2017","unstructured":"Wu J,Hong D,Zhang X,Lu X,Miao J. PD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis. Sci Rep. 2017;7:44173. DOI: 10.1038\/srep44173"},{"key":"i2590-017X-9-4-153-b256","series-title":"Cancer Immunol Immunother","first-page":"15","article-title":"Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody","volume":"69","author":"Shibaki","year":"2020","unstructured":"Shibaki R,Murakami S,Matsumoto Y, et al. Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody. Cancer Immunol Immunother. 2020;69:15\u201322. DOI: 10.1007\/s00262-019-02431-8"},{"key":"i2590-017X-9-4-153-b257","series-title":"J Clin Oncol","first-page":"480","article-title":"Type, timing, and patient characteristics associated with immune-related adverse event development in patients with advanced solid tumors treated with immune checkpoint inhibitors","volume":"38","author":"Qin","year":"2020","unstructured":"Qin Q,Patel VG,Mellgard G, et al. Type, timing, and patient characteristics associated with immune-related adverse event development in patients with advanced solid tumors treated with immune checkpoint inhibitors. J Clin Oncol. 2020;38:480. DOI: 10.1200\/JCO.2020.38.15_suppl.e15160"},{"key":"i2590-017X-9-4-153-b258","series-title":"J Immunother Cancer","first-page":"e001731","article-title":"Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes","volume":"9","author":"Balaji","year":"2021","unstructured":"Balaji A,Hsu M,Lin CT, et al. Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes. J Immunother Cancer. 2021;9:e001731. DOI: 10.1136\/jitc-2020-001731"},{"key":"i2590-017X-9-4-153-b259","series-title":"JAMA Netw Open","first-page":"e2513727","article-title":"Immune checkpoint inhibitors for patients with preexisting autoimmune neurologic disorders","volume":"8","author":"Fletcher","year":"2025","unstructured":"Fletcher K,Machaalani M,El Hajj Chehade R, et al. Immune checkpoint inhibitors for patients with preexisting autoimmune neurologic disorders. JAMA Netw Open. 2025;8:e2513727. DOI: 10.1001\/jamanetworkopen.2025.13727"},{"key":"i2590-017X-9-4-153-b260","series-title":"Radiology","first-page":"550","article-title":"Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the Fleischner Society","volume":"298","author":"Johkoh","year":"2021","unstructured":"Johkoh T,Lee KS,Nishino M, et al. Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: a position paper from the Fleischner Society. Radiology. 2021;298:550\u2013566. DOI: 10.1148\/radiol.2021203427"},{"key":"i2590-017X-9-4-153-b261","series-title":"BMC Pulm Med","first-page":"155","article-title":"Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer","volume":"21","author":"Nishiyama","year":"2021","unstructured":"Nishiyama O,Shimizu S,Haratani K, et al. Clinical implications of bronchoscopy for immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. BMC Pulm Med. 2021;21:155. DOI: 10.1186\/s12890-021-01523-5"},{"key":"i2590-017X-9-4-153-b262","series-title":"Am J Respir Cell Mol Biol","first-page":"454","article-title":"Macrophage CCL18 promotes lung inflammation in checkpoint inhibitor pneumonitis","volume":"74","author":"Ghanbar","year":"2026","unstructured":"Ghanbar MI,Villabona-Rueda A,Philip N, et al. Macrophage CCL18 promotes lung inflammation in checkpoint inhibitor pneumonitis. Am J Respir Cell Mol Biol. 2026;74:454\u2013465. DOI: 10.1165\/rcmb.2025-0405OC"},{"key":"i2590-017X-9-4-153-b263","series-title":"J Immunother Cancer","first-page":"e006398","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology","volume":"11","author":"Naidoo","year":"2023","unstructured":"Naidoo J,Murphy C,Atkins MB, et al. Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology. J Immunother Cancer. 2023;11:e006398. DOI: 10.1136\/jitc-2022-006398"},{"key":"i2590-017X-9-4-153-b264","series-title":"J Immunother Cancer","first-page":"e001884","article-title":"Success and failure of additional immune modulators in steroid-refractory\/resistant pneumonitis related to immune checkpoint blockade","volume":"9","author":"Beattie","year":"2021","unstructured":"Beattie J,Rizvi H,Fuentes P, et al. Success and failure of additional immune modulators in steroid-refractory\/resistant pneumonitis related to immune checkpoint blockade. J Immunother Cancer. 2021;9:e001884. DOI: 10.1136\/jitc-2020-001884"},{"key":"i2590-017X-9-4-153-b265","series-title":"Chest Crit Care","first-page":"100126","article-title":"Managing immune checkpoint inhibitor pneumonitis in the ICU","volume":"3","author":"Montemayor","year":"2025","unstructured":"Montemayor K,Ghanbar MI,Koch AL,Suresh K,Stephens RS. Managing immune checkpoint inhibitor pneumonitis in the ICU. Chest Crit Care. 2025;3:100126. DOI: 10.1016\/j.chstcc.2024.100126"},{"key":"i2590-017X-9-4-153-b266","series-title":"Front Oncol","first-page":"1621045","article-title":"Immune checkpoint inhibitor-associated autoimmune encephalitis and other neurological immune-mediated adverse events: a pharmacovigilance study using the FAERS and JADER","volume":"15","author":"Di","year":"2025","unstructured":"Di X,Shi X,Gai F,Wang J. Immune checkpoint inhibitor-associated autoimmune encephalitis and other neurological immune-mediated adverse events: a pharmacovigilance study using the FAERS and JADER. Front Oncol. 2025;15:1621045. DOI: 10.3389\/fonc.2025.1621045"},{"key":"i2590-017X-9-4-153-b267","series-title":"J Neurol Neurosurg Psychiatry","first-page":"1024","article-title":"Neurological immune-related adverse events with checkpoint inhibitor therapy: challenges for the neurologist","volume":"96","author":"Willis","year":"2025","unstructured":"Willis MD,Schroeder B,Marandino L,Turajlic S,Carr AS. Neurological immune-related adverse events with checkpoint inhibitor therapy: challenges for the neurologist. J Neurol Neurosurg Psychiatry. 2025;96:1024\u20131037. DOI: 10.1136\/jnnp-2025-335998"},{"key":"i2590-017X-9-4-153-b268","series-title":"Pract Neurol","first-page":"116","article-title":"Neurological complications of immune checkpoint inhibitors: a practical guide","volume":"25","author":"Carr","year":"2025","unstructured":"Carr AS,Vonberg FW,Koay S, et al. Neurological complications of immune checkpoint inhibitors: a practical guide. Pract Neurol. 2025;25:116\u2013126. DOI: 10.1136\/pn-2024-004327"},{"key":"i2590-017X-9-4-153-b269","series-title":"Neurooncol Adv","first-page":"v108","article-title":"A review of neurotoxicities associated with immunotherapy and a framework for evaluation","volume":"3","author":"Burton","year":"2021","unstructured":"Burton LB,Eskian M,Guidon AC,Reynolds KL. A review of neurotoxicities associated with immunotherapy and a framework for evaluation. Neurooncol Adv. 2021;3:v108\u2013v120. DOI: 10.1093\/noajnl\/vdab107"},{"key":"i2590-017X-9-4-153-b270","series-title":"J Immunother Cancer","first-page":"e002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","unstructured":"Guidon AC,Burton LB,Chwalisz BK, et al. Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. 2021;9:e002890. DOI: 10.1136\/jitc-2021-002890"},{"key":"i2590-017X-9-4-153-b271","series-title":"Brain Sci","first-page":"764","article-title":"Unravelling the acute, chronic and steroid-refractory management of high-grade neurological immune-related adverse events: a call to action","volume":"14","author":"Malvaso","year":"2024","unstructured":"Malvaso A,Giglio P,Diamanti L, et al. Unravelling the acute, chronic and steroid-refractory management of high-grade neurological immune-related adverse events: a call to action. Brain Sci. 2024;14:764. DOI: 10.3390\/brainsci14080764"},{"key":"i2590-017X-9-4-153-b272","series-title":"Rev Neurol (Paris)","first-page":"982","article-title":"Soluble biomarkers for immune checkpoint inhibitor-related encephalitis: a mini-review","volume":"180","author":"Farina","year":"2024","unstructured":"Farina A,Villagran-Garcia M,Joubert B. Soluble biomarkers for immune checkpoint inhibitor-related encephalitis: a mini-review. Rev Neurol (Paris). 2024;180:982\u2013988. DOI: 10.1016\/j.neurol.2024.08.007"},{"key":"i2590-017X-9-4-153-b273","series-title":"Front Immunol","first-page":"1671964","article-title":"Efgartigimod for the treatment of immune checkpoint inhibitor-associated myocarditis complicated with impending crisis state of myasthenia gravis: a case report","volume":"16","author":"Lu","year":"2025","unstructured":"Lu M,Muhetaer A,Su C, et al. Efgartigimod for the treatment of immune checkpoint inhibitor-associated myocarditis complicated with impending crisis state of myasthenia gravis: a case report. Front Immunol. 2025;16:1671964. DOI: 10.3389\/fimmu.2025.1671964"},{"key":"i2590-017X-9-4-153-b274","series-title":"J Immunother Cancer","first-page":"e013214","article-title":"JAK inhibitors for the treatment of life-threatening and refractory immune-related adverse events secondary to immune checkpoint inhibitors: a prospective cohort study","volume":"13","author":"Habib","year":"2025","unstructured":"Habib R,Miller WH,Papadopoulos T, et al. JAK inhibitors for the treatment of life-threatening and refractory immune-related adverse events secondary to immune checkpoint inhibitors: a prospective cohort study. J Immunother Cancer. 2025;13:e013214. DOI: 10.1136\/jitc-2025-013214"},{"key":"i2590-017X-9-4-153-b275","series-title":"Front Immunol","first-page":"1548897","article-title":"Prediction, prevention, and precision treatment of immune checkpoint inhibitor neurological toxicity using autoantibodies, cytokines, and microbiota","volume":"16","author":"Vogrig","year":"2025","unstructured":"Vogrig A,Dentoni M,Florean I, et al. Prediction, prevention, and precision treatment of immune checkpoint inhibitor neurological toxicity using autoantibodies, cytokines, and microbiota. Front Immunol. 2025;16:1548897. DOI: 10.3389\/fimmu.2025.1548897"},{"key":"i2590-017X-9-4-153-b276","series-title":"Curr Neurol Neurosci Rep","first-page":"735","article-title":"Immune checkpoint inhibitors in patients with pre-existing neurologic autoimmune disorders","volume":"23","author":"Aoun","year":"2023","unstructured":"Aoun R,Gratch D,Kaminetzky D,Kister I. Immune checkpoint inhibitors in patients with pre-existing neurologic autoimmune disorders. Curr Neurol Neurosci Rep. 2023;23:735\u2013750. DOI: 10.1007\/s11910-023-01306-x"},{"key":"i2590-017X-9-4-153-b277","series-title":"Front Oncol","first-page":"1716014","article-title":"Serum autoantibody profiles in cancer patients treated with immune checkpoint inhibitors: a cross-sectional study","volume":"15","author":"Chen","year":"2025","unstructured":"Chen K,Guo B,Liu R, et al. Serum autoantibody profiles in cancer patients treated with immune checkpoint inhibitors: a cross-sectional study. Front Oncol. 2025;15:1716014. DOI: 10.3389\/fonc.2025.1716014"},{"key":"i2590-017X-9-4-153-b278","series-title":"Neurol-Neuroimmunol","first-page":"e200314","article-title":"Clinical course of neurologic adverse events associated with immune checkpoint inhibitors focus on chronic toxicities","volume":"11","author":"Rossi","year":"2024","unstructured":"Rossi S,Farina A,Malvaso A, et al. Clinical course of neurologic adverse events associated with immune checkpoint inhibitors focus on chronic toxicities. Neurol-Neuroimmunol. 2024;11:e200314. DOI: 10.1212\/NXI.0000000000200314"},{"key":"i2590-017X-9-4-153-b279","series-title":"Front Immunol","first-page":"1540442","article-title":"Immune checkpoint inhibitors and cancer-related cognitive decline: a propensity score matched analysis in active chemotherapy patients","volume":"16","author":"Jian","year":"2025","unstructured":"Jian G,Zeng J,Lu J, et al. Immune checkpoint inhibitors and cancer-related cognitive decline: a propensity score matched analysis in active chemotherapy patients. Front Immunol. 2025;16:1540442. DOI: 10.3389\/fimmu.2025.1540442"},{"key":"i2590-017X-9-4-153-b280","series-title":"Support Care Cancer","first-page":"523","article-title":"Incidence and predictors of immune checkpoint inhibitor treatment-related cognitive impairment in a racial and ethnic diverse population","volume":"33","author":"Sayer","year":"2025","unstructured":"Sayer M,Agrawal P,Ng DQ, et al. Incidence and predictors of immune checkpoint inhibitor treatment-related cognitive impairment in a racial and ethnic diverse population. Support Care Cancer. 2025;33:523. DOI: 10.1007\/s00520-025-09560-0"},{"key":"i2590-017X-9-4-153-b281","series-title":"J Clin Oncol","first-page":"e14609","article-title":"Immune checkpoint inhibitor (ICI) rechallenge after immune-related adverse events (irAE) requiring hospitalization: a single-center 10-year experience","volume":"42","author":"Wu","year":"2024","unstructured":"Wu C-Y,Zubiri L,Rouhani SJ, et al. Immune checkpoint inhibitor (ICI) rechallenge after immune-related adverse events (irAE) requiring hospitalization: a single-center 10-year experience. J Clin Oncol. 2024;42:e14609. DOI: 10.1200\/JCO.2024.42.16_suppl.e14609"},{"key":"i2590-017X-9-4-153-b282","series-title":"Front Immunol","first-page":"1546886","article-title":"Case report: successful immune checkpoint inhibitor rechallenge after sintilimab-induced Guillain-Barr\u00e9 syndrome","volume":"16","author":"Ye","year":"2025","unstructured":"Ye L,Yue WR,Shi H,Li JR,Qun YY. Case report: successful immune checkpoint inhibitor rechallenge after sintilimab-induced Guillain-Barr\u00e9 syndrome. Front Immunol. 2025;16:1546886. DOI: 10.3389\/fimmu.2025.1546886"},{"key":"i2590-017X-9-4-153-b283","series-title":"Cancers (Basel)","first-page":"881","article-title":"Immune checkpoint inhibitors in cancer therapy-How can we improve clinical benefits","volume":"15","author":"Baxevanis","year":"2023","unstructured":"Baxevanis CN. Immune checkpoint inhibitors in cancer therapy-How can we improve clinical benefits? Cancers (Basel). 2023;15:881. DOI: 10.3390\/cancers15030881"},{"key":"i2590-017X-9-4-153-b284","series-title":"Arthritis Care Res (Hoboken)","first-page":"1751","article-title":"Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature","volume":"69","author":"Cappelli","year":"2017","unstructured":"Cappelli LC,Gutierrez AK,Bingham CO 3rd,Shah AA. Rheumatic and musculoskeletal immune-related adverse events due to immune checkpoint inhibitors: a systematic review of the literature. Arthritis Care Res (Hoboken). 2017;69:1751\u20131763. DOI: 10.1002\/acr.23177"},{"key":"i2590-017X-9-4-153-b285","series-title":"Rheumatology (Oxford)","first-page":"1637","article-title":"Incidence of checkpoint inhibitor-associated inflammatory arthritis, immunomodulation and mortality in cancer patients on immunotherapy: a retrospective cohort study","volume":"64","author":"Bass","year":"2025","unstructured":"Bass AR,Xie F,Jannat-Khah D, et al. Incidence of checkpoint inhibitor-associated inflammatory arthritis, immunomodulation and mortality in cancer patients on immunotherapy: a retrospective cohort study. Rheumatology (Oxford). 2025;64:1637\u20131642. DOI: 10.1093\/rheumatology\/keae343"},{"key":"i2590-017X-9-4-153-b286","series-title":"Arthritis Res Ther","first-page":"74","article-title":"Higher levels of VEGF-A and TNF\u03b1 in patients with immune checkpoint inhibitor-induced inflammatory arthritis","volume":"27","author":"Gray-Gaillard","year":"2025","unstructured":"Gray-Gaillard EF,Shah AA,Bingham Iii CO, et al. Higher levels of VEGF-A and TNF\u03b1 in patients with immune checkpoint inhibitor-induced inflammatory arthritis. Arthritis Res Ther. 2025;27:74. DOI: 10.1186\/s13075-025-03546-3"},{"key":"i2590-017X-9-4-153-b287","series-title":"Sci Immunol","first-page":"eaaw2262","article-title":"T(H)17 cells require ongoing classic IL-6 receptor signaling to retain transcriptional and functional identity","volume":"5","author":"Harbour","year":"2020","unstructured":"Harbour SN,DiToro DF,Witte SJ, et al. T(H)17 cells require ongoing classic IL-6 receptor signaling to retain transcriptional and functional identity. Sci Immunol. 2020;5:eaaw2262. DOI: 10.1126\/sciimmunol.aaw2262"},{"key":"i2590-017X-9-4-153-b288","series-title":"N Engl J Med","first-page":"1749","article-title":"Fulminant myocarditis with combination immune checkpoint blockade","volume":"375","author":"Johnson","year":"2016","unstructured":"Johnson DB,Balko JM,Compton ML, et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med. 2016;375:1749\u20131755. DOI: 10.1056\/NEJMoa1609214"},{"key":"i2590-017X-9-4-153-b289","series-title":"J Clin Rheumatol","first-page":"e317","article-title":"Checkpoint inhibitor-associated arthritis: a systematic review of case reports and case series","volume":"27","author":"Ghosh","year":"2021","unstructured":"Ghosh N,Tiongson MD,Stewart C, et al. Checkpoint inhibitor-associated arthritis: a systematic review of case reports and case series. J Clin Rheumatol. 2021;27:e317\u2013e22. DOI: 10.1097\/RHU.0000000000001370"},{"key":"i2590-017X-9-4-153-b290","series-title":"Arthritis Rheumatol","first-page":"468","article-title":"Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients","volume":"71","author":"Richter","year":"2019","unstructured":"Richter MD,Crowson C,Kottschade LA, et al. Rheumatic syndromes associated with immune checkpoint inhibitors: a single-center cohort of sixty-one patients. Arthritis Rheumatol. 2019;71:468\u2013475. DOI: 10.1002\/art.40745"},{"key":"i2590-017X-9-4-153-b291","series-title":"Arthritis Care Res (Hoboken)","first-page":"362","article-title":"Arthritis after cancer immunotherapy: symptom duration and treatment response","volume":"71","author":"Smith","year":"2019","unstructured":"Smith MH,Bass AR. Arthritis after cancer immunotherapy: symptom duration and treatment response. Arthritis Care Res (Hoboken). 2019;71:362\u2013366. DOI: 10.1002\/acr.23467"},{"key":"i2590-017X-9-4-153-b292","series-title":"Ann Rheum Dis","first-page":"332","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation","volume":"79","author":"Braaten","year":"2020","unstructured":"Braaten TJ,Brahmer JR,Forde PM, et al. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis. 2020;79:332\u2013338. DOI: 10.1136\/annrheumdis-2019-216109"},{"key":"i2590-017X-9-4-153-b293","series-title":"ACR Open Rheumatol","first-page":"e70002","article-title":"Chronicity of immune checkpoint inhibitor-associated inflammatory arthritis after immunotherapy discontinuation: results from the Canadian Research Group of Rheumatology in Immuno-Oncology Database","volume":"7","author":"Ladouceur","year":"2025","unstructured":"Ladouceur A,Jamal S,Saltman A, et al. Chronicity of immune checkpoint inhibitor-associated inflammatory arthritis after immunotherapy discontinuation: results from the Canadian Research Group of Rheumatology in Immuno-Oncology Database. ACR Open Rheumatol. 2025;7:e70002. DOI: 10.1002\/acr2.70002"},{"key":"i2590-017X-9-4-153-b294","series-title":"Ann Rheum Dis","first-page":"393","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-Centre prospective cohort study","volume":"77","author":"Kostine","year":"2018","unstructured":"Kostine M,Rouxel L,Barnetche T, et al. Rheumatic disorders associated with immune checkpoint inhibitors in patients with cancer-clinical aspects and relationship with tumour response: a single-Centre prospective cohort study. Ann Rheum Dis. 2018;77:393\u2013398. DOI: 10.1136\/annrheumdis-2017-212257"},{"key":"i2590-017X-9-4-153-b295","series-title":"Front Immunol","first-page":"943574","article-title":"Contribution of pathogenic T helper 1 and 17 cells to bursitis and tenosynovitis in polymyalgia rheumatica","volume":"13","author":"Reitsema","year":"2022","unstructured":"Reitsema RD,Jiemy WF,Wekema L, et al. Contribution of pathogenic T helper 1 and 17 cells to bursitis and tenosynovitis in polymyalgia rheumatica. Front Immunol. 2022;13:943574. DOI: 10.3389\/fimmu.2022.943574"},{"key":"i2590-017X-9-4-153-b296","series-title":"Rheum Dis Clin North Am","first-page":"255","article-title":"Immune checkpoint inhibitor-induced polymyalgia rheumatica","volume":"50","author":"Liew","year":"2024","unstructured":"Liew DFL,Mackie SL,Tison A, et al. Immune checkpoint inhibitor-induced polymyalgia rheumatica. Rheum Dis Clin North Am. 2024;50:255\u2013267. DOI: 10.1016\/j.rdc.2024.02.001"},{"key":"i2590-017X-9-4-153-b297","series-title":"RMD Open","first-page":"e000906","article-title":"Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature","volume":"5","author":"Calabrese","year":"2019","unstructured":"Calabrese C,Cappelli LC,Kostine M, et al. Polymyalgia rheumatica-like syndrome from checkpoint inhibitor therapy: case series and systematic review of the literature. RMD Open. 2019;5:e000906. DOI: 10.1136\/rmdopen-2019-000906"},{"key":"i2590-017X-9-4-153-b298","series-title":"Autoimmun Rev","first-page":"103589","article-title":"Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: a systematic literature review highlighting differences from the idiopathic forms","volume":"23","author":"Hysa","year":"2024","unstructured":"Hysa E,Casabella A,Gotelli E, et al. Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: a systematic literature review highlighting differences from the idiopathic forms. Autoimmun Rev. 2024;23:103589. DOI: 10.1016\/j.autrev.2024.103589"},{"key":"i2590-017X-9-4-153-b299","series-title":"Rheumatology (Oxford)","first-page":"771","article-title":"Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement","volume":"64","author":"Vermeulen","year":"2025","unstructured":"Vermeulen OCB,Brouwer E,Slart RHJA, et al. Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement. Rheumatology (Oxford). 2025;64:771\u2013779. DOI: 10.1093\/rheumatology\/keae099"},{"key":"i2590-017X-9-4-153-b300","series-title":"Ann Rheum Dis","first-page":"43","article-title":"Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab","volume":"76","author":"Cappelli","year":"2017","unstructured":"Cappelli LC,Gutierrez AK,Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis. 2017;76:43\u201350. DOI: 10.1136\/annrheumdis-2016-209595"},{"key":"i2590-017X-9-4-153-b301","series-title":"Oncologist","first-page":"1259","article-title":"Sicca syndrome associated with immune checkpoint inhibitor therapy","volume":"24","author":"Warner","year":"2019","unstructured":"Warner BM,Baer AN,Lipson EJ, et al. Sicca syndrome associated with immune checkpoint inhibitor therapy. Oncologist. 2019;24:1259\u20131269. DOI: 10.1634\/theoncologist.2018-0823"},{"key":"i2590-017X-9-4-153-b302","series-title":"Arthritis Res Ther","first-page":"178","article-title":"CD4 T lymphocyte autophagy is upregulated in the salivary glands of primary Sjogren\u2019s syndrome patients and correlates with focus score and disease activity","volume":"19","author":"Alessandri","year":"2017","unstructured":"Alessandri C,Ciccia F,Priori R, et al. CD4 T lymphocyte autophagy is upregulated in the salivary glands of primary Sjogren\u2019s syndrome patients and correlates with focus score and disease activity. Arthritis Res Ther. 2017;19:178. DOI: 10.1186\/s13075-017-1385-y"},{"key":"i2590-017X-9-4-153-b303","series-title":"J Dent Res","first-page":"772","article-title":"Profiling autoantibodies against salivary proteins in sicca conditions","volume":"98","author":"Burbelo","year":"2019","unstructured":"Burbelo PD,Ferre EMN,Chaturvedi A, et al. Profiling autoantibodies against salivary proteins in sicca conditions. J Dent Res. 2019;98:772\u2013778. DOI: 10.1177\/0022034519850564"},{"key":"i2590-017X-9-4-153-b304","series-title":"Arthritis Res Ther","first-page":"21","article-title":"B-cell and T-cell quantification in minor salivary glands in primary Sjogren\u2019s syndrome: development and validation of a pixel-based digital procedure","volume":"18","author":"Costa","year":"2016","unstructured":"Costa S,Schutz S,Cornec D, et al. B-cell and T-cell quantification in minor salivary glands in primary Sjogren\u2019s syndrome: development and validation of a pixel-based digital procedure. Arthritis Res Ther. 2016;18:21. DOI: 10.1186\/s13075-016-0924-2"},{"key":"i2590-017X-9-4-153-b305","series-title":"Arthritis Rheumatol","first-page":"866","article-title":"Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors","volume":"73","author":"Aldrich","year":"2021","unstructured":"Aldrich J,Pundole X,Tummala S, et al. Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors. Arthritis Rheumatol. 2021;73:866\u2013874. DOI: 10.1002\/art.41604"},{"key":"i2590-017X-9-4-153-b306","series-title":"Autoimmun Rev","first-page":"102586","article-title":"Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities","volume":"19","author":"Allenbach","year":"2020","unstructured":"Allenbach Y,Anquetil C,Manouchehri A, et al. Immune checkpoint inhibitor-induced myositis, the earliest and most lethal complication among rheumatic and musculoskeletal toxicities. Autoimmun Rev. 2020;19:102586. DOI: 10.1016\/j.autrev.2020.102586"},{"key":"i2590-017X-9-4-153-b307","series-title":"Ann Rheum Dis","first-page":"e32","article-title":"Rheumatic disorders associated with immune checkpoint inhibitors: What about myositis? An analysis of the WHO's adverse drug reactions database","volume":"81","author":"Nguy\u011bn","year":"2022","unstructured":"Nguy\u011bn T,Maria ATJ,Ladhari C, et al. Rheumatic disorders associated with immune checkpoint inhibitors: What about myositis? An analysis of the WHO's adverse drug reactions database. Ann Rheum Dis. 2022;81:e32. DOI: 10.1136\/annrheumdis-2020-217018"},{"key":"i2590-017X-9-4-153-b308","series-title":"Nature","first-page":"818","article-title":"T cells specific for alpha-myosin drive immunotherapy-related myocarditis","volume":"611","author":"Axelrod","year":"2022","unstructured":"Axelrod ML,Meijers WC,Screever EM, et al. T cells specific for alpha-myosin drive immunotherapy-related myocarditis. Nature. 2022;611:818\u2013826. DOI: 10.1038\/s41586-022-05432-3"},{"key":"i2590-017X-9-4-153-b309","series-title":"Ophthal Plast Recons","first-page":"50","article-title":"Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor therapy in cancer patients","volume":"35","author":"Sagiv","year":"2019","unstructured":"Sagiv O,Kandl TJ,Thakar SD, et al. Extraocular muscle enlargement and thyroid eye disease-like orbital inflammation associated with immune checkpoint inhibitor therapy in cancer patients. Ophthal Plast Recons. 2019;35:50\u201352. DOI: 10.1097\/IOP.0000000000001161"},{"key":"i2590-017X-9-4-153-b310","series-title":"Front Immunol","first-page":"803410","article-title":"Incidence and distinct features of immune checkpoint inhibitor-related myositis from idiopathic inflammatory myositis: a single-center experience with systematic literature review and meta-analysis","volume":"12","author":"Hamada","year":"2021","unstructured":"Hamada N,Maeda A,Takase-Minegishi K, et al. Incidence and distinct features of immune checkpoint inhibitor-related myositis from idiopathic inflammatory myositis: a single-center experience with systematic literature review and meta-analysis. Front Immunol. 2021;12:803410. DOI: 10.3389\/fimmu.2021.803410"},{"key":"i2590-017X-9-4-153-b311","series-title":"Eur J Cancer","first-page":"474","article-title":"Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events","volume":"157","author":"Kostine","year":"2021","unstructured":"Kostine M,Mauric E,Tison A, et al. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events. Eur J Cancer. 2021;157:474\u2013484. DOI: 10.1016\/j.ejca.2021.08.036"},{"key":"i2590-017X-9-4-153-b312","series-title":"Clin Rheumatol","first-page":"1513","article-title":"Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis","volume":"38","author":"Roberts","year":"2019","unstructured":"Roberts J,Smylie M,Walker J, et al. Hydroxychloroquine is a safe and effective steroid-sparing agent for immune checkpoint inhibitor-induced inflammatory arthritis. Clin Rheumatol. 2019;38:1513\u20131519. DOI: 10.1007\/s10067-019-04451-2"},{"key":"i2590-017X-9-4-153-b313","series-title":"RMD Open","first-page":"e000714","article-title":"Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy","volume":"4","author":"Leipe","year":"2018","unstructured":"Leipe J,Christ LA,Arnoldi AP, et al. Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy. RMD Open. 2018;4:e000714. DOI: 10.1136\/rmdopen-2018-000714"},{"key":"i2590-017X-9-4-153-b314","series-title":"Ann Rheum Dis","first-page":"920","article-title":"Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis","volume":"82","author":"Bass","year":"2023","unstructured":"Bass AR,Abdel-Wahab N,Reid PD, et al. Comparative safety and effectiveness of TNF inhibitors, IL6 inhibitors and methotrexate for the treatment of immune checkpoint inhibitor-associated arthritis. Ann Rheum Dis. 2023;82:920\u2013926. DOI: 10.1136\/ard-2023-223885"},{"key":"i2590-017X-9-4-153-b315","series-title":"Ann Oncol","first-page":"43","article-title":"Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study","volume":"36","author":"Petit","year":"2025","unstructured":"Petit P-F,Daoudlarian D,Latifyan S, et al. Tocilizumab provides dual benefits in treating immune checkpoint inhibitor-associated arthritis and preventing relapse during ICI rechallenge: the TAPIR study. Ann Oncol. 2025;36:43\u201353. DOI: 10.1016\/j.annonc.2024.08.2340"},{"key":"i2590-017X-9-4-153-b316","series-title":"RMD Open","first-page":"e003795","article-title":"Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study","volume":"9","author":"Ladouceur","year":"2023","unstructured":"Ladouceur A,Barnetche T,Mouterde G, et al. Immune checkpoint inhibitor rechallenge in patients who previously experienced immune-related inflammatory arthritis: a multicentre observational study. RMD Open. 2023;9:e003795. DOI: 10.1136\/rmdopen-2023-003795"},{"key":"i2590-017X-9-4-153-b317","series-title":"Cancer Cell","first-page":"509","article-title":"Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity","volume":"40","author":"Hailemichael","year":"2022","unstructured":"Hailemichael Y,Johnson DH,Abdel-Wahab N, et al. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022;40:509\u2013523 e6. DOI: 10.1016\/j.ccell.2022.04.004"},{"key":"i2590-017X-9-4-153-b318","series-title":"RMD Open","first-page":"e002612","article-title":"Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study","volume":"8","author":"De La Fuente","year":"2022","unstructured":"De La Fuente F,Belkhir R,Henry J, et al. Use of a bDMARD or tsDMARD for the management of inflammatory arthritis under checkpoint inhibitors: an observational study. RMD Open. 2022;8:e002612. DOI: 10.1136\/rmdopen-2022-002612"},{"key":"i2590-017X-9-4-153-b319","series-title":"Joint Bone Spine","first-page":"105938","article-title":"Practical management of rheumatic immune-related adverse events occurring with immune checkpoint inhibitors: a narrative review","volume":"93","author":"Tison","year":"2026","unstructured":"Tison A,Escoda T,Kostine M,Cornec D,Chiche L. Practical management of rheumatic immune-related adverse events occurring with immune checkpoint inhibitors: a narrative review. Joint Bone Spine. 2026;93:105938. DOI: 10.1016\/j.jbspin.2025.105938"},{"key":"i2590-017X-9-4-153-b320","series-title":"Best Pract Res Clin Rheumatol","first-page":"101805","article-title":"Treatment of rheumatic adverse events of cancer immunotherapy","volume":"36","author":"Reid","year":"2022","unstructured":"Reid P,Cappelli LC. Treatment of rheumatic adverse events of cancer immunotherapy. Best Pract Res Clin Rheumatol. 2022;36:101805. DOI: 10.1016\/j.berh.2022.101805"},{"key":"i2590-017X-9-4-153-b321","series-title":"Ann Rheum Dis","first-page":"1","article-title":"Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases","volume":"76","author":"Calabrese","year":"2017","unstructured":"Calabrese L,Velcheti V. Checkpoint immunotherapy: good for cancer therapy, bad for rheumatic diseases. Ann Rheum Dis. 2017;76:1\u20133. DOI: 10.1136\/annrheumdis-2016-209782"},{"key":"i2590-017X-9-4-153-b322","series-title":"J Rheumatol","first-page":"57","article-title":"Description of immune checkpoint inhibitor associated Sicca-Like syndrome from the Canadian research group of rheumatology in Immuno-Oncology database: a case series","volume":"52","author":"Greenwood","year":"2025","unstructured":"Greenwood B,Jamal S,Hudson M, et al. Description of immune checkpoint inhibitor associated Sicca-Like syndrome from the Canadian research group of rheumatology in Immuno-Oncology database: a case series. J Rheumatol. 2025;52:57\u201358. DOI: 10.3899\/jrheum.2025-0314.30"},{"key":"i2590-017X-9-4-153-b323","series-title":"J Immunotherapy Cancer","first-page":"319","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","unstructured":"Safa H,Johnson DH,Trinh VA, et al. Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunotherapy Cancer. 2019;7:319. DOI: 10.1186\/s40425-019-0774-y"},{"key":"i2590-017X-9-4-153-b324","series-title":"JAMA Oncol","first-page":"1390","article-title":"Immune checkpoint inhibitor-induced cardiotoxicity: a systematic review and meta-analysis","volume":"10","author":"Nielsen","year":"2024","unstructured":"Nielsen DL,Juhl CB,Nielsen OH,Chen IM,Herrmann J. Immune checkpoint inhibitor-induced cardiotoxicity: a systematic review and meta-analysis. JAMA Oncol. 2024;10:1390\u20131399. DOI: 10.1001\/jamaoncol.2024.3065"},{"key":"i2590-017X-9-4-153-b325","series-title":"IJMS","first-page":"3054","article-title":"Immune checkpoint inhibitor-related myositis: from biology to bedside","volume":"21","author":"Solimando","year":"2020","unstructured":"Solimando AG,Crudele L,Leone P, et al. Immune checkpoint inhibitor-related myositis: from biology to bedside. IJMS. 2020;21:3054. DOI: 10.3390\/ijms21093054"},{"key":"i2590-017X-9-4-153-b326","series-title":"Front Pharmacol","first-page":"884776","article-title":"Immune checkpoint inhibitor-related myositis overlapping with myocarditis: an institutional case series and a systematic review of literature","volume":"13","author":"Nakagomi","year":"2022","unstructured":"Nakagomi Y,Tajiri K,Shimada S, et al. Immune checkpoint inhibitor-related myositis overlapping with myocarditis: an institutional case series and a systematic review of literature. Front Pharmacol. 2022;13:884776. DOI: 10.3389\/fphar.2022.884776"},{"key":"i2590-017X-9-4-153-b327","series-title":"Neurol Neuroimmunol Neuroinflamm","first-page":"e200484","article-title":"Outcomes in patients with immune checkpoint inhibitor-related myopathy and prolonged follow-up","volume":"12","author":"Segal","year":"2025","unstructured":"Segal Y,Mangioris G,Toledano M, et al. Outcomes in patients with immune checkpoint inhibitor-related myopathy and prolonged follow-up. Neurol Neuroimmunol Neuroinflamm. 2025;12:e200484. DOI: 10.1212\/NXI.0000000000200484"},{"key":"i2590-017X-9-4-153-b328","series-title":"Cell Rep Med","first-page":"100878","article-title":"CD8(+) T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy","volume":"4","author":"Huseni","year":"2023","unstructured":"Huseni MA,Wang L,Klementowicz JE, et al. CD8(+) T cell-intrinsic IL-6 signaling promotes resistance to anti-PD-L1 immunotherapy. Cell Rep Med. 2023;4:100878. DOI: 10.1016\/j.xcrm.2022.100878"},{"key":"i2590-017X-9-4-153-b329","series-title":"Cancer Res","first-page":"5011","article-title":"Combined blockade of IL6 and PD-1\/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment","volume":"78","author":"Tsukamoto","year":"2018","unstructured":"Tsukamoto H,Fujieda K,Miyashita A, et al. Combined blockade of IL6 and PD-1\/PD-L1 signaling abrogates mutual regulation of their immunosuppressive effects in the tumor microenvironment. Cancer Res. 2018;78:5011\u20135022. DOI: 10.1158\/0008-5472.CAN-18-0118"},{"key":"i2590-017X-9-4-153-b330","series-title":"J Immunother Cancer","first-page":"e002856","article-title":"IL-6 contributes to metastatic switch via the differentiation of monocytic-dendritic progenitors into prometastatic immune cells","volume":"9","author":"Magidey-Klein","year":"2021","unstructured":"Magidey-Klein K,Cooper TJ,Kveler K, et al. IL-6 contributes to metastatic switch via the differentiation of monocytic-dendritic progenitors into prometastatic immune cells. J Immunother Cancer. 2021;9:e002856. DOI: 10.1136\/jitc-2021-002856"},{"key":"i2590-017X-9-4-153-b331","series-title":"Rev Esp Enferm Dig","first-page":"356","article-title":"Ustekinumab for corticodependent immune-mediated colitis by pembrolizumab, an alternative for patients with concomitant liver injury","volume":"114","author":"Fernandez-Gordon Sanchez","year":"2022","unstructured":"Fernandez-Gordon Sanchez FM,Gomez-Dominguez E,Paredes Ruiz D, et al. Ustekinumab for corticodependent immune-mediated colitis by pembrolizumab, an alternative for patients with concomitant liver injury. Rev Esp Enferm Dig. 2022;114:356\u2013357. DOI: 10.17235\/reed.2022.8618\/2022"},{"key":"i2590-017X-9-4-153-b332","series-title":"J Cutan Pathol","first-page":"472","article-title":"Severe de novo pustular psoriasiform immune-related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinoma","volume":"49","author":"Seervai","year":"2022","unstructured":"Seervai RNH,Heberton M,Cho WC, et al. Severe de novo pustular psoriasiform immune-related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinoma. J Cutan Pathol. 2022;49:472\u2013481. DOI: 10.1111\/cup.14185"},{"key":"i2590-017X-9-4-153-b333","series-title":"Immunotherapy","first-page":"593","article-title":"Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy","volume":"14","author":"Ma","year":"2022","unstructured":"Ma VT,Lao CD,Fecher LA,Schiopu E. Successful use of secukinumab in two melanoma patients with immune checkpoint inhibitor-induced inflammatory arthropathy. Immunotherapy. 2022;14:593\u2013598. DOI: 10.2217\/imt-2021-0274"},{"key":"i2590-017X-9-4-153-b334","series-title":"RMD Open","first-page":"e004308","article-title":"Successful management of pre-existing psoriatic arthritis through targeting the IL-23\/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series","volume":"10","author":"Li","year":"2024","unstructured":"Li YJ,Msaouel P,Campbell M, et al. Successful management of pre-existing psoriatic arthritis through targeting the IL-23\/IL-17 axis in cancer patients receiving immune checkpoint inhibitor therapy: a case series. RMD Open. 2024;10:e004308. DOI: 10.1136\/rmdopen-2024-004308"},{"key":"i2590-017X-9-4-153-b335","series-title":"Ann Rheum Dis","first-page":"1747","article-title":"Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment","volume":"76","author":"Belkhir","year":"2017","unstructured":"Belkhir R,Burel SL,Dunogeant L, et al. Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatment. Ann Rheum Dis. 2017;76:1747\u20131750. DOI: 10.1136\/annrheumdis-2017-211216"},{"key":"i2590-017X-9-4-153-b336","series-title":"JCO Oncol Pract","first-page":"1073","article-title":"Oral immune-related adverse events secondary to immune checkpoint inhibitors: call to action","volume":"21","author":"Villa","year":"2025","unstructured":"Villa A,Schneider BJ,Lacchetti C,Oliver TK,Peterson DE. Oral immune-related adverse events secondary to immune checkpoint inhibitors: call to action. JCO Oncol Pract. 2025;21:1073\u20131078. DOI: 10.1200\/OP-24-00812"},{"key":"i2590-017X-9-4-153-b337","series-title":"JCI Insight","first-page":"e163030","article-title":"A randomized, phase II study of sequential belimumab and rituximab in primary Sjogren's syndrome","volume":"7","author":"Mariette","year":"2022","unstructured":"Mariette X,Barone F,Baldini C, et al. A randomized, phase II study of sequential belimumab and rituximab in primary Sjogren's syndrome. JCI Insight. 2022;7:e163030. DOI: 10.1172\/jci.insight.163030"},{"issue":"Suppl 118","key":"i2590-017X-9-4-153-b338","series-title":"Clin Exp Rheumatol","first-page":"217","article-title":"B cell depletion with rituximab in the treatment of primary Sjogren's syndrome: What have we learnt","volume":"37","author":"Grigoriadou","year":"2019","unstructured":"Grigoriadou S,Chowdhury F,Pontarini E, et al. B cell depletion with rituximab in the treatment of primary Sjogren's syndrome: What have we learnt? Clin Exp Rheumatol. 2019;37(Suppl 118):217\u2013224."},{"key":"i2590-017X-9-4-153-b339","series-title":"JACC CardioOncol","first-page":"300","article-title":"Rechallenge after severe immune checkpoint inhibitor myocarditis: venturing into the unknown","volume":"7","author":"Bailly","year":"2025","unstructured":"Bailly G,Robert-Halabi M,Vion PA, et al. Rechallenge after severe immune checkpoint inhibitor myocarditis: venturing into the unknown. JACC CardioOncol. 2025;7:300\u2013304. DOI: 10.1016\/j.jaccao.2025.02.004"},{"key":"i2590-017X-9-4-153-b340","series-title":"Am J Cardiol","first-page":"33","article-title":"Immune checkpoint inhibitor rechallenge in a patient with previous fulminant myocarditis","volume":"199","author":"Menachery","year":"2023","unstructured":"Menachery SM,Hang Y,Pritchard L,Poklepovic A,Bottinor W. Immune checkpoint inhibitor rechallenge in a patient with previous fulminant myocarditis. Am J Cardiol. 2023;199:33\u201336. DOI: 10.1016\/j.amjcard.2023.04.037"},{"key":"i2590-017X-9-4-153-b341","series-title":"Nat Commun","first-page":"1970","article-title":"Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy","volume":"13","author":"Kim","year":"2022","unstructured":"Kim ST,Chu Y,Misoi M, et al. Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. Nat Commun. 2022;13:1970. DOI: 10.1038\/s41467-022-29539-3"},{"key":"i2590-017X-9-4-153-b342","series-title":"Clin Cancer Res","first-page":"1557","article-title":"Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy","volume":"25","author":"Lim","year":"2019","unstructured":"Lim SY,Lee JH,Gide TN, et al. Circulating cytokines predict immune-related toxicity in melanoma patients receiving anti-PD-1-based immunotherapy. Clin Cancer Res. 2019;25:1557\u20131563. DOI: 10.1158\/1078-0432.CCR-18-2795"},{"key":"i2590-017X-9-4-153-b343","series-title":"Eur J Cancer","first-page":"198","article-title":"Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency","volume":"130","author":"Yano","year":"2020","unstructured":"Yano S,Ashida K,Sakamoto R, et al. Human leucocyte antigen DR15, a possible predictive marker for immune checkpoint inhibitor-induced secondary adrenal insufficiency. Eur J Cancer. 2020;130:198\u2013203. DOI: 10.1016\/j.ejca.2020.02.049"},{"key":"i2590-017X-9-4-153-b344","series-title":"Rheumatology (Oxford)","first-page":"476","article-title":"Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis","volume":"58","author":"Cappelli","year":"2019","unstructured":"Cappelli LC,Dorak MT,Bettinotti MP,Bingham CO,Shah AA. Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritis. Rheumatology (Oxford). 2019;58:476\u2013480. DOI: 10.1093\/rheumatology\/key358"},{"key":"i2590-017X-9-4-153-b345","series-title":"JAMA Oncol","first-page":"1043","article-title":"Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer","volume":"5","author":"Berner","year":"2019","unstructured":"Berner F,Bomze D,Diem S, et al. Association of checkpoint inhibitor-induced toxic effects with shared cancer and tissue antigens in non-small cell lung cancer. JAMA Oncol. 2019;5:1043\u20131047. DOI: 10.1001\/jamaoncol.2019.0402"},{"key":"i2590-017X-9-4-153-b346","series-title":"Arthritis Res Ther","first-page":"118","article-title":"Are biologics more effective than classical disease-modifying antirheumatic drugs","volume":"10","author":"Nurmohamed","year":"2008","unstructured":"Nurmohamed MT,Dijkmans BA. Are biologics more effective than classical disease-modifying antirheumatic drugs? Arthritis Res Ther. 2008;10:118. DOI: 10.1186\/ar2491"},{"key":"i2590-017X-9-4-153-b347","series-title":"Kidney Int","first-page":"638","article-title":"Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors","volume":"90","author":"Cortazar","year":"2016","unstructured":"Cortazar FB,Marrone KA,Troxell ML, et al. Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016;90:638\u2013647. DOI: 10.1016\/j.kint.2016.04.008"},{"key":"i2590-017X-9-4-153-b348","series-title":"Eur J Cancer","first-page":"29","article-title":"Renal adverse effects of immune checkpoints inhibitors in clinical practice: immuNoTox study","volume":"147","author":"Espi","year":"2021","unstructured":"Espi M,Teuma C,Novel-Catin E, et al. Renal adverse effects of immune checkpoints inhibitors in clinical practice: immuNoTox study. Eur J Cancer. 2021;147:29\u201339. DOI: 10.1016\/j.ejca.2021.01.005"},{"key":"i2590-017X-9-4-153-b349","series-title":"Nephrology Dialysis Transplantation","first-page":"108","article-title":"Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis","volume":"34","author":"Manohar","year":"2019","unstructured":"Manohar S,Kompotiatis P,Thongprayoon C, et al. Programmed cell death protein 1 inhibitor treatment is associated with acute kidney injury and hypocalcemia: meta-analysis. Nephrology Dialysis Transplantation. 2019;34:108\u2013117. DOI: 10.1093\/ndt\/gfy105"},{"key":"i2590-017X-9-4-153-b350","series-title":"CJASN","first-page":"1692","article-title":"The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors","volume":"14","author":"Seethapathy","year":"2019","unstructured":"Seethapathy H,Zhao S,Chute DF, et al. The incidence, causes, and risk factors of acute kidney injury in patients receiving immune checkpoint inhibitors. CJASN. 2019;14:1692\u20131700. DOI: 10.2215\/CJN.00990119"},{"key":"i2590-017X-9-4-153-b351","series-title":"PLoS ONE","first-page":"e0252978","article-title":"Immune checkpoint inhibitor-associated acute kidney injury and mortality: an observational study","volume":"16","author":"Koks","year":"2021","unstructured":"Koks MS,Ocak G,Suelmann BBM, et al. Immune checkpoint inhibitor-associated acute kidney injury and mortality: an observational study. PLoS ONE. 2021;16:e0252978. DOI: 10.1371\/journal.pone.0252978"},{"key":"i2590-017X-9-4-153-b352","series-title":"J Immunother Cancer","first-page":"e000467","article-title":"Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes","volume":"8","author":"Meraz-Mu\u00f1oz","year":"2020","unstructured":"Meraz-Mu\u00f1oz A,Amir E,Ng P, et al. Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes. J Immunother Cancer. 2020;8:e000467. DOI: 10.1136\/jitc-2019-000467"},{"key":"i2590-017X-9-4-153-b353","series-title":"J Immunother Cancer","first-page":"e003467","article-title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","volume":"9","author":"Gupta","year":"2021","unstructured":"Gupta S,Short SAP,Sise ME, et al. Acute kidney injury in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021;9:e003467. DOI: 10.1136\/jitc-2021-003467"},{"key":"i2590-017X-9-4-153-b354","series-title":"Kidney Int Rep","first-page":"66","article-title":"A systematic review of immune checkpoint inhibitor-associated glomerular disease","volume":"6","author":"Kitchlu","year":"2021","unstructured":"Kitchlu A,Jhaveri KD,Wadhwani S, et al. A systematic review of immune checkpoint inhibitor-associated glomerular disease. Kidney Int Rep. 2021;6:66\u201377. DOI: 10.1016\/j.ekir.2020.10.002"},{"key":"i2590-017X-9-4-153-b355","series-title":"Kidney Med","first-page":"657","article-title":"Renal tubular acidosis and immune checkpoint inhibitor therapy: an immune-related adverse event of PD-1 inhibitor-a report of 3 cases","volume":"2","author":"Herrmann","year":"2020","unstructured":"Herrmann SM,Alexander MP,Romero MF,Zand L. Renal tubular acidosis and immune checkpoint inhibitor therapy: an immune-related adverse event of PD-1 inhibitor-a report of 3 cases. Kidney Med. 2020;2:657\u2013662. DOI: 10.1016\/j.xkme.2020.05.015"},{"key":"i2590-017X-9-4-153-b356","series-title":"Kidney Int Rep","first-page":"4285","article-title":"Incidence of immune checkpoint inhibitor-associated renal tubular acidosis","volume":"10","author":"Shah","year":"2025","unstructured":"Shah CV,Kim EM,Mathavan A, et al. Incidence of immune checkpoint inhibitor-associated renal tubular acidosis. Kidney Int Rep. 2025;10:4285\u20134288. DOI: 10.1016\/j.ekir.2025.09.023"},{"key":"i2590-017X-9-4-153-b357","series-title":"CJASN","first-page":"922","article-title":"Electrolyte and acid-base disorders associated with cancer immunotherapy","volume":"17","author":"Uppal","year":"2022","unstructured":"Uppal NN,Workeneh BT,Rondon-Berrios H,Jhaveri KD. Electrolyte and acid-base disorders associated with cancer immunotherapy. CJASN. 2022;17:922\u2013933. DOI: 10.2215\/CJN.14671121"},{"key":"i2590-017X-9-4-153-b358","series-title":"Nephrol Dial Transplant","first-page":"2241","article-title":"Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors","volume":"36","author":"Seethapathy","year":"2021","unstructured":"Seethapathy H,Rusibamayila N,Chute DF, et al. Hyponatremia and other electrolyte abnormalities in patients receiving immune checkpoint inhibitors. Nephrol Dial Transplant. 2021;36:2241\u20132247. DOI: 10.1093\/ndt\/gfaa272"},{"key":"i2590-017X-9-4-153-b359","series-title":"Nephrol Dial Transplant","first-page":"1598","article-title":"Immune checkpoint inhibitor-associated hypercalcaemia","volume":"37","author":"Izzedine","year":"2022","unstructured":"Izzedine H,Chazal T,Wanchoo R,Jhaveri KD. Immune checkpoint inhibitor-associated hypercalcaemia. Nephrol Dial Transplant. 2022;37:1598\u20131608. DOI: 10.1093\/ndt\/gfaa326"},{"key":"i2590-017X-9-4-153-b360","series-title":"Immunity","first-page":"141","article-title":"Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor","volume":"11","author":"Nishimura","year":"1999","unstructured":"Nishimura H,Nose M,Hiai H,Minato N,Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity. 1999;11:141\u2013151. DOI: 10.1016\/S1074-7613(00)80089-8"},{"key":"i2590-017X-9-4-153-b361","series-title":"Science (1979)","first-page":"985","article-title":"Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4","volume":"270","author":"Waterhouse","year":"1995","unstructured":"Waterhouse P,Penninger JM,Timms E, et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science (1979). 1995;270:985\u2013988. DOI: 10.1126\/science.270.5238.985"},{"key":"i2590-017X-9-4-153-b362","series-title":"Cell Rep","first-page":"111611","article-title":"Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis","volume":"41","author":"Won","year":"2022","unstructured":"Won T,Kalinoski HM,Wood MK, et al. Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis. Cell Rep. 2022;41:111611. DOI: 10.1016\/j.celrep.2022.111611"},{"key":"i2590-017X-9-4-153-b363","series-title":"Kidney Int Rep","first-page":"628","article-title":"Cytokines and immune cell phenotype in acute kidney injury associated with immune checkpoint inhibitors","volume":"8","author":"Farooqui","year":"2023","unstructured":"Farooqui N,Zaidi M,Vaughan L, et al. Cytokines and immune cell phenotype in acute kidney injury associated with immune checkpoint inhibitors. Kidney Int Rep. 2023;8:628\u2013641. DOI: 10.1016\/j.ekir.2022.11.020"},{"key":"i2590-017X-9-4-153-b364","series-title":"Cell Mol Immunol","first-page":"1066","article-title":"Tissue-resident memory T cells break tolerance to renal autoantigens and orchestrate immune-mediated nephritis","volume":"21","author":"Arnold","year":"2024","unstructured":"Arnold F,Kupferschmid L,Weissenborn P, et al. Tissue-resident memory T cells break tolerance to renal autoantigens and orchestrate immune-mediated nephritis. Cell Mol Immunol. 2024;21:1066\u20131081. DOI: 10.1038\/s41423-024-01197-z"},{"key":"i2590-017X-9-4-153-b365","series-title":"Nat Rev Nephrol","first-page":"794","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury","volume":"18","author":"Sprangers","year":"2022","unstructured":"Sprangers B,Leaf DE,Porta C,Soler MJ,Perazella MA. Diagnosis and management of immune checkpoint inhibitor-associated acute kidney injury. Nat Rev Nephrol. 2022;18:794\u2013805. DOI: 10.1038\/s41581-022-00630-8"},{"key":"i2590-017X-9-4-153-b366","series-title":"Circulation","first-page":"48","article-title":"Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis","volume":"149","author":"Ma","year":"2024","unstructured":"Ma P,Liu J,Qin J, et al. Expansion of pathogenic cardiac macrophages in immune checkpoint inhibitor myocarditis. Circulation. 2024;149:48\u201366. DOI: 10.1161\/CIRCULATIONAHA.122.062551"},{"key":"i2590-017X-9-4-153-b367","series-title":"Nature","first-page":"215","article-title":"Immune responses in checkpoint myocarditis across heart, blood and tumour","volume":"636","author":"Blum","year":"2024","unstructured":"Blum SM,Zlotoff DA,Smith NP, et al. Immune responses in checkpoint myocarditis across heart, blood and tumour. Nature. 2024;636:215\u2013223. DOI: 10.1038\/s41586-024-08105-5"},{"key":"i2590-017X-9-4-153-b368","series-title":"JCI Insight","article-title":"Tertiary lymphoid structure signatures are associated with immune checkpoint inhibitor related acute interstitial nephritis","author":"Singh","year":"2022","unstructured":"Singh S,Long JP,Tchakarov A, et al. Tertiary lymphoid structure signatures are associated with immune checkpoint inhibitor related acute interstitial nephritis. JCI Insight. 2022. DOI: 10.1172\/jci.insight.165108"},{"key":"i2590-017X-9-4-153-b369","series-title":"Nat Commun","first-page":"1549","article-title":"Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy","volume":"14","author":"Dunlap","year":"2023","unstructured":"Dunlap GS,DiToro D,Henderson J, et al. Clonal dynamics of alloreactive T cells in kidney allograft rejection after anti-PD-1 therapy. Nat Commun. 2023;14:1549. DOI: 10.1038\/s41467-023-37230-4"},{"key":"i2590-017X-9-4-153-b370","series-title":"J Am Soc Nephrol","first-page":"435","article-title":"Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study","volume":"31","author":"Cortazar","year":"2020","unstructured":"Cortazar FB,Kibbelaar ZA,Glezerman IG, et al. Clinical features and outcomes of immune checkpoint inhibitor-associated AKI: a multicenter study. J Am Soc Nephrol. 2020;31:435\u2013446. DOI: 10.1681\/ASN.2019070676"},{"key":"i2590-017X-9-4-153-b371","series-title":"Kidney Int Rep","first-page":"1022","article-title":"Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events","volume":"6","author":"Isik","year":"2021","unstructured":"Isik B,Alexander MP,Manohar S, et al. Biomarkers, clinical features, and rechallenge for immune checkpoint inhibitor renal immune-related adverse events. Kidney Int Rep. 2021;6:1022\u20131031. DOI: 10.1016\/j.ekir.2021.01.013"},{"key":"i2590-017X-9-4-153-b372","series-title":"Clin Exp Nephrol","first-page":"603","article-title":"Immune checkpoint inhibitor-associated acute kidney injury in patients with cancer: a systematic review and meta-analysis of risk factors","volume":"27","author":"Yan","year":"2023","unstructured":"Yan H,Tang M,Zhu W,Yang Y. Immune checkpoint inhibitor-associated acute kidney injury in patients with cancer: a systematic review and meta-analysis of risk factors. Clin Exp Nephrol. 2023;27:603\u2013612. DOI: 10.1007\/s10157-023-02344-y"},{"key":"i2590-017X-9-4-153-b373","series-title":"Am J Nephrol","first-page":"439","article-title":"Association of proton pump inhibitor use and immune checkpoint inhibitor-mediated acute kidney injury: a meta-analysis and a review of related outcomes","volume":"55","author":"Mohan","year":"2024","unstructured":"Mohan A,Krisanapan P,Tangpanithandee S, et al. Association of proton pump inhibitor use and immune checkpoint inhibitor-mediated acute kidney injury: a meta-analysis and a review of related outcomes. Am J Nephrol. 2024;55:439\u2013449. DOI: 10.1159\/000538274"},{"key":"i2590-017X-9-4-153-b374","series-title":"Ther Adv Med Oncol","first-page":"17588359221111703","article-title":"Association of proton pump inhibitor use with survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"14","author":"Chen","year":"2022","unstructured":"Chen B,Yang C,Dragomir MP, et al. Association of proton pump inhibitor use with survival outcomes in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Ther Adv Med Oncol. 2022;14:17588359221111703. DOI: 10.1177\/17588359221111703"},{"key":"i2590-017X-9-4-153-b375","series-title":"Clin Kidney J","first-page":"sfad292","article-title":"All-cause and immune checkpoint inhibitor-associated acute kidney injury in immune checkpoint inhibitor users: a meta-analysis of occurrence rate, risk factors and mortality","volume":"17","author":"Chen","year":"2024","unstructured":"Chen J-J,Lee T-H,Kuo G, et al. All-cause and immune checkpoint inhibitor-associated acute kidney injury in immune checkpoint inhibitor users: a meta-analysis of occurrence rate, risk factors and mortality. Clin Kidney J. 2024;17:sfad292. DOI: 10.1093\/ckj\/sfad292"},{"key":"i2590-017X-9-4-153-b376","series-title":"Kidney Int Rep","first-page":"1139","article-title":"Immune checkpoint inhibitors and immune-related adverse renal events","volume":"5","author":"Herrmann","year":"2020","unstructured":"Herrmann SM,Perazella MA. Immune checkpoint inhibitors and immune-related adverse renal events. Kidney Int Rep. 2020;5:1139\u20131148. DOI: 10.1016\/j.ekir.2020.04.018"},{"key":"i2590-017X-9-4-153-b377","series-title":"Nephrol Dial Transplant","first-page":"1785","article-title":"Immune checkpoint inhibitor-associated nephritis-treatment standard","volume":"39","author":"Barbir","year":"2024","unstructured":"Barbir EB,Kitchlu A,Herrmann SM. Immune checkpoint inhibitor-associated nephritis-treatment standard. Nephrol Dial Transplant. 2024;39:1785\u20131798. DOI: 10.1093\/ndt\/gfae184"},{"key":"i2590-017X-9-4-153-b378","series-title":"Kidney Int","first-page":"21","article-title":"Diagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onco-Nephrology","volume":"107","author":"Herrmann","year":"2025","unstructured":"Herrmann SM,Abudayyeh A,Gupta S, et al. Diagnosis and management of immune checkpoint inhibitor-associated nephrotoxicity: a position statement from the American Society of Onco-Nephrology. Kidney Int. 2025;107:21\u201332. DOI: 10.1016\/j.kint.2024.09.017"},{"key":"i2590-017X-9-4-153-b379","series-title":"J Immunother Cancer","first-page":"e005646","article-title":"Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI","volume":"10","author":"Gupta","year":"2022","unstructured":"Gupta S,Garcia-Carro C,Prosek JM, et al. Shorter versus longer corticosteroid duration and recurrent immune checkpoint inhibitor-associated AKI. J Immunother Cancer. 2022;10:e005646. DOI: 10.1136\/jitc-2022-005646"},{"key":"i2590-017X-9-4-153-b380","series-title":"J Immunother Cancer","first-page":"e002292","article-title":"Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study","volume":"9","author":"Lee","year":"2021","unstructured":"Lee MD,Seethapathy H,Strohbehn IA, et al. Rapid corticosteroid taper versus standard of care for immune checkpoint inhibitor induced nephritis: a single-center retrospective cohort study. J Immunother Cancer. 2021;9:e002292. DOI: 10.1136\/jitc-2020-002292"},{"key":"i2590-017X-9-4-153-b381","series-title":"Kidney Int Rep","first-page":"32","article-title":"Infliximab for grade III or IV immune checkpoint inhibitor nephritis clinical and translational evidence","volume":"11","author":"Youssef","year":"2026","unstructured":"Youssef N,Habeeb M,Chen H, et al. Infliximab for grade III or IV immune checkpoint inhibitor nephritis clinical and translational evidence. Kidney Int Rep. 2026;11:32\u201342. DOI: 10.1016\/j.ekir.2025.10.018"},{"key":"i2590-017X-9-4-153-b382","series-title":"Nephrol Dial Transplant","first-page":"602","article-title":"Biomarker-guided infliximab therapy for immune checkpoint inhibitor-induced acute interstitial nephritis","volume":"40","author":"Barbir","year":"2025","unstructured":"Barbir EB,Mohan A,Koirala P, et al. Biomarker-guided infliximab therapy for immune checkpoint inhibitor-induced acute interstitial nephritis. Nephrol Dial Transplant. 2025;40:602\u2013604. DOI: 10.1093\/ndt\/gfae257"},{"key":"i2590-017X-9-4-153-b383","series-title":"Oncoimmunology","first-page":"1877415","article-title":"Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis","volume":"10","author":"Lin","year":"2021","unstructured":"Lin JS,Mamlouk O,Selamet U, et al. Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis. Oncoimmunology. 2021;10:1877415. DOI: 10.1080\/2162402X.2021.1877415"},{"key":"i2590-017X-9-4-153-b384","series-title":"Cancer Immunol Immunother","first-page":"324","article-title":"Immune checkpoint inhibitors-associated acute kidney injury: a systematic review and meta-analysis of incidence, kidney recovery, and recurrent risk","volume":"74","author":"Ho","year":"2025","unstructured":"Ho C-W,Kang N-W,Yeh T-H, et al. Immune checkpoint inhibitors-associated acute kidney injury: a systematic review and meta-analysis of incidence, kidney recovery, and recurrent risk. Cancer Immunol Immunother. 2025;74:324. DOI: 10.1007\/s00262-025-04147-4"},{"key":"i2590-017X-9-4-153-b385","series-title":"J Immunother Cancer","first-page":"e006222","article-title":"Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis","volume":"11","author":"Sise","year":"2023","unstructured":"Sise ME,Wang Q,Seethapathy H, et al. Soluble and cell-based markers of immune checkpoint inhibitor-associated nephritis. J Immunother Cancer. 2023;11:e006222. DOI: 10.1136\/jitc-2022-006222"},{"key":"i2590-017X-9-4-153-b386","series-title":"J Immunother Cancer","first-page":"e010680","article-title":"Urine proteomics defines an immune checkpoint-associated nephritis signature","volume":"13","author":"Long","year":"2025","unstructured":"Long JP,Singh S,Dong Y,Yee C,Lin JS. Urine proteomics defines an immune checkpoint-associated nephritis signature. J Immunother Cancer. 2025;13:e010680. DOI: 10.1136\/jitc-2024-010680"},{"key":"i2590-017X-9-4-153-b387","series-title":"Kidney Int","first-page":"491","article-title":"Urinary C-X-C-motif ligand 9 (CXCL9) in immune checkpoint inhibitor-associated acute interstitial nephritis","volume":"108","author":"Gupta","year":"2025","unstructured":"Gupta S,Mistry K,Alikhan FM, et al. Urinary C-X-C-motif ligand 9 (CXCL9) in immune checkpoint inhibitor-associated acute interstitial nephritis. Kidney Int. 2025;108:491\u2013496. DOI: 10.1016\/j.kint.2025.05.029"},{"key":"i2590-017X-9-4-153-b388","series-title":"J Clin Invest","article-title":"Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis","volume":"133","author":"Moledina","year":"2023","unstructured":"Moledina DG,Obeid W,Smith RN, et al. Identification and validation of urinary CXCL9 as a biomarker for diagnosis of acute interstitial nephritis. J Clin Invest. 2023;133. DOI: 10.1172\/JCI168950"},{"key":"i2590-017X-9-4-153-b389","series-title":"J Clin Invest","article-title":"F18-FDG PET imaging as a diagnostic tool for immune checkpoint inhibitor-associated acute kidney injury","volume":"134","author":"Gupta","year":"2024","unstructured":"Gupta S,Green-Lingren O,Bhimaniya S, et al. F18-FDG PET imaging as a diagnostic tool for immune checkpoint inhibitor-associated acute kidney injury. J Clin Invest. 2024;134. DOI: 10.1172\/JCI182275"},{"key":"i2590-017X-9-4-153-b390","series-title":"Kidney Int","first-page":"196","article-title":"A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant","volume":"100","author":"Murakami","year":"2021","unstructured":"Murakami N,Mulvaney P,Danesh M, et al. A multi-center study on safety and efficacy of immune checkpoint inhibitors in cancer patients with kidney transplant. Kidney Int. 2021;100:196\u2013205. DOI: 10.1016\/j.kint.2020.12.015"},{"key":"i2590-017X-9-4-153-b391","series-title":"Eur J Cancer","first-page":"36","article-title":"Transplant rejections associated with immune checkpoint inhibitors: a pharmacovigilance study and systematic literature review","volume":"148","author":"Nguyen","year":"2021","unstructured":"Nguyen LS,Ortuno S,Lebrun-Vignes B, et al. Transplant rejections associated with immune checkpoint inhibitors: a pharmacovigilance study and systematic literature review. Eur J Cancer. 2021;148:36\u201347. DOI: 10.1016\/j.ejca.2021.01.038"},{"key":"i2590-017X-9-4-153-b392","series-title":"J Clin Oncol","first-page":"1021","article-title":"Cemiplimab for kidney transplant recipients with advanced cutaneous squamous cell carcinoma","volume":"42","author":"Hanna","year":"2024","unstructured":"Hanna GJ,Dharanesswaran H,Giobbie-Hurder A, et al. Cemiplimab for kidney transplant recipients with advanced cutaneous squamous cell carcinoma. J Clin Oncol. 2024;42:1021\u20131030. DOI: 10.1200\/JCO.23.01498"},{"key":"i2590-017X-9-4-153-b393","article-title":"A Phase Ib Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO)","year":"Jul 16, 2019","unstructured":"A Phase Ib Study of Nivolumab in Patients with Autoimmune Disorders and Advanced Malignancies (AIM-NIVO). Accessed Jul 16, 2019. clinicaltrials.gov\/study\/NCT03816345"},{"key":"i2590-017X-9-4-153-b394","series-title":"JAMA Oncol","first-page":"1721","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","unstructured":"Wang DY,Salem J-E,Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4:1721\u20131728. DOI: 10.1001\/jamaoncol.2018.3923"},{"key":"i2590-017X-9-4-153-b395","series-title":"Intl Journal of Cancer","first-page":"2352","article-title":"How many people in the US are eligible for and respond to checkpoint inhibitors: an empirical analysis","volume":"156","author":"Haslam","year":"2025","unstructured":"Haslam A,Olivier T,Prasad V. How many people in the US are eligible for and respond to checkpoint inhibitors: an empirical analysis. Intl Journal of Cancer. 2025;156:2352\u20132359. DOI: 10.1002\/ijc.35347"},{"key":"i2590-017X-9-4-153-b396","series-title":"Cancer Discov","first-page":"1100","article-title":"Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem","year":"2023","unstructured":"Salem J-E,Bretagne M,Abbar B, et al. Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis. Cancer Discov. 2023;13:1100\u20131115. DOI: 10.1158\/2159-8290.CD-22-1180"},{"key":"i2590-017X-9-4-153-b397","series-title":"Cureus","first-page":"e42071","article-title":"A systematic review of myocarditis induced by immune checkpoint inhibitors: How concerning is the most common cardiotoxicity of immune checkpoint inhibitors","volume":"15","author":"Moradi","year":"2023","unstructured":"Moradi A,Kodali A,Okoye C, et al. A systematic review of myocarditis induced by immune checkpoint inhibitors: How concerning is the most common cardiotoxicity of immune checkpoint inhibitors? Cureus. 2023;15:e42071. DOI: 10.7759\/cureus.42071"},{"key":"i2590-017X-9-4-153-b398","series-title":"Eur Heart J","article-title":"Immune checkpoint inhibitor-associated myocarditis: a novel risk score","author":"Power","year":"2025","unstructured":"Power JR,Dolladille C,Ozbay B, et al. Immune checkpoint inhibitor-associated myocarditis: a novel risk score. Eur Heart J. 2025. DOI: 10.1093\/eurheartj\/ehaf315"},{"key":"i2590-017X-9-4-153-b399","series-title":"J Am Coll Cardiol","article-title":"Diagnosis and management of cardiovascular adverse effects of targeted oncology therapies: Bruton's tyrosine kinase, immune checkpoint, and vascular endothelial growth factor inhibitors: 2025 ACC Concise Clinical Guidance: a report of the American College of Cardiology Solution Set Oversight Committee","author":"Ganatra","year":"2025","unstructured":"Ganatra S,Barac A,Armenian S, et al. Diagnosis and management of cardiovascular adverse effects of targeted oncology therapies: Bruton's tyrosine kinase, immune checkpoint, and vascular endothelial growth factor inhibitors: 2025 ACC Concise Clinical Guidance: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2025. DOI: 10.1016\/j.jacc.2025.10.018"},{"key":"i2590-017X-9-4-153-b400","series-title":"JAHA","first-page":"e038719","article-title":"Predictors of long-term survival in patients with immune checkpoint inhibitor-associated myocarditis","volume":"14","author":"Dubey","year":"2025","unstructured":"Dubey N,Wu C,Zubiri L, et al. Predictors of long-term survival in patients with immune checkpoint inhibitor-associated myocarditis. JAHA. 2025;14:e038719. DOI: 10.1161\/JAHA.124.038719"},{"key":"i2590-017X-9-4-153-b401","series-title":"Eur Heart J","first-page":"4229","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","unstructured":"Lyon AR,L\u00f3pez-Fern\u00e1ndez T,Couch LS, et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022;43:4229\u20134361. DOI: 10.1093\/eurheartj\/ehac244"},{"key":"i2590-017X-9-4-153-b402","series-title":"Circulation","first-page":"2031","article-title":"Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis","volume":"141","author":"Zhang","year":"2020","unstructured":"Zhang L,Zlotoff DA,Awadalla M, et al. Major adverse cardiovascular events and the timing and dose of corticosteroids in immune checkpoint inhibitor-associated myocarditis. Circulation. 2020;141:2031\u20132034. DOI: 10.1161\/CIRCULATIONAHA.119.044703"},{"key":"i2590-017X-9-4-153-b403","series-title":"JACC CardioOncol","first-page":"800","article-title":"Steroids in immune checkpoint inhibitor myocarditis","volume":"6","author":"Palaskas","year":"2024","unstructured":"Palaskas NL,Siddiqui BA,Deswal A. Steroids in immune checkpoint inhibitor myocarditis. JACC CardioOncol. 2024;6:800\u2013803. DOI: 10.1016\/j.jaccao.2024.07.002"},{"key":"i2590-017X-9-4-153-b404","series-title":"J Immunotherapy Cancer","first-page":"11","article-title":"Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma","volume":"3","author":"L\u00e4ubli","year":"2015","unstructured":"L\u00e4ubli H,Balmelli C,Bossard M, et al. Acute heart failure due to autoimmune myocarditis under pembrolizumab treatment for metastatic melanoma. J Immunotherapy Cancer. 2015;3:11. DOI: 10.1186\/s40425-015-0057-1"},{"key":"i2590-017X-9-4-153-b405","series-title":"Eur J Heart Fail","first-page":"1725","article-title":"Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy","volume":"23","author":"Palaskas","year":"2021","unstructured":"Palaskas NL,Segura A,Lelenwa L, et al. Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy. Eur J Heart Fail. 2021;23:1725\u20131735. DOI: 10.1002\/ejhf.2265"},{"key":"i2590-017X-9-4-153-b406","series-title":"JACC Cardio Oncol","first-page":"732","article-title":"Severe vs nonsevere immune checkpoint inhibitor-induced myocarditis: contemporary 1-year outcomes","volume":"5","author":"Itzhaki Ben Zadok","year":"2023","unstructured":"Itzhaki Ben Zadok O,Levi A,Divakaran S,Nohria A. Severe vs nonsevere immune checkpoint inhibitor-induced myocarditis: contemporary 1-year outcomes. JACC Cardio Oncol. 2023;5:732\u2013744. DOI: 10.1016\/j.jaccao.2023.09.004"},{"key":"i2590-017X-9-4-153-b407","series-title":"Cancer Discov","first-page":"614","article-title":"A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention","volume":"11","author":"Wei","year":"2021","unstructured":"Wei SC,Meijers WC,Axelrod ML, et al. A genetic mouse model recapitulates immune checkpoint inhibitor-associated myocarditis and supports a mechanism-based therapeutic intervention. Cancer Discov. 2021;11:614\u2013625. DOI: 10.1158\/2159-8290.CD-20-0856"},{"key":"i2590-017X-9-4-153-b408","series-title":"Arch Cardiovasc Dis","first-page":"106","article-title":"Abatacept dose-finding phase II trial for immune checkpoint inhibitors myocarditis (ACHLYS) trial design","volume":"118","author":"Salem","year":"2025","unstructured":"Salem J-E,Ederhy S,Belin L, et al. Abatacept dose-finding phase II trial for immune checkpoint inhibitors myocarditis (ACHLYS) trial design. Arch Cardiovasc Dis. 2025;118:106\u2013115. DOI: 10.1016\/j.acvd.2024.12.005"},{"key":"i2590-017X-9-4-153-b409","series-title":"Ann Oncol","first-page":"1824","article-title":"A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors","volume":"26","author":"Chen","year":"2015","unstructured":"Chen TW,Razak AR,Bedard PL,Siu LL,Hansen AR. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol. 2015;26:1824\u20131829. DOI: 10.1093\/annonc\/mdv182"},{"key":"i2590-017X-9-4-153-b410","series-title":"Front Immunol","first-page":"874829","article-title":"Adverse event reporting quality in cancer clinical trials evaluating immune checkpoint inhibitor therapy: a systematic review","volume":"13","author":"Wang","year":"2022","unstructured":"Wang Y,Chen C,Du W, et al. Adverse event reporting quality in cancer clinical trials evaluating immune checkpoint inhibitor therapy: a systematic review. Front Immunol. 2022;13:874829. DOI: 10.3389\/fimmu.2022.874829"},{"key":"i2590-017X-9-4-153-b411","series-title":"Eur J Cancer","first-page":"7","article-title":"Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis","volume":"103","author":"Petrelli","year":"2018","unstructured":"Petrelli F,Ardito R,Borgonovo K, et al. Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2018;103:7\u201316. DOI: 10.1016\/j.ejca.2018.07.129"},{"key":"i2590-017X-9-4-153-b412","series-title":"Eur J Cancer","first-page":"170","article-title":"Hematological immune related adverse events after treatment with immune checkpoint inhibitors","volume":"147","author":"Kramer","year":"2021","unstructured":"Kramer R,Zaremba A,Moreira A, et al. Hematological immune related adverse events after treatment with immune checkpoint inhibitors. Eur J Cancer. 2021;147:170\u2013181. DOI: 10.1016\/j.ejca.2021.01.013"},{"key":"i2590-017X-9-4-153-b413","series-title":"Ann Hematol","first-page":"3537","article-title":"Immunotherapy-associated hemostatic abnormalities: bleeding and thrombotic complications","volume":"104","author":"Li","year":"2025","unstructured":"Li Y,Jiang H,Luo L,Mei H. Immunotherapy-associated hemostatic abnormalities: bleeding and thrombotic complications. Ann Hematol. 2025;104:3537\u20133551. DOI: 10.1007\/s00277-025-06482-z"},{"key":"i2590-017X-9-4-153-b414","series-title":"Front Pharmacol","first-page":"1453429","article-title":"Delayed immune-related adverse events profile associated with immune checkpoint inhibitors: a real-world analysis","volume":"15","author":"Yang","year":"2024","unstructured":"Yang Y,Li L,Tian J, et al. Delayed immune-related adverse events profile associated with immune checkpoint inhibitors: a real-world analysis. Front Pharmacol. 2024;15:1453429. DOI: 10.3389\/fphar.2024.1453429"},{"key":"i2590-017X-9-4-153-b415","series-title":"J Clin Oncol","first-page":"2649","article-title":"Impact of immune checkpoint inhibitor (ICI)-associated autoimmune hemolytic anemia (AIHA) on mortality in cancer patients: a retrospective analysis","volume":"43","author":"Sohail","year":"2025","unstructured":"Sohail H,Amin N,Collins J,Kamran A. Impact of immune checkpoint inhibitor (ICI)-associated autoimmune hemolytic anemia (AIHA) on mortality in cancer patients: a retrospective analysis. J Clin Oncol. 2025;43:2649. DOI: 10.1200\/JCO.2025.43.16_suppl.2649"},{"key":"i2590-017X-9-4-153-b416","series-title":"Lancet Haematol","first-page":"e48","article-title":"Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study","volume":"6","author":"Delanoy","year":"2019","unstructured":"Delanoy N,Michot J-M,Comont T, et al. Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study. Lancet Haematol. 2019;6:e48\u2013e57. DOI: 10.1016\/S2352-3026(18)30175-3"},{"key":"i2590-017X-9-4-153-b417","series-title":"Eur J Haematol","first-page":"157","article-title":"Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the food and drug administration database and review","volume":"102","author":"Tanios","year":"2019","unstructured":"Tanios GE,Doley PB,Munker R. Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the food and drug administration database and review. Eur J Haematol. 2019;102:157\u2013162. DOI: 10.1111\/ejh.13187"},{"key":"i2590-017X-9-4-153-b418","series-title":"Blood","first-page":"841","article-title":"Immune thrombocytopenia in patients treated with immune checkpoint inhibitors","volume":"146","author":"Leaf","year":"2025","unstructured":"Leaf R,Mones J,Shenoy T, et al. Immune thrombocytopenia in patients treated with immune checkpoint inhibitors. Blood. 2025;146:841. DOI: 10.1182\/blood-2025-841"},{"key":"i2590-017X-9-4-153-b419","series-title":"J Immunother","first-page":"67","article-title":"Immune-related neutropenia following treatment with immune checkpoint inhibitors","volume":"43","author":"Finkel","year":"2020","unstructured":"Finkel I,Sternschuss M,Wollner M, et al. Immune-related neutropenia following treatment with immune checkpoint inhibitors. J Immunother. 2020;43:67\u201374. DOI: 10.1097\/CJI.0000000000000293"},{"key":"i2590-017X-9-4-153-b420","series-title":"Int Immunopharmacol","first-page":"109490","article-title":"Immune checkpoint inhibitor-induced pure red cell aplasia: case series and large-scale pharmacovigilance analysis","volume":"114","author":"Guo","year":"2023","unstructured":"Guo Q,Gao J,Guo H,Xie J,Cheng J. Immune checkpoint inhibitor-induced pure red cell aplasia: case series and large-scale pharmacovigilance analysis. Int Immunopharmacol. 2023;114:109490. DOI: 10.1016\/j.intimp.2022.109490"},{"key":"i2590-017X-9-4-153-b421","series-title":"Front Oncol","first-page":"1760","article-title":"Case report: successful treatment of steroid-refractory immune checkpoint inhibitor-related pure red cell aplasia with cyclosporin","volume":"10","author":"G\u00e9rard","year":"2020","unstructured":"G\u00e9rard A,Romani S,Van-Obberghen E, et al. Case report: successful treatment of steroid-refractory immune checkpoint inhibitor-related pure red cell aplasia with cyclosporin. Front Oncol. 2020;10:1760. DOI: 10.3389\/fonc.2020.01760"},{"key":"i2590-017X-9-4-153-b422","series-title":"Intern Med","first-page":"2041","article-title":"Pembrolizumab-induced pure red cell aplasia successfully treated with intravenous immunoglobulin","volume":"59","author":"Isoda","year":"2020","unstructured":"Isoda A,Miyazawa Y,Tahara K, et al. Pembrolizumab-induced pure red cell aplasia successfully treated with intravenous immunoglobulin. Intern Med. 2020;59:2041\u20132045. DOI: 10.2169\/internalmedicine.4467-20"},{"key":"i2590-017X-9-4-153-b423","series-title":"Intern Med","first-page":"562","article-title":"A case of successful treatment of aplastic anemia induced by immune checkpoint inhibitors for lung cancer","volume":"65","author":"Sumi","year":"2026","unstructured":"Sumi C,Yamamoto M,Sasaki R, et al. A case of successful treatment of aplastic anemia induced by immune checkpoint inhibitors for lung cancer. Intern Med. 2026;65:562\u2013568. DOI: 10.2169\/internalmedicine.5590-25"},{"key":"i2590-017X-9-4-153-b424","series-title":"Int Immunopharmacol","first-page":"109015","article-title":"Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: a real-world study of the FDA adverse event reporting system","volume":"110","author":"Moore","year":"2022","unstructured":"Moore DC,Elmes JB,Arnall JR,Strassels SA,Patel JN. Acquired thrombotic thrombocytopenic purpura associated with immune checkpoint inhibitors: a real-world study of the FDA adverse event reporting system. Int Immunopharmacol. 2022;110:109015. DOI: 10.1016\/j.intimp.2022.109015"},{"key":"i2590-017X-9-4-153-b425","series-title":"Oncologist","first-page":"1009","article-title":"Nivolumab-induced thrombotic thrombocytopenic purpura in a patient with anal squamous cell carcinoma: a lesson on hematologic toxicity from immunotherapy","volume":"25","author":"Gergi","year":"2020","unstructured":"Gergi M,Landry KK,Ades S, et al. Nivolumab-induced thrombotic thrombocytopenic purpura in a patient with anal squamous cell carcinoma: a lesson on hematologic toxicity from immunotherapy. Oncologist. 2020;25:1009\u20131012. DOI: 10.1002\/onco.13553"},{"key":"i2590-017X-9-4-153-b426","series-title":"Transfusion","first-page":"1241","article-title":"Durable remission of thrombotic thrombocytopenic purpura in the setting of pembrolizumab therapy","volume":"63","author":"Kozak","year":"2023","unstructured":"Kozak M,Rubenstein W,Okwan\u2010Duodu D, et al. Durable remission of thrombotic thrombocytopenic purpura in the setting of pembrolizumab therapy. Transfusion. 2023;63:1241\u20131245. DOI: 10.1111\/trf.17378"},{"key":"i2590-017X-9-4-153-b427","series-title":"N Engl J Med","first-page":"584","article-title":"Hemophagocytic lymphohistiocytosis","volume":"392","author":"Henter","year":"2025","unstructured":"Henter JI. Hemophagocytic lymphohistiocytosis. N Engl J Med. 2025;392:584\u2013598. DOI: 10.1056\/NEJMra231400539908433"},{"key":"i2590-017X-9-4-153-b428","series-title":"Pediatr Blood Cancer","first-page":"e27929","article-title":"Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the North American Consortium for Histiocytosis (NACHO)","volume":"66","author":"Jordan","year":"2019","unstructured":"Jordan MB,Allen CE,Greenberg J, et al. Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: recommendations from the North American Consortium for Histiocytosis (NACHO). Pediatr Blood Cancer. 2019;66:e27929. DOI: 10.1002\/pbc.27929"},{"key":"i2590-017X-9-4-153-b429","series-title":"Blood","first-page":"1098","article-title":"An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis","volume":"139","author":"Zoref-Lorenz","year":"2022","unstructured":"Zoref-Lorenz A,Murakami J,Hofstetter L, et al. An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis. Blood. 2022;139:1098\u20131110. DOI: 10.1182\/blood.2021012764"},{"key":"i2590-017X-9-4-153-b430","series-title":"Ann Oncol","first-page":"444","article-title":"Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy","volume":"36","author":"Daoudlarian","year":"2025","unstructured":"Daoudlarian D,Segot A,Latifyan S, et al. Tocilizumab and immune signatures for targeted management of cytokine release syndrome in immune checkpoint therapy. Ann Oncol. 2025;36:444\u2013459. DOI: 10.1016\/j.annonc.2024.12.004"},{"key":"i2590-017X-9-4-153-b431","series-title":"Orphanet J Rare Dis","first-page":"363","article-title":"Limited efficacy of tocilizumab in adult patients with secondary hemophagocytic lymphohistiocytosis: a retrospective cohort study","volume":"17","author":"Kim","year":"2022","unstructured":"Kim JY,Kim M,Park JK, et al. Limited efficacy of tocilizumab in adult patients with secondary hemophagocytic lymphohistiocytosis: a retrospective cohort study. Orphanet J Rare Dis. 2022;17:363. DOI: 10.1186\/s13023-022-02516-1"},{"key":"i2590-017X-9-4-153-b432","series-title":"J Med Case Rep","first-page":"535","article-title":"Treatment-refractory immune checkpoint inhibitor-induced hemophagocytic lymphohistiocytosis in the setting of adjuvant pembrolizumab for resected stage IIC melanoma: a case report","volume":"19","author":"Chow","year":"2025","unstructured":"Chow KVC,Mui K,Hunt S,Gan CL. Treatment-refractory immune checkpoint inhibitor-induced hemophagocytic lymphohistiocytosis in the setting of adjuvant pembrolizumab for resected stage IIC melanoma: a case report. J Med Case Rep. 2025;19:535. DOI: 10.1186\/s13256-025-05302-2"},{"key":"i2590-017X-9-4-153-b433","series-title":"Haematologica","first-page":"2998","article-title":"Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosis","volume":"109","author":"Johnson","year":"2024","unstructured":"Johnson WT,Epstein-Peterson ZD,Ganesan N, et al. Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosis. Haematologica. 2024;109:2998\u20133003. DOI: 10.3324\/haematol.2023.284179"},{"key":"i2590-017X-9-4-153-b434","series-title":"Blood","first-page":"1959","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","unstructured":"Mulder FI,Horv\u00e1th-Puh\u00f3 E,van Es N, et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood. 2021;137:1959\u20131969. DOI: 10.1182\/blood.2020007338"},{"key":"i2590-017X-9-4-153-b435","series-title":"J Thromb Haemost","first-page":"2921","article-title":"The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: a Danish cohort study","volume":"20","author":"Overvad","year":"2022","unstructured":"Overvad TF,Skjoth F,Piazza G, et al. The Khorana score and venous and arterial thrombosis in patients with cancer treated with immune checkpoint inhibitors: a Danish cohort study. J Thromb Haemost. 2022;20:2921\u20132929. DOI: 10.1111\/jth.15883"},{"key":"i2590-017X-9-4-153-b436","series-title":"Eur J Haematol","first-page":"271","article-title":"Assessing the risk of thromboembolism in cancer patients receiving immunotherapy","volume":"108","author":"Goel","year":"2022","unstructured":"Goel A,Khorana A,Kartika T, et al. Assessing the risk of thromboembolism in cancer patients receiving immunotherapy. Eur J Haematol. 2022;108:271\u2013277. DOI: 10.1111\/ejh.13734"},{"key":"i2590-017X-9-4-153-b437","series-title":"Blood","first-page":"1669","article-title":"Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy","volume":"137","author":"Moik","year":"2021","unstructured":"Moik F,Chan W-SE,Wiedemann S, et al. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood. 2021;137:1669\u20131678. DOI: 10.1182\/blood.2020007878"},{"key":"i2590-017X-9-4-153-b438","series-title":"J Immunother Cancer","first-page":"e010761","article-title":"Immune checkpoint inhibitor-associated risk for venous thromboembolism: a comprehensive analysis","volume":"13","author":"Sussman","year":"2025","unstructured":"Sussman TA,Giobbie-Hurder A,Dryg ID, et al. Immune checkpoint inhibitor-associated risk for venous thromboembolism: a comprehensive analysis. J Immunother Cancer. 2025;13:e010761. DOI: 10.1136\/jitc-2024-010761"},{"key":"i2590-017X-9-4-153-b439","series-title":"Am J Hematol","first-page":"563","article-title":"Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors","volume":"94","author":"Leaf","year":"2019","unstructured":"Leaf RK,Ferreri C,Rangachari D, et al. Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. Am J Hematol. 2019;94:563\u2013574. DOI: 10.1002\/ajh.25448"},{"key":"i2590-017X-9-4-153-b440","series-title":"J Immunother Cancer","first-page":"e009902","article-title":"Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase","volume":"12","author":"Noseda","year":"2024","unstructured":"Noseda R,Bedussi F,Giunchi V, et al. Reporting of late-onset immune-related adverse events with immune checkpoint inhibitors in VigiBase. J Immunother Cancer. 2024;12:e009902. DOI: 10.1136\/jitc-2024-009902"},{"key":"i2590-017X-9-4-153-b441","series-title":"Cancers (Basel)","first-page":"5804","article-title":"Autoimmune hemolytic anemia in chronic lymphocytic leukemia: a comprehensive review","volume":"13","author":"Autore","year":"2021","unstructured":"Autore F,Pasquale R,Innocenti I, et al. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: a comprehensive review. Cancers (Basel). 2021;13:5804. DOI: 10.3390\/cancers13225804"},{"key":"i2590-017X-9-4-153-b442","series-title":"Curr Hematol Malig Rep","first-page":"29","article-title":"A concise review of autoimmune cytopenias in chronic lymphocytic leukemia","volume":"12","author":"Tsang","year":"2017","unstructured":"Tsang M,Parikh SA. A concise review of autoimmune cytopenias in chronic lymphocytic leukemia. Curr Hematol Malig Rep. 2017;12:29\u201338. DOI: 10.1007\/s11899-017-0366-1"},{"key":"i2590-017X-9-4-153-b443","series-title":"Cancer Med","first-page":"569","article-title":"Association of hearing loss and tinnitus symptoms with health-related quality of life among long-term oropharyngeal cancer survivors","volume":"12","author":"Aggarwal","year":"2023","unstructured":"Aggarwal P,Nader M,Gidley PW, et al. Association of hearing loss and tinnitus symptoms with health-related quality of life among long-term oropharyngeal cancer survivors. Cancer Med. 2023;12:569\u2013583. DOI: 10.1002\/cam4.4931"},{"key":"i2590-017X-9-4-153-b444","series-title":"Otolaryngol-Head Neck Surg","first-page":"243","article-title":"The effects of metformin on cisplatin-induced ototoxicity in diabetic patients","volume":"172","author":"Nader","year":"2025","unstructured":"Nader M,Choi J,Hernandez M, et al. The effects of metformin on cisplatin-induced ototoxicity in diabetic patients. Otolaryngol-Head Neck Surg. 2025;172:243\u2013253. DOI: 10.1002\/ohn.1032"},{"key":"i2590-017X-9-4-153-b445","series-title":"J Cancer Surviv","first-page":"59","article-title":"Associations among hearing loss, multiple co-occurring symptoms, and quality of life outcomes in cancer survivors","volume":"17","author":"Miaskowski","year":"2023","unstructured":"Miaskowski C,Mastick J,Paul S, et al. Associations among hearing loss, multiple co-occurring symptoms, and quality of life outcomes in cancer survivors. J Cancer Surviv. 2023;17:59\u201368. DOI: 10.1007\/s11764-022-01301-0"},{"key":"i2590-017X-9-4-153-b446","series-title":"Immunotherapy","first-page":"531","article-title":"Ear and labyrinth toxicities induced by immune checkpoint inhibitors: a disproportionality analysis from 2014 to 2019","volume":"12","author":"Hu","year":"2020","unstructured":"Hu F,Ye X,Zhai Y, et al. Ear and labyrinth toxicities induced by immune checkpoint inhibitors: a disproportionality analysis from 2014 to 2019. Immunotherapy. 2020;12:531\u2013540. DOI: 10.2217\/imt-2019-0120"},{"key":"i2590-017X-9-4-153-b447","series-title":"J Immunother Cancer","first-page":"e001675","article-title":"Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma","volume":"8","author":"Rosner","year":"2020","unstructured":"Rosner S,Agrawal Y,Sun DQ, et al. Immune-mediated ototoxicity associated with immune checkpoint inhibitors in patients with melanoma. J Immunother Cancer. 2020;8:e001675. DOI: 10.1136\/jitc-2020-001675"},{"key":"i2590-017X-9-4-153-b448","series-title":"Ear Nose Throat J","first-page":"286S","article-title":"Bilateral sensorineural hearing loss associated with nivolumab therapy for stage IV malignant melanoma","volume":"100","author":"Tampio","year":"2021","unstructured":"Tampio AJF,Dhanireddy S,Sivapiragasam A,Nicholas BD. Bilateral sensorineural hearing loss associated with nivolumab therapy for stage IV malignant melanoma. Ear Nose Throat J. 2021;100:286S\u2013291S. DOI: 10.1177\/0145561320940847"},{"key":"i2590-017X-9-4-153-b449","series-title":"Sci Rep","first-page":"27558","article-title":"Effects of neoadjuvant immunotherapy on hearing in patients with head and neck squamous cell carcinoma","volume":"15","author":"Hambach","year":"2025","unstructured":"Hambach B,Bilokon A,Lee J, et al. Effects of neoadjuvant immunotherapy on hearing in patients with head and neck squamous cell carcinoma. Sci Rep. 2025;15:27558. DOI: 10.1038\/s41598-025-13706-9"},{"key":"i2590-017X-9-4-153-b450","series-title":"Head Neck","first-page":"E35","article-title":"Recurrent audiovestibular dysfunction and associated neurological immune-related adverse events in a melanoma patient treated with nivolumab and ipilimumab","volume":"42","author":"Choi","year":"2020","unstructured":"Choi JS,Chen M,McQuade JL, et al. Recurrent audiovestibular dysfunction and associated neurological immune-related adverse events in a melanoma patient treated with nivolumab and ipilimumab. Head Neck. 2020;42:E35\u2013E42. DOI: 10.1002\/hed.26455"},{"key":"i2590-017X-9-4-153-b451","series-title":"J Immunother Precis Oncol","first-page":"2","article-title":"Audiovestibular toxicity secondary to immunotherapy: case series and literature review","volume":"5","author":"Page","year":"2022","unstructured":"Page JC,Gidley PW,Nader ME. Audiovestibular toxicity secondary to immunotherapy: case series and literature review. J Immunother Precis Oncol. 2022;5:2\u20136. DOI: 10.36401\/JIPO-21-17"},{"key":"i2590-017X-9-4-153-b452","series-title":"Eur J Cancer","first-page":"116","article-title":"Cochleovestibular toxicity induced by immune checkpoint inhibition: a case series","volume":"117","author":"Lemasson","year":"2019","unstructured":"Lemasson J,Cuzzubbo S,Doucet L, et al. Cochleovestibular toxicity induced by immune checkpoint inhibition: a case series. Eur J Cancer. 2019;117:116\u2013118. DOI: 10.1016\/j.ejca.2019.05.022"},{"key":"i2590-017X-9-4-153-b453","series-title":"Cochlear Implants Int","first-page":"268","article-title":"Bilateral cochlear implantation after immunotherapy-related profound hearing loss: a case report","volume":"24","author":"Schlacter","year":"2023","unstructured":"Schlacter JA,Kay-Rivest E,McMenomey SO, et al. Bilateral cochlear implantation after immunotherapy-related profound hearing loss: a case report. Cochlear Implants Int. 2023;24:268\u2013272. DOI: 10.1080\/14670100.2023.2193918"},{"key":"i2590-017X-9-4-153-b454","series-title":"J Immunother","first-page":"193","article-title":"Sudden otovestibular dysfunction in 3 metastatic melanoma patients treated with immune checkpoint inhibitors","volume":"44","author":"Sturmer","year":"2021","unstructured":"Sturmer SH,Lechner A,Berking C. Sudden otovestibular dysfunction in 3 metastatic melanoma patients treated with immune checkpoint inhibitors. J Immunother. 2021;44:193\u2013197. DOI: 10.1097\/CJI.0000000000000367"},{"key":"i2590-017X-9-4-153-b455","series-title":"Otolaryngol-Head Neck Surg","first-page":"658","article-title":"Ototoxicity review: a growing number of non-platinum-based chemo- and immunotherapies","volume":"168","author":"Naples","year":"2023","unstructured":"Naples JG,Rice-Narusch W,Watson NW, et al. Ototoxicity review: a growing number of non-platinum-based chemo- and immunotherapies. Otolaryngol-Head Neck Surg. 2023;168:658\u2013668. DOI: 10.1177\/01945998221094457"},{"key":"i2590-017X-9-4-153-b456","series-title":"Otolaryngol Pol","first-page":"38","article-title":"Ototoxicity in immune checkpoint inhibitors therapy","volume":"78","author":"Wierzbicka","year":"2024","unstructured":"Wierzbicka M,Mielnik J,Ko\u0142odziejska E, et al. Ototoxicity in immune checkpoint inhibitors therapy. Otolaryngol Pol. 2024;78:38\u201342. DOI: 10.5604\/01.3001.0054.4669"},{"key":"i2590-017X-9-4-153-b457","series-title":"Support Care Cancer","first-page":"624","article-title":"Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data","volume":"31","author":"Guven","year":"2023","unstructured":"Guven DC,Erul E,Kaygusuz Y, et al. Immune checkpoint inhibitor-related hearing loss: a systematic review and analysis of individual patient data. Support Care Cancer. 2023;31:624. DOI: 10.1007\/s00520-023-08083-w"},{"key":"i2590-017X-9-4-153-b458","series-title":"J Thorac Oncol","first-page":"1606","article-title":"Vogt-Koyanagi-Harada syndrome induced by pembrolizumab in a patient with non-small cell lung cancer","volume":"13","author":"Tamura","year":"2018","unstructured":"Tamura T,Akimoto E,Matsumoto C, et al. Vogt-Koyanagi-Harada syndrome induced by pembrolizumab in a patient with non-small cell lung cancer. J Thorac Oncol. 2018;13:1606\u20131607. DOI: 10.1016\/j.jtho.2018.04.026"},{"key":"i2590-017X-9-4-153-b459","series-title":"Laryngoscope","first-page":"4347","article-title":"Sudden deafness and vestibulopathy in a patient with antibody treatment for metastatic lung cancer","volume":"134","author":"Trache","year":"2024","unstructured":"Trache MC,Kontopf J,Stolzel K,Haussler SM. Sudden deafness and vestibulopathy in a patient with antibody treatment for metastatic lung cancer. Laryngoscope. 2024;134:4347\u20134350. DOI: 10.1002\/lary.31459"},{"key":"i2590-017X-9-4-153-b460","series-title":"Otolaryngol Head Neck Surg","first-page":"1348","article-title":"Efficacy of nortriptyline-topiramate and verapamil-paroxetine in tinnitus management: a randomized placebo-controlled trial","volume":"172","author":"Abouzari","year":"2025","unstructured":"Abouzari M,Tawk K,Kim JK, et al. Efficacy of nortriptyline-topiramate and verapamil-paroxetine in tinnitus management: a randomized placebo-controlled trial. Otolaryngol Head Neck Surg. 2025;172:1348\u20131356. DOI: 10.1002\/ohn.106339588680"},{"key":"i2590-017X-9-4-153-b461","series-title":"Development","first-page":"453","article-title":"Another role for melanocytes: their importance for normal stria vascularis development in the mammalian inner ear","volume":"107","author":"Steel","year":"1989","unstructured":"Steel KP,Barkway C. Another role for melanocytes: their importance for normal stria vascularis development in the mammalian inner ear. Development. 1989;107:453\u2013463. DOI: 10.1242\/dev.107.3.453"},{"key":"i2590-017X-9-4-153-b462","series-title":"Cureus","first-page":"e66611","article-title":"Clinical patterns and factors contributing to ophthalmic and otologic events associated with immune checkpoint inhibitors: a narrative review","volume":"16","author":"Sunyur","year":"2024","unstructured":"Sunyur AM,Alkhayat D,Mohammad HA, et al. Clinical patterns and factors contributing to ophthalmic and otologic events associated with immune checkpoint inhibitors: a narrative review. Cureus. 2024;16:e66611. DOI: 10.7759\/cureus.66611"},{"key":"i2590-017X-9-4-153-b463","series-title":"Int J Med Sci","first-page":"179","article-title":"Investigating the process of autoimmune inner ear disease: unveiling the intricacies of pathogenesis and therapeutic strategies","volume":"22","author":"Wang","year":"2025","unstructured":"Wang M,Zhang P,Li Q,Kong C. Investigating the process of autoimmune inner ear disease: unveiling the intricacies of pathogenesis and therapeutic strategies. Int J Med Sci. 2025;22:179\u2013187. DOI: 10.7150\/ijms.97831"},{"key":"i2590-017X-9-4-153-b464","series-title":"J Neuroimmunol","first-page":"173","article-title":"Interferon-gamma production to inner ear antigens by T cells from patients with autoimmune sensorineural hearing loss","volume":"130","author":"Lorenz","year":"2002","unstructured":"Lorenz RR,Solares CA,Williams P, et al. Interferon-gamma production to inner ear antigens by T cells from patients with autoimmune sensorineural hearing loss. J Neuroimmunol. 2002;130:173\u2013178. DOI: 10.1016\/S0165-5728(02)00190-X"},{"key":"i2590-017X-9-4-153-b465","series-title":"J Clin Invest","first-page":"1210","article-title":"Murine autoimmune hearing loss mediated by CD4+ T cells specific for inner ear peptides","volume":"113","author":"Solares","year":"2004","unstructured":"Solares CA,Edling AE,Johnson JM, et al. Murine autoimmune hearing loss mediated by CD4+ T cells specific for inner ear peptides. J Clin Invest. 2004;113:1210\u20131217. DOI: 10.1172\/JCI200418195"},{"key":"i2590-017X-9-4-153-b466","series-title":"J Neuroimmunol","first-page":"1","article-title":"Autoimmune sensorineural hearing loss: an immunologic perspective","volume":"138","author":"Solares","year":"2003","unstructured":"Solares CA,Hughes GB,Tuohy VK. Autoimmune sensorineural hearing loss: an immunologic perspective. J Neuroimmunol. 2003;138:1\u20137. DOI: 10.1016\/S0165-5728(03)00077-8"},{"key":"i2590-017X-9-4-153-b467","series-title":"Otolaryng Head Neck","article-title":"Rate of hearing loss in platinum-na\u00efve patients receiving immune checkpoint inhibitors","author":"Brooks","year":"2026","unstructured":"Brooks KA,Gidley CG,Grimley O, et al. Rate of hearing loss in platinum-na\u00efve patients receiving immune checkpoint inhibitors. Otolaryng Head Neck. 2026. DOI: 10.1002\/ohn.70191"},{"key":"i2590-017X-9-4-153-b468","series-title":"Ann Otol Rhinol Laryngol","first-page":"711","article-title":"A new grading system for ototoxicity in adults","volume":"123","author":"Theunissen","year":"2014","unstructured":"Theunissen EAR,Dreschler WA,Latenstein MN, et al. A new grading system for ototoxicity in adults. Ann Otol Rhinol Laryngol. 2014;123:711\u2013718. DOI: 10.1177\/0003489414534010"},{"key":"i2590-017X-9-4-153-b469","article-title":"Common terminology criteria for adverse events (CTCAE). Version 5","author":"US Department of Health and Human Services","year":"2017","unstructured":"US Department of Health and Human Services. Common terminology criteria for adverse events (CTCAE). Version 5. 2017."},{"key":"i2590-017X-9-4-153-b470","series-title":"Eye (Lond)","first-page":"2854","article-title":"Impact of immune checkpoint inhibitors on vision and eye health","volume":"38","author":"Masalkhi","year":"2024","unstructured":"Masalkhi M,Wahoud N,Moran B,Elhassadi E. Impact of immune checkpoint inhibitors on vision and eye health. Eye (Lond). 2024;38:2854\u20132856. DOI: 10.1038\/s41433-024-03212-z"},{"key":"i2590-017X-9-4-153-b471","series-title":"J Immunother Cancer","first-page":"e011049","article-title":"Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors","volume":"13","author":"Chang","year":"2025","unstructured":"Chang EL,Liu R,Keyhanian K, et al. Consensus disease definitions for ophthalmic immune-related adverse events of immune checkpoint inhibitors. J Immunother Cancer. 2025;13:e011049. DOI: 10.1136\/jitc-2024-011049"},{"key":"i2590-017X-9-4-153-b472","series-title":"Ophthalmology","first-page":"910","article-title":"Ophthalmic immune-related adverse events after anti-CTLA-4 or PD-1 therapy recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry","volume":"128","author":"Sun","year":"2021","unstructured":"Sun MM,Kelly SP,Mylavarapu, Bs AL, et al. Ophthalmic immune-related adverse events after anti-CTLA-4 or PD-1 therapy recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry. Ophthalmology. 2021;128:910\u2013919. DOI: 10.1016\/j.ophtha.2020.11.001"},{"key":"i2590-017X-9-4-153-b473","series-title":"Ocul Immunol Inflamm","first-page":"203","article-title":"Immune checkpoint inhibitor-associated uveitis: review of treatments and outcomes","volume":"29","author":"Dow","year":"2021","unstructured":"Dow ER,Yung M,Tsui E. Immune checkpoint inhibitor-associated uveitis: review of treatments and outcomes. Ocul Immunol Inflamm. 2021;29:203\u2013211. DOI: 10.1080\/09273948.2020.1781902"},{"key":"i2590-017X-9-4-153-b474","series-title":"Ophthalmology","first-page":"1058","article-title":"Ophthalmic immune-related adverse events of immunotherapy: a single-site case series","volume":"126","author":"Kim","year":"2019","unstructured":"Kim JM,Materin MA,Sznol M, et al. Ophthalmic immune-related adverse events of immunotherapy: a single-site case series. Ophthalmology. 2019;126:1058\u20131062. DOI: 10.1016\/j.ophtha.2019.01.031"},{"key":"i2590-017X-9-4-153-b475","series-title":"Retina","first-page":"1063","article-title":"Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects","volume":"38","author":"Dalvin","year":"2018","unstructured":"Dalvin LA,Shields CL,Orloff M,Sato T,Shields JA. Checkpoint inhibitor immune therapy: systemic indications and ophthalmic side effects. Retina. 2018;38:1063\u20131078. DOI: 10.1097\/IAE.0000000000002181"},{"key":"i2590-017X-9-4-153-b476","series-title":"Nat Rev Dis Primers","first-page":"38","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","unstructured":"Ramos-Casals M,Brahmer JR,Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 2020;6:38. DOI: 10.1038\/s41572-020-0160-6"},{"key":"i2590-017X-9-4-153-b477","series-title":"Cancer","first-page":"1796","article-title":"Oral side effects of immune checkpoint inhibitor therapy (ICIT): an analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women's Hospital, and the Dana-Farber Cancer Institute, 2011 to 2019","volume":"127","author":"Xu","year":"2021","unstructured":"Xu Y,Wen N,Sonis ST,Villa A. Oral side effects of immune checkpoint inhibitor therapy (ICIT): an analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women's Hospital, and the Dana-Farber Cancer Institute, 2011 to 2019. Cancer. 2021;127:1796\u20131804. DOI: 10.1002\/cncr.33436"},{"key":"i2590-017X-9-4-153-b478","series-title":"Cancers (Basel)","first-page":"4781","article-title":"Immunotherapy-related oral adverse effects: immediate sequelae, chronicity and secondary cancer","volume":"15","author":"Elad","year":"2023","unstructured":"Elad S,Yarom N,Zadik Y. Immunotherapy-related oral adverse effects: immediate sequelae, chronicity and secondary cancer. Cancers (Basel). 2023;15:4781. DOI: 10.3390\/cancers15194781"},{"key":"i2590-017X-9-4-153-b479","series-title":"Front Oral Health","first-page":"968157","article-title":"Immune checkpoint inhibitors in cancer therapy: review of orofacial adverse events and role of the oral healthcare provider","volume":"3","author":"Klein","year":"2022","unstructured":"Klein BA,Shazib MA,Villa A, et al. Immune checkpoint inhibitors in cancer therapy: review of orofacial adverse events and role of the oral healthcare provider. Front Oral Health. 2022;3:968157. DOI: 10.3389\/froh.2022.968157"},{"key":"i2590-017X-9-4-153-b480","series-title":"Oral Surg Oral Med Oral Pathol Oral Radiol","first-page":"e301","article-title":"Severe oral erosive lichenoid reaction to pembrolizumab therapy","volume":"130","author":"Bhattacharyya","year":"2020","unstructured":"Bhattacharyya I,Chehal H,Migliorati C. Severe oral erosive lichenoid reaction to pembrolizumab therapy. Oral Surg Oral Med Oral Pathol Oral Radiol. 2020;130:e301\u2013e307. DOI: 10.1016\/j.oooo.2020.06.014"},{"key":"i2590-017X-9-4-153-b481","series-title":"Support Care Cancer","first-page":"4705","article-title":"Oral mucositis-case series of a rare adverse effect associated with immunotherapy","volume":"29","author":"Sheth","year":"2021","unstructured":"Sheth H,Pragya R,Kovale S, et al. Oral mucositis-case series of a rare adverse effect associated with immunotherapy. Support Care Cancer. 2021;29:4705\u20134709. DOI: 10.1007\/s00520-021-05993-5"},{"key":"i2590-017X-9-4-153-b482","series-title":"Oral Dis","first-page":"9","article-title":"Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors","volume":"28","author":"Klein","year":"2022","unstructured":"Klein BA,Alves FA,de Santana Rodrigues Velho J, et al. Oral manifestations of immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. Oral Dis. 2022;28:9\u201322. DOI: 10.1111\/odi.13964"},{"key":"i2590-017X-9-4-153-b483","series-title":"Front Med","first-page":"268","article-title":"Mucous membrane pemphigoid, bullous pemphigoid, and anti-programmed death-1\/programmed death-ligand 1: a case report of an elderly woman with mucous membrane pemphigoid developing after pembrolizumab therapy for metastatic melanoma and review of the literature","volume":"5","author":"Zumelzu","year":"2018","unstructured":"Zumelzu C,Alexandre M,Le Roux C, et al. Mucous membrane pemphigoid, bullous pemphigoid, and anti-programmed death-1\/programmed death-ligand 1: a case report of an elderly woman with mucous membrane pemphigoid developing after pembrolizumab therapy for metastatic melanoma and review of the literature. Front Med. 2018;5:268. DOI: 10.3389\/fmed.2018.00268"},{"key":"i2590-017X-9-4-153-b484","series-title":"Cancer Immunol Res","first-page":"383","article-title":"Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1","volume":"4","author":"Naidoo","year":"2016","unstructured":"Naidoo J,Schindler K,Querfeld C, et al. Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res. 2016;4:383\u2013389. DOI: 10.1158\/2326-6066.CIR-15-0123"},{"key":"i2590-017X-9-4-153-b485","series-title":"Front Oncol","first-page":"1495446","article-title":"Case report: oral lichenoid mucositis in a patient with metastatic renal cell carcinoma undergoing treatment with pembrolizumab and axitinib","volume":"15","author":"Wellen","year":"2025","unstructured":"Wellen A,Pierro MJ,Wanat KA,Nelson AA. Case report: oral lichenoid mucositis in a patient with metastatic renal cell carcinoma undergoing treatment with pembrolizumab and axitinib. Front Oncol. 2025;15:1495446. DOI: 10.3389\/fonc.2025.1495446"},{"key":"i2590-017X-9-4-153-b486","series-title":"Int J Oral Maxillofac Surg","first-page":"488","article-title":"Drug-induced oral lichenoid reaction during nivolumab therapy","volume":"48","author":"Enomoto","year":"2019","unstructured":"Enomoto Y,Nakatani H,Kondo S,Kasai T,Tsuchiya Y. Drug-induced oral lichenoid reaction during nivolumab therapy. Int J Oral Maxillofac Surg. 2019;48:488\u2013491. DOI: 10.1016\/j.ijom.2018.07.025"},{"key":"i2590-017X-9-4-153-b487","series-title":"Acad Dermatol Venereol","first-page":"e112","article-title":"Mucous membrane pemphigoid and lichenoid reactions after immune checkpoint inhibitors: common pathomechanisms","volume":"34","author":"F\u00e4ssler","year":"2020","unstructured":"F\u00e4ssler M,Rammlmair A,Feldmeyer L, et al. Mucous membrane pemphigoid and lichenoid reactions after immune checkpoint inhibitors: common pathomechanisms. Acad Dermatol Venereol. 2020;34:e112\u2013e115. DOI: 10.1111\/jdv.16036"},{"key":"i2590-017X-9-4-153-b488","series-title":"Oncologist","first-page":"e12","article-title":"Lichenoid mucosal reaction to rituximab","volume":"19","author":"Kuten-Shorrer","year":"2014","unstructured":"Kuten-Shorrer M,Hochberg EP,Woo SB. Lichenoid mucosal reaction to rituximab. Oncologist. 2014;19:e12\u2013e13. DOI: 10.1634\/theoncologist.2014-0169"},{"key":"i2590-017X-9-4-153-b489","series-title":"J Dermatol","first-page":"587","article-title":"Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: a report of two cases and published work review","volume":"45","author":"Obara","year":"2018","unstructured":"Obara K,Masuzawa M,Amoh Y. Oral lichenoid reaction showing multiple ulcers associated with anti-programmed death cell receptor-1 treatment: a report of two cases and published work review. J Dermatol. 2018;45:587\u2013591. DOI: 10.1111\/1346-8138.14205"},{"issue":"Suppl 118","key":"i2590-017X-9-4-153-b490","series-title":"Clin Exp Rheumatol","first-page":"114","article-title":"Sicca\/Sj\u00f6gren's syndrome triggered by PD-1\/PD-L1 checkpoint inhibitors. Data from the International Immuno Cancer Registry (ICIR)","volume":"37","author":"Ramos-Casals","year":"2019","unstructured":"Ramos-Casals M,Maria A,Su\u00e1rez-Almazor ME, et al. Sicca\/Sj\u00f6gren's syndrome triggered by PD-1\/PD-L1 checkpoint inhibitors. Data from the International Immuno Cancer Registry (ICIR). Clin Exp Rheumatol. 2019;37(Suppl 118):114\u2013122."},{"key":"i2590-017X-9-4-153-b491","series-title":"Cancers (Basel)","first-page":"792","article-title":"Oral immune-related adverse events caused by immune checkpoint inhibitors: salivary gland dysfunction and mucosal diseases","volume":"14","author":"Yura","year":"2022","unstructured":"Yura Y,Hamada M. Oral immune-related adverse events caused by immune checkpoint inhibitors: salivary gland dysfunction and mucosal diseases. Cancers (Basel). 2022;14:792. DOI: 10.3390\/cancers14030792"},{"key":"i2590-017X-9-4-153-b492","series-title":"Oxf Med Case Reports","first-page":"omad146","article-title":"Pazopanib-induced trismus in a young male with metastatic renal cell carcinoma: a case report and literature review","volume":"2024","author":"Benhima","year":"2024","unstructured":"Benhima N,El Fadli M,Ess\u00e2di I,Belbaraka R. Pazopanib-induced trismus in a young male with metastatic renal cell carcinoma: a case report and literature review. Oxf Med Case Reports. 2024;2024:omad146. DOI: 10.1093\/omcr\/omad146"},{"key":"i2590-017X-9-4-153-b493","series-title":"Indian J Urol","first-page":"76","article-title":"Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma","volume":"33","author":"Iyer","year":"2017","unstructured":"Iyer R,Montgomery B,Pandha HS. Induction of trismus by sunitinib and pazopanib in metastatic renal cell carcinoma. Indian J Urol. 2017;33:76\u201378. DOI: 10.4103\/0970-1591.194787"},{"key":"i2590-017X-9-4-153-b494","series-title":"J Cutan Pathol","first-page":"158","article-title":"Diverse types of dermatologic toxicities from immune checkpoint blockade therapy","volume":"44","author":"Curry","year":"2017","unstructured":"Curry JL,Tetzlaff MT,Nagarajan P, et al. Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017;44:158\u2013176. DOI: 10.1111\/cup.12858"},{"key":"i2590-017X-9-4-153-b495","series-title":"J Pharm Health Care Sci","first-page":"19","article-title":"Drug-induced gingival hyperplasia: a retrospective study using spontaneous reporting system databases","volume":"3","author":"Hatahira","year":"2017","unstructured":"Hatahira H,Abe J,Hane Y, et al. Drug-induced gingival hyperplasia: a retrospective study using spontaneous reporting system databases. J Pharm Health Care Sci. 2017;3:19. DOI: 10.1186\/s40780-017-0088-5"},{"key":"i2590-017X-9-4-153-b496","series-title":"Support Care Cancer","first-page":"851","article-title":"MASCC\/ISOO clinical practice statement: management of oral complications of immunotherapy","volume":"33","author":"Fregnani","year":"2025","unstructured":"Fregnani ER,Epstein JB,Blijlevens NMA, et al. MASCC\/ISOO clinical practice statement: management of oral complications of immunotherapy. Support Care Cancer. 2025;33:851. DOI: 10.1007\/s00520-025-09806-x"},{"key":"i2590-017X-9-4-153-b497","series-title":"Support Care Cancer","first-page":"548","article-title":"MASCC\/ISOO clinical practice statement: management of salivary gland hypofunction and xerostomia in cancer patients","volume":"32","author":"Hong","year":"2024","unstructured":"Hong C,Jensen SB,Vissink A, et al. MASCC\/ISOO clinical practice statement: management of salivary gland hypofunction and xerostomia in cancer patients. Support Care Cancer. 2024;32:548. DOI: 10.1007\/s00520-024-08688-939048728"},{"key":"i2590-017X-9-4-153-b498","series-title":"Support Care Cancer","first-page":"549","article-title":"MASCC\/ISOO clinical practice statement: management of oral complications of targeted therapy","volume":"32","author":"Villa","year":"2024","unstructured":"Villa A,Epstein JB,Yarom N, et al. MASCC\/ISOO clinical practice statement: management of oral complications of targeted therapy. Support Care Cancer. 2024;32:549. DOI: 10.1007\/s00520-024-08689-8"},{"key":"i2590-017X-9-4-153-b499","series-title":"Oral Surg Oral Med Oral Pathol Oral Radiol","first-page":"e162","article-title":"Unusual gingival presentation following treatment with pembrolizumab: a case report","volume":"136","author":"Singh","year":"2023","unstructured":"Singh A,Marcinczyk J,Huryn J,Estilo C. Unusual gingival presentation following treatment with pembrolizumab: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol. 2023;136:e162. DOI: 10.1016\/j.oooo.2023.07.026"},{"key":"i2590-017X-9-4-153-b500","series-title":"Nat Rev Rheumatol","first-page":"333","article-title":"Epithelial-immune cell interplay in primary Sj\u00f6gren syndrome salivary gland pathogenesis","volume":"17","author":"Verstappen","year":"2021","unstructured":"Verstappen GM,Pringle S,Bootsma H,Kroese FGM. Epithelial-immune cell interplay in primary Sj\u00f6gren syndrome salivary gland pathogenesis. Nat Rev Rheumatol. 2021;17:333\u2013348. DOI: 10.1038\/s41584-021-00605-2"},{"key":"i2590-017X-9-4-153-b501","series-title":"Intern Med","first-page":"2499","article-title":"Sj\u00f6gren's syndrome as an immune-related adverse event of nivolumab treatment for gastric cancer","volume":"59","author":"Higashi","year":"2020","unstructured":"Higashi T,Miyamoto H,Yoshida R, et al. Sj\u00f6gren's syndrome as an immune-related adverse event of nivolumab treatment for gastric cancer. Intern Med. 2020;59:2499\u20132504. DOI: 10.2169\/internalmedicine.4701-20"},{"key":"i2590-017X-9-4-153-b502","series-title":"J Oncol Pharm Pract","first-page":"1029","article-title":"Sjogren's syndrome due to immune checkpoint inhibitors (ICIs): insights from a single-institution series and systematic review of the literature","volume":"31","author":"Soliman","year":"2025","unstructured":"Soliman A,Hassan R,Codreanu I,Plaxe SC,Dasanu CA. Sjogren's syndrome due to immune checkpoint inhibitors (ICIs): insights from a single-institution series and systematic review of the literature. J Oncol Pharm Pract. 2025;31:1029\u20131036. DOI: 10.1177\/10781552241271753"},{"key":"i2590-017X-9-4-153-b503","series-title":"Angiogenesis","first-page":"1","article-title":"Anti-angiogenic tyrosine kinase inhibitors: What is their mechanism of action","volume":"13","author":"Gotink","year":"2010","unstructured":"Gotink KJ,Verheul HM. Anti-angiogenic tyrosine kinase inhibitors: What is their mechanism of action? Angiogenesis. 2010;13:1\u201314. DOI: 10.1007\/s10456-009-9160-6"},{"key":"i2590-017X-9-4-153-b504","series-title":"Cytokine Growth Factor Rev","first-page":"297","article-title":"Angiogenic factors in bone local environment","volume":"24","author":"Chim","year":"2013","unstructured":"Chim SM,Tickner J,Chow ST, et al. Angiogenic factors in bone local environment. Cytokine Growth Factor Rev. 2013;24:297\u2013310. DOI: 10.1016\/j.cytogfr.2013.03.008"},{"key":"i2590-017X-9-4-153-b505","series-title":"J Stomatol Oral Maxillofac Surg","first-page":"740","article-title":"Medication-related osteonecrosis of the jaw related to epacadostat and pembrolizumab","volume":"121","author":"Decaux","year":"2020","unstructured":"Decaux J,Magremanne M. Medication-related osteonecrosis of the jaw related to epacadostat and pembrolizumab. J Stomatol Oral Maxillofac Surg. 2020;121:740\u2013742. DOI: 10.1016\/j.jormas.2020.05.001"},{"key":"i2590-017X-9-4-153-b506","series-title":"Clin Case Rep","first-page":"61","article-title":"New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy","volume":"9","author":"Guida","year":"2021","unstructured":"Guida A,Perri F,Ionna F,Ascierto PA,Grimaldi AM. New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy. Clin Case Rep. 2021;9:61\u201366. DOI: 10.1002\/ccr3.3418"},{"key":"i2590-017X-9-4-153-b507","series-title":"Quintessence Int","first-page":"244","article-title":"Adverse jaw outcomes from immune checkpoint inhibitors for head and neck cancer? Case reports","volume":"55","author":"Subramanian","year":"2024","unstructured":"Subramanian G,Yeung V,Baredes S, et al. Adverse jaw outcomes from immune checkpoint inhibitors for head and neck cancer? Case reports. Quintessence Int. 2024;55:244\u2013249. DOI: 10.3290\/j.qi.b512866338534035"},{"key":"i2590-017X-9-4-153-b508","series-title":"J Bone Miner Res","first-page":"950","article-title":"Programmed cell death protein 1 (PD-1) blockade regulates skeletal remodeling in a sex- and age-dependent manner","volume":"40","author":"Joseph","year":"2025","unstructured":"Joseph GJ,Vecchi Iii LA,Uppuganti S, et al. Programmed cell death protein 1 (PD-1) blockade regulates skeletal remodeling in a sex- and age-dependent manner. J Bone Miner Res. 2025;40:950\u2013964. DOI: 10.1093\/jbmr\/zjaf055"},{"key":"i2590-017X-9-4-153-b509","series-title":"Dent J (Basel)","first-page":"232","article-title":"Oral side effects in patients with metastatic renal cell carcinoma receiving the antiangiogenic agent pazopanib-report of three cases","volume":"10","author":"Papadopoulou","year":"2022","unstructured":"Papadopoulou E,Vardas E,Tziveleka S, et al. Oral side effects in patients with metastatic renal cell carcinoma receiving the antiangiogenic agent pazopanib-report of three cases. Dent J (Basel). 2022;10:232. DOI: 10.3390\/dj10120232"},{"key":"i2590-017X-9-4-153-b510","series-title":"Oral Surg Oral Med Oral Pathol Oral Radiol","first-page":"491","article-title":"Systematic review of the use of pentoxifylline and tocopherol for the treatment of medication-related osteonecrosis of the jaw","volume":"128","author":"Heifetz-Li","year":"2019","unstructured":"Heifetz-Li JJ,Abdelsamie S,Campbell CB, et al. Systematic review of the use of pentoxifylline and tocopherol for the treatment of medication-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;128:491\u2013497 e2. DOI: 10.1016\/j.oooo.2019.08.004"},{"key":"i2590-017X-9-4-153-b511","series-title":"J Transl Med","first-page":"592","article-title":"Osteonecrosis of the jaw induced by immune checkpoint inhibitors: an urgent need for attention","volume":"21","author":"Li","year":"2023","unstructured":"Li X,Song Z,Zhao R. Osteonecrosis of the jaw induced by immune checkpoint inhibitors: an urgent need for attention. J Transl Med. 2023;21:592. DOI: 10.1186\/s12967-023-04482-z"},{"key":"i2590-017X-9-4-153-b512","series-title":"Br J Oral Maxillofac Surg","first-page":"704","article-title":"Pembrolizumab related osteonecrosis of the jaw","volume":"61","author":"Patel","year":"2023","unstructured":"Patel V,Carey B. Pembrolizumab related osteonecrosis of the jaw. Br J Oral Maxillofac Surg. 2023;61:704\u2013706. DOI: 10.1016\/j.bjoms.2023.08.241"},{"key":"i2590-017X-9-4-153-b513","series-title":"Oral Oncol","first-page":"e100","article-title":"Osteonecrosis of the jaw a new complication related to ipilimumab","volume":"51","author":"Owosho","year":"2015","unstructured":"Owosho AA,Scordo M,Yom SK, et al. Osteonecrosis of the jaw a new complication related to ipilimumab. Oral Oncol. 2015;51:e100\u2013e101. DOI: 10.1016\/j.oraloncology.2015.08.014"},{"key":"i2590-017X-9-4-153-b514","series-title":"Oral Surg Oral Med Oral Pathol Oral Radiol","first-page":"e11","article-title":"Osteonecrosis of the jaw associated with pembrolizumab","volume":"136","author":"Pennings","year":"2023","unstructured":"Pennings I,Moskowitz A,Shah G, et al. Osteonecrosis of the jaw associated with pembrolizumab. Oral Surg Oral Med Oral Pathol Oral Radiol. 2023;136:e11\u2013e4. DOI: 10.1016\/j.oooo.2022.12.013"},{"key":"i2590-017X-9-4-153-b515","series-title":"Immunotherapy","first-page":"1213","article-title":"Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case report","volume":"12","author":"Pundole","year":"2020","unstructured":"Pundole X,Jones AL,Tetzlaff MT, et al. Osteonecrosis of the jaw induced by treatment with anti-PD-1 immunotherapy: a case report. Immunotherapy. 2020;12:1213\u20131219. DOI: 10.2217\/imt-2020-0108"},{"key":"i2590-017X-9-4-153-b516","series-title":"J Oral Med Oral Surg","first-page":"38","article-title":"Maxillary osteonecrosis linked to pembrolizumab therapy: a case report","volume":"30","author":"Gosselin-Rousselle","year":"2024","unstructured":"Gosselin-Rousselle L,Gaudimier Z,Pamelard P-O, et al. Maxillary osteonecrosis linked to pembrolizumab therapy: a case report. J Oral Med Oral Surg. 2024;30:38. DOI: 10.1051\/mbcb\/2024041"},{"key":"i2590-017X-9-4-153-b517","series-title":"Oral Surg Oral Med Oral Pathol Oral Radiol","first-page":"485","article-title":"Intralesional triamcinolone acetonide therapy for inflammatory oral ulcers","volume":"128","author":"Fantozzi","year":"2019","unstructured":"Fantozzi PJ,Treister N,Shekar R, et al. Intralesional triamcinolone acetonide therapy for inflammatory oral ulcers. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019;128:485\u2013490. DOI: 10.1016\/j.oooo.2019.07.024"},{"key":"i2590-017X-9-4-153-b518","series-title":"CRR","first-page":"400","article-title":"Current state of platelet-rich plasma in the treatment of rheumatic disease: a retrospective review of the literature","volume":"19","author":"Jacobs","year":"2023","unstructured":"Jacobs A,Elghawy O,Baruqui DL,Elghawy AA. Current state of platelet-rich plasma in the treatment of rheumatic disease: a retrospective review of the literature. CRR. 2023;19:400\u2013407. DOI: 10.2174\/1573397119666230420112017"},{"key":"i2590-017X-9-4-153-b519","series-title":"J Cosmet Dermatol","first-page":"1481","article-title":"Intralesional injection of platelet-rich plasma versus steroid in the treatment of oral lichen planus","volume":"22","author":"ElGhareeb","year":"2023","unstructured":"ElGhareeb MI,Ghoneimy S,Elsayed A. Intralesional injection of platelet-rich plasma versus steroid in the treatment of oral lichen planus. J Cosmet Dermatol. 2023;22:1481\u20131487. DOI: 10.1111\/jocd.15622"},{"key":"i2590-017X-9-4-153-b520","series-title":"BMC Oral Health","first-page":"832","article-title":"Use of platelet-rich plasma (PRP) and injectable platelet-rich fibrin (i-PRF) in oral lichen planus treatment: a systematic review of randomized controlled trials","volume":"25","author":"Niemczyk","year":"2025","unstructured":"Niemczyk W,Janik K,Niemczyk S, et al. Use of platelet-rich plasma (PRP) and injectable platelet-rich fibrin (i-PRF) in oral lichen planus treatment: a systematic review of randomized controlled trials. BMC Oral Health. 2025;25:832. DOI: 10.1186\/s12903-025-06189-7"},{"key":"i2590-017X-9-4-153-b521","series-title":"Oral Dis","first-page":"325","article-title":"Oral immune-related adverse events associated with PD-1 inhibitor therapy: a case series","volume":"26","author":"Shazib","year":"2020","unstructured":"Shazib MA,Woo S,Sroussi H, et al. Oral immune-related adverse events associated with PD-1 inhibitor therapy: a case series. Oral Dis. 2020;26:325\u2013333. DOI: 10.1111\/odi.13218"},{"key":"i2590-017X-9-4-153-b522","series-title":"J Immunotherapy Cancer","first-page":"192","article-title":"A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients","volume":"7","author":"Hurkmans","year":"2019","unstructured":"Hurkmans DP,Basak EA,van Dijk T, et al. A prospective cohort study on the pharmacokinetics of nivolumab in metastatic non-small cell lung cancer, melanoma, and renal cell cancer patients. J Immunotherapy Cancer. 2019;7:192. DOI: 10.1186\/s40425-019-0669-y"},{"key":"i2590-017X-9-4-153-b523","series-title":"J Immunotherapy Cancer","first-page":"72","article-title":"Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy","volume":"4","author":"Agrawal","year":"2016","unstructured":"Agrawal S,Feng Y,Roy A, et al. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J Immunotherapy Cancer. 2016;4:72. DOI: 10.1186\/s40425-016-0177-2"},{"key":"i2590-017X-9-4-153-b524","series-title":"Int J Gynecol Cancer","first-page":"101997","article-title":"Oral mucositis associated with antibody-drug conjugates in gynecologic oncology: strategies for prevention and treatment","volume":"35","author":"Lightfoot","year":"2025","unstructured":"Lightfoot MDS,Rubinstein MM,Monk BJ, et al. Oral mucositis associated with antibody-drug conjugates in gynecologic oncology: strategies for prevention and treatment. Int J Gynecol Cancer. 2025;35:101997. DOI: 10.1016\/j.ijgc.2025.101997"},{"key":"i2590-017X-9-4-153-b525","series-title":"Oncologist","first-page":"oyaf031","article-title":"Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis\/stomatitis","volume":"30","author":"Meric-Bernstam","year":"2025","unstructured":"Meric-Bernstam F,Bardia A,Bossi P, et al. Prophylaxis, clinical management, and monitoring of datopotamab deruxtecan-associated oral mucositis\/stomatitis. Oncologist. 2025;30:oyaf031. DOI: 10.1093\/oncolo\/oyaf03140139260"},{"key":"i2590-017X-9-4-153-b526","series-title":"Proc Natl Acad Sci USA","first-page":"14194","article-title":"EGFR and HER2 receptor kinase signaling mediate epithelial cell invasion by Candida albicans during oropharyngeal infection","volume":"109","author":"Zhu","year":"2012","unstructured":"Zhu W,Phan QT,Boontheung P, et al. EGFR and HER2 receptor kinase signaling mediate epithelial cell invasion by Candida albicans during oropharyngeal infection. Proc Natl Acad Sci USA. 2012;109:14194\u201314199. DOI: 10.1073\/pnas.1117676109"},{"key":"i2590-017X-9-4-153-b527","series-title":"Oral Oncol","first-page":"106692","article-title":"Unsung oral toxicities of antibody drug conjugate","volume":"150","author":"Chirravur","year":"2024","unstructured":"Chirravur P. Unsung oral toxicities of antibody drug conjugate. Oral Oncol. 2024;150:106692. DOI: 10.1016\/j.oraloncology.2024.106692"},{"key":"i2590-017X-9-4-153-b528","series-title":"Support Care Cancer","first-page":"1713","article-title":"Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors","volume":"25","author":"Vigarios","year":"2017","unstructured":"Vigarios E,Epstein JB,Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer. 2017;25:1713\u20131739. DOI: 10.1007\/s00520-017-3629-4"},{"key":"i2590-017X-9-4-153-b529","series-title":"Dermatol Ther","first-page":"e14629","article-title":"Scrotal erythema and geographic tongue subsequent to multikinase inhibiting therapy with pazopanib","volume":"34","author":"Gerber","year":"2021","unstructured":"Gerber F,Jungo P,Navarini AA,Vasconcelos-Berg R. Scrotal erythema and geographic tongue subsequent to multikinase inhibiting therapy with pazopanib. Dermatol Ther. 2021;34:e14629. DOI: 10.1111\/dth.14629"},{"key":"i2590-017X-9-4-153-b530","series-title":"Br J Dermatol","first-page":"993","article-title":"Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma","volume":"179","author":"Haug","year":"2018","unstructured":"Haug V,Behle V,Benoit S, et al. Pembrolizumab-associated mucous membrane pemphigoid in a patient with Merkel cell carcinoma. Br J Dermatol. 2018;179:993\u2013994. DOI: 10.1111\/bjd.16780"},{"key":"i2590-017X-9-4-153-b531","series-title":"JAMA Dermatol","first-page":"603","article-title":"Rituximab treatment of nivolumab-induced bullous pemphigoid","volume":"153","author":"Sowerby","year":"2017","unstructured":"Sowerby L,Dewan AK,Granter S,Gandhi L,LeBoeuf NR. Rituximab treatment of nivolumab-induced bullous pemphigoid. JAMA Dermatol. 2017;153:603\u2013605. DOI: 10.1001\/jamadermatol.2017.0091"},{"key":"i2590-017X-9-4-153-b532","series-title":"Front Immunol","first-page":"588582","article-title":"Retrospective analysis of checkpoint inhibitor therapy-associated cases of bullous pemphigoid from six German dermatology centers","volume":"11","author":"Sadik","year":"2021","unstructured":"Sadik CD,Langan EA,Gutzmer R, et al. Retrospective analysis of checkpoint inhibitor therapy-associated cases of bullous pemphigoid from six German dermatology centers. Front Immunol. 2021;11:588582. DOI: 10.3389\/fimmu.2020.588582"},{"key":"i2590-017X-9-4-153-b533","series-title":"JAMA Otolaryngol Head Neck Surg","first-page":"935","article-title":"Association of neoadjuvant pembrolizumab for oral cavity squamous cell carcinoma with adverse events after surgery in treatment-naive patients","volume":"148","author":"Tang","year":"2022","unstructured":"Tang AL,O\u2019Neil T,McDermott S, et al. Association of neoadjuvant pembrolizumab for oral cavity squamous cell carcinoma with adverse events after surgery in treatment-naive patients. JAMA Otolaryngol Head Neck Surg. 2022;148:935\u2013939. DOI: 10.1001\/jamaoto.2022.2291"},{"key":"i2590-017X-9-4-153-b534","series-title":"Front Immunol","first-page":"1688699","article-title":"Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies","volume":"16","author":"Wang","year":"2025","unstructured":"Wang X,He J,Ding G,Tang Y,Wang Q. Overcoming resistance to PD-1 and CTLA-4 blockade mechanisms and therapeutic strategies. Front Immunol. 2025;16:1688699. DOI: 10.3389\/fimmu.2025.1688699"},{"key":"i2590-017X-9-4-153-b535","series-title":"Annu Rev Immunol","first-page":"521","article-title":"Beyond the barrier: unraveling the mechanisms of immunotherapy resistance","volume":"42","author":"Bell","year":"2024","unstructured":"Bell HN,Zou W. Beyond the barrier: unraveling the mechanisms of immunotherapy resistance. Annu Rev Immunol. 2024;42:521\u2013550. DOI: 10.1146\/annurev-immunol-101819-024752"},{"key":"i2590-017X-9-4-153-b536","series-title":"BioDrugs","first-page":"215","article-title":"Primary and acquired resistance to immunotherapy with checkpoint inhibitors in NSCLC: from bedside to bench and back","volume":"39","author":"Mariniello","year":"2025","unstructured":"Mariniello A,Borgeaud M,Weiner M, et al. Primary and acquired resistance to immunotherapy with checkpoint inhibitors in NSCLC: from bedside to bench and back. BioDrugs. 2025;39:215\u2013235. DOI: 10.1007\/s40259-024-00700-2"},{"key":"i2590-017X-9-4-153-b537","series-title":"J Immunother Cancer","first-page":"e000398","article-title":"Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC immunotherapy resistance taskforce","volume":"8","author":"Kluger","year":"2020","unstructured":"Kluger HM,Tawbi HA,Ascierto ML, et al. Defining tumor resistance to PD-1 pathway blockade: recommendations from the first meeting of the SITC immunotherapy resistance taskforce. J Immunother Cancer. 2020;8:e000398. DOI: 10.1136\/jitc-2019-000398"},{"key":"i2590-017X-9-4-153-b538","series-title":"Nat Rev Cancer","first-page":"133","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","unstructured":"Havel JJ,Chowell D,Chan TA. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy. Nat Rev Cancer. 2019;19:133\u2013150. DOI: 10.1038\/s41568-019-0116-x"},{"key":"i2590-017X-9-4-153-b539","series-title":"Ann Oncol","first-page":"385","article-title":"Novel patterns of response under immunotherapy","volume":"30","author":"Borcoman","year":"2019","unstructured":"Borcoman E,Kanjanapan Y,Champiat S, et al. Novel patterns of response under immunotherapy. Ann Oncol. 2019;30:385\u2013396. DOI: 10.1093\/annonc\/mdz003"},{"key":"i2590-017X-9-4-153-b540","series-title":"Clin Cancer Res","first-page":"7412","article-title":"Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria","volume":"15","author":"Wolchok","year":"2009","unstructured":"Wolchok JD,Hoos A,O\u2019Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412\u20137420. DOI: 10.1158\/1078-0432.CCR-09-1624"},{"key":"i2590-017X-9-4-153-b541","series-title":"JCO","first-page":"1510","article-title":"Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab","volume":"34","author":"Hodi","year":"2016","unstructured":"Hodi FS,Hwu W-J,Kefford R, et al. Evaluation of immune-related response criteria and RECIST v1.1 in patients with advanced melanoma treated with pembrolizumab. JCO. 2016;34:1510\u20131517. DOI: 10.1200\/JCO.2015.64.0391"},{"key":"i2590-017X-9-4-153-b542","series-title":"Cancer Immunol Immunother","first-page":"1297","article-title":"Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases","volume":"58","author":"Di Giacomo","year":"2009","unstructured":"Di Giacomo AM,Danielli R,Guidoboni M, et al. Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. Cancer Immunol Immunother. 2009;58:1297\u20131306. DOI: 10.1007\/s00262-008-0642-y"},{"key":"i2590-017X-9-4-153-b543","series-title":"Biodrugs","first-page":"463","article-title":"Pseudoprogression and hyperprogression as new forms of response to immunotherapy","volume":"34","author":"Frelaut","year":"2020","unstructured":"Frelaut M,Du Rusquec P,de Moura A, et al. Pseudoprogression and hyperprogression as new forms of response to immunotherapy. Biodrugs. 2020;34:463\u2013476. DOI: 10.1007\/s40259-020-00425-y"},{"key":"i2590-017X-9-4-153-b544","series-title":"Cancer Biol Med","first-page":"655","article-title":"The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy","volume":"16","author":"Jia","year":"2019","unstructured":"Jia W,Gao Q,Han A, et al. The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy. Cancer Biol Med. 2019;16:655\u2013670. DOI: 10.20892\/j.issn.2095-3941.2019.0144"},{"key":"i2590-017X-9-4-153-b545","series-title":"Lancet Oncol","first-page":"e463","article-title":"Treatment after progression in the era of immunotherapy","volume":"21","author":"Billan","year":"2020","unstructured":"Billan S,Kaidar-Person O,Gil Z. Treatment after progression in the era of immunotherapy. Lancet Oncol. 2020;21:e463\u2013e476. DOI: 10.1016\/S1470-2045(20)30328-4"},{"key":"i2590-017X-9-4-153-b546","series-title":"Ther Adv Med Oncol","first-page":"17588359221096877","article-title":"Immune-related dissociated response as a specific atypical response pattern in solid tumors with immune checkpoint blockade","volume":"14","author":"Guan","year":"2022","unstructured":"Guan YP,Feng DF,Yin BB,Li K,Wang J. Immune-related dissociated response as a specific atypical response pattern in solid tumors with immune checkpoint blockade. Ther Adv Med Oncol. 2022;14:17588359221096877. DOI: 10.1177\/17588359221096877"},{"key":"i2590-017X-9-4-153-b547","series-title":"Sci Rep","first-page":"32147","article-title":"Dissociated response and treatment outcome with immune checkpoint blockade in advanced cancer","volume":"14","author":"Guan","year":"2024","unstructured":"Guan Y,Cui Y,Gong Y, et al. Dissociated response and treatment outcome with immune checkpoint blockade in advanced cancer. Sci Rep. 2024;14:32147. DOI: 10.1038\/s41598-024-84009-8"},{"key":"i2590-017X-9-4-153-b548","series-title":"Eur J Cancer","first-page":"38","article-title":"Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria","volume":"88","author":"Tazdait","year":"2018","unstructured":"Tazdait M,Mezquita L,Lahmar J, et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer. 2018;88:38\u201347. DOI: 10.1016\/j.ejca.2017.10.017"},{"key":"i2590-017X-9-4-153-b549","series-title":"Front Immunol","first-page":"693609","article-title":"Acquired resistance to immune checkpoint blockades: the underlying mechanisms and potential strategies","volume":"12","author":"Zhou","year":"2021","unstructured":"Zhou B,Gao Y,Zhang P,Chu Q. Acquired resistance to immune checkpoint blockades: the underlying mechanisms and potential strategies. Front Immunol. 2021;12:693609. DOI: 10.3389\/fimmu.2021.693609"},{"key":"i2590-017X-9-4-153-b550","series-title":"Ann Oncol","first-page":"314","article-title":"Intratumoral heterogeneity and immunotherapy resistance: clinical implications","volume":"37","author":"Keenan","year":"2026","unstructured":"Keenan BP,Yadav M,Ansstas G, et al. Intratumoral heterogeneity and immunotherapy resistance: clinical implications. Ann Oncol. 2026;37:314\u2013328. DOI: 10.1016\/j.annonc.2025.10.123941203206"},{"key":"i2590-017X-9-4-153-b551","series-title":"Nat Med","first-page":"212","article-title":"Intratumoral heterogeneity in cancer progression and response to immunotherapy","volume":"27","author":"Vitale","year":"2021","unstructured":"Vitale I,Shema E,Loi S,Galluzzi L. Intratumoral heterogeneity in cancer progression and response to immunotherapy. Nat Med. 2021;27:212\u2013224. DOI: 10.1038\/s41591-021-01233-9"},{"key":"i2590-017X-9-4-153-b552","series-title":"Cancer Cell","first-page":"471","article-title":"Intratumor heterogeneity: the Rosetta stone of therapy resistance","volume":"37","author":"Marusyk","year":"2020","unstructured":"Marusyk A,Janiszewska M,Polyak K. Intratumor heterogeneity: the Rosetta stone of therapy resistance. Cancer Cell. 2020;37:471\u2013484. DOI: 10.1016\/j.ccell.2020.03.007"},{"key":"i2590-017X-9-4-153-b553","series-title":"Nat Med","first-page":"541","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","unstructured":"Binnewies M,Roberts EW,Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat Med. 2018;24:541\u2013550. DOI: 10.1038\/s41591-018-0014-x"},{"key":"i2590-017X-9-4-153-b554","series-title":"Nature","first-page":"321","article-title":"Elements of cancer immunity and the cancer-immune set point","volume":"541","author":"Chen","year":"2017","unstructured":"Chen DS,Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321\u2013330. DOI: 10.1038\/nature21349"},{"key":"i2590-017X-9-4-153-b555","series-title":"Front Immunol","first-page":"784","article-title":"The tumor microenvironment in the response to immune checkpoint blockade therapies","volume":"11","author":"Petitprez","year":"2020","unstructured":"Petitprez F,Meylan M,de Reyni\u00e8s A,Saut\u00e8s-Fridman C,Fridman WH. The tumor microenvironment in the response to immune checkpoint blockade therapies. Front Immunol. 2020;11:784. DOI: 10.3389\/fimmu.2020.00784"},{"key":"i2590-017X-9-4-153-b556","series-title":"Cell","first-page":"707","article-title":"Primary, adaptive, and acquired resistance to cancer immunotherapy","volume":"168","author":"Sharma","year":"2017","unstructured":"Sharma P,Hu-Lieskovan S,Wargo JA,Ribas A. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168:707\u2013723. DOI: 10.1016\/j.cell.2017.01.017"},{"key":"i2590-017X-9-4-153-b557","series-title":"J Immunother Cancer","first-page":"e001204","article-title":"Impact of anatomic site on antigen-presenting cells in cancer","volume":"8","author":"Zagorulya","year":"2020","unstructured":"Zagorulya M,Duong E,Spranger S. Impact of anatomic site on antigen-presenting cells in cancer. J Immunother Cancer. 2020;8:e001204. DOI: 10.1136\/jitc-2020-001204"},{"key":"i2590-017X-9-4-153-b558","series-title":"Lancet Oncol","first-page":"e731","article-title":"De-novo and acquired resistance to immune checkpoint targeting","volume":"18","author":"Syn","year":"2017","unstructured":"Syn NL,Teng MWL,Mok TSK,Soo RA. De-novo and acquired resistance to immune checkpoint targeting. Lancet Oncol. 2017;18:e731\u2013e741. DOI: 10.1016\/S1470-2045(17)30607-1"},{"key":"i2590-017X-9-4-153-b559","series-title":"Expert Opin Biol Ther","first-page":"1575","article-title":"Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors","volume":"21","author":"Pezeshki","year":"2021","unstructured":"Pezeshki PS,Mahdavi Sharif P,Rezaei N. Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors. Expert Opin Biol Ther. 2021;21:1575\u20131590. DOI: 10.1080\/14712598.2021.1929919"},{"key":"i2590-017X-9-4-153-b560","series-title":"Nat Commun","first-page":"1897","article-title":"Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition","volume":"11","author":"Lee","year":"2020","unstructured":"Lee JH,Shklovskaya E,Lim SY, et al. Transcriptional downregulation of MHC class I and melanoma de-differentiation in resistance to PD-1 inhibition. Nat Commun. 2020;11:1897. DOI: 10.1038\/s41467-020-15726-7"},{"key":"i2590-017X-9-4-153-b561","series-title":"Nat Commun","first-page":"3075","article-title":"Molecular patterns of resistance to immune checkpoint blockade in melanoma","volume":"15","author":"Lauss","year":"2024","unstructured":"Lauss M,Phung B,Borch TH, et al. Molecular patterns of resistance to immune checkpoint blockade in melanoma. Nat Commun. 2024;15:3075. DOI: 10.1038\/s41467-024-47425-y"},{"key":"i2590-017X-9-4-153-b562","series-title":"Nat Commun","first-page":"1136","article-title":"Resistance to checkpoint blockade therapy through inactivation of antigen presentation","volume":"8","author":"Sade-Feldman","year":"2017","unstructured":"Sade-Feldman M,Jiao YJ,Chen JH, et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat Commun. 2017;8:1136. DOI: 10.1038\/s41467-017-01062-w"},{"key":"i2590-017X-9-4-153-b563","series-title":"Cancer Lett","first-page":"216182","article-title":"Immune-checkpoint inhibitor resistance in cancer treatment: current progress and future directions","volume":"562","author":"Zhang","year":"2023","unstructured":"Zhang C,Zhang C,Wang H. Immune-checkpoint inhibitor resistance in cancer treatment: current progress and future directions. Cancer Lett. 2023;562:216182. DOI: 10.1016\/j.canlet.2023.216182"},{"key":"i2590-017X-9-4-153-b564","series-title":"Cancer Cell","first-page":"443","article-title":"Acquired resistance to immune checkpoint inhibitors","volume":"37","author":"Schoenfeld","year":"2020","unstructured":"Schoenfeld AJ,Hellmann MD. Acquired resistance to immune checkpoint inhibitors. Cancer Cell. 2020;37:443\u2013455. DOI: 10.1016\/j.ccell.2020.03.017"},{"key":"i2590-017X-9-4-153-b565","series-title":"Immunity","first-page":"17","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","unstructured":"Hegde PS,Chen DS. Top 10 challenges in cancer immunotherapy. Immunity. 2020;52:17\u201335. DOI: 10.1016\/j.immuni.2019.12.011"},{"key":"i2590-017X-9-4-153-b566","series-title":"Curr Opin Immunol","first-page":"23","article-title":"Monitoring immune responses in the tumor microenvironment","volume":"41","author":"Wargo","year":"2016","unstructured":"Wargo JA,Reddy SM,Reuben A,Sharma P. Monitoring immune responses in the tumor microenvironment. Curr Opin Immunol. 2016;41:23\u201331. DOI: 10.1016\/j.coi.2016.05.006"},{"key":"i2590-017X-9-4-153-b567","series-title":"Trends Mol Med","first-page":"1008","article-title":"Acquired resistance to immunotherapy in solid tumors","volume":"31","author":"Verdys","year":"2025","unstructured":"Verdys P,Johansen AZ,Gupta A, et al. Acquired resistance to immunotherapy in solid tumors. Trends Mol Med. 2025;31:1008\u20131020. DOI: 10.1016\/j.molmed.2025.03.010"},{"key":"i2590-017X-9-4-153-b568","series-title":"Cancer Discovery","first-page":"827","article-title":"Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade","volume":"6","author":"Chen","year":"2016","unstructured":"Chen P-L,Roh W,Reuben A, et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discovery. 2016;6:827\u2013837. DOI: 10.1158\/2159-8290.CD-15-1545"},{"key":"i2590-017X-9-4-153-b569","series-title":"Cancer Immunol Res","first-page":"127","article-title":"Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab","volume":"2","author":"Yuan","year":"2014","unstructured":"Yuan J,Zhou J,Dong Z, et al. Pretreatment serum VEGF is associated with clinical response and overall survival in advanced melanoma patients treated with ipilimumab. Cancer Immunol Res. 2014;2:127\u2013132. DOI: 10.1158\/2326-6066.CIR-13-0163"},{"key":"i2590-017X-9-4-153-b570","series-title":"Nat Biotechnol","first-page":"1152","article-title":"Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes","volume":"33","author":"Shukla","year":"2015","unstructured":"Shukla SA,Rooney MS,Rajasagi M,Tiao G,Dixon PM,Lawrence MS, et al. Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes. Nat Biotechnol. 2015;33:1152. DOI: 10.1038\/nbt.3344"},{"key":"i2590-017X-9-4-153-b571","series-title":"N Engl J Med","first-page":"819","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","unstructured":"Zaretsky JM,Garcia-Diaz A,Shin DS, et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N Engl J Med. 2016;375:819\u2013829. DOI: 10.1056\/NEJMoa1604958"},{"key":"i2590-017X-9-4-153-b572","series-title":"JCO","first-page":"1311","article-title":"Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in non-small-cell lung cancer","volume":"42","author":"Ricciuti","year":"2024","unstructured":"Ricciuti B,Lamberti G,Puchala SR, et al. Genomic and immunophenotypic landscape of acquired resistance to PD-(L)1 blockade in non-small-cell lung cancer. JCO. 2024;42:1311\u20131321. DOI: 10.1200\/JCO.23.00580"},{"key":"i2590-017X-9-4-153-b573","series-title":"J Immunother Cancer","first-page":"e012629","article-title":"Longitudinal tissue analysis reveals microenvironmental changes correlate with combined immunotherapy and targeted therapy response in metastatic breast cancer","volume":"13","author":"Liao","year":"2025","unstructured":"Liao J-Y,Wang J,Li H, et al. Longitudinal tissue analysis reveals microenvironmental changes correlate with combined immunotherapy and targeted therapy response in metastatic breast cancer. J Immunother Cancer. 2025;13:e012629. DOI: 10.1136\/jitc-2025-012629"},{"key":"i2590-017X-9-4-153-b574","series-title":"Cancer Epidemiol Biomarkers Prev","first-page":"2688","article-title":"Methods for sample acquisition and processing of serial blood and tumor biopsies for multicenter diffuse large B-cell lymphoma clinical trials","volume":"23","author":"Nielsen","year":"2014","unstructured":"Nielsen TH,Diaz Z,Christodoulopoulos R, et al. Methods for sample acquisition and processing of serial blood and tumor biopsies for multicenter diffuse large B-cell lymphoma clinical trials. Cancer Epidemiol Biomarkers Prev. 2014;23:2688\u20132693. DOI: 10.1158\/1055-9965.EPI-14-0549"},{"key":"i2590-017X-9-4-153-b575","series-title":"J Immunother Precis Oncol","first-page":"45","article-title":"Implementation of a novel web-based lesion selection tool to improve acquisition of tumor biopsy specimens","volume":"4","author":"Xu","year":"2021","unstructured":"Xu M,Tapia C,Hajjar J, et al. Implementation of a novel web-based lesion selection tool to improve acquisition of tumor biopsy specimens. J Immunother Precis Oncol. 2021;4:45\u201352. DOI: 10.36401\/JIPO-21-5"},{"key":"i2590-017X-9-4-153-b576","series-title":"Clin Cancer Res","first-page":"333","article-title":"Broad utility of ultrasensitive analysis of ctDNA dynamics across solid tumors treated with immunotherapy","volume":"32","author":"Garralda","year":"2026","unstructured":"Garralda E,Abbott C,Calahorro A, et al. Broad utility of ultrasensitive analysis of ctDNA dynamics across solid tumors treated with immunotherapy. Clin Cancer Res. 2026;32:333\u2013349. DOI: 10.1158\/1078-0432.CCR-25-2312"},{"key":"i2590-017X-9-4-153-b577","series-title":"Oncotarget","first-page":"42008","article-title":"Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma","volume":"6","author":"Gray","year":"2015","unstructured":"Gray ES,Rizos H,Reid AL, et al. Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma. Oncotarget. 2015;6:42008\u201342018. DOI: 10.18632\/oncotarget.5788"},{"key":"i2590-017X-9-4-153-b578","series-title":"Int J Mol Sci","first-page":"4414","article-title":"Immuno-metabolism and microenvironment in cancer: key players for immunotherapy","volume":"21","author":"Giannone","year":"2020","unstructured":"Giannone G,Ghisoni E,Genta S, et al. Immuno-metabolism and microenvironment in cancer: key players for immunotherapy. Int J Mol Sci. 2020;21:4414. DOI: 10.3390\/ijms21124414"},{"key":"i2590-017X-9-4-153-b579","series-title":"Oncoimmunology","first-page":"e1507670","article-title":"Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors","volume":"7","author":"Ahmed","year":"2018","unstructured":"Ahmed J,Kumar A,Parikh K, et al. Use of broad-spectrum antibiotics impacts outcome in patients treated with immune checkpoint inhibitors. Oncoimmunology. 2018;7:e1507670. DOI: 10.1080\/2162402X.2018.1507670"},{"key":"i2590-017X-9-4-153-b580","series-title":"J Clin Oncol","first-page":"3089","article-title":"Antibiotic therapy: the cornerstone of iatrogenic resistance to immune checkpoint inhibitors","volume":"41","author":"Pinato","year":"2023","unstructured":"Pinato DJ,Cortellini A. Antibiotic therapy: the cornerstone of iatrogenic resistance to immune checkpoint inhibitors. J Clin Oncol. 2023;41:3089\u20133091. DOI: 10.1200\/JCO.23.00049"},{"key":"i2590-017X-9-4-153-b581","series-title":"Crit Rev Oncol Hematol","first-page":"108","article-title":"Biomarkers of response to immune checkpoint blockade in cancer treatment","volume":"130","author":"Fujii","year":"2018","unstructured":"Fujii T,Naing A,Rolfo C,Hajjar J. Biomarkers of response to immune checkpoint blockade in cancer treatment. Crit Rev Oncol Hematol. 2018;130:108\u2013120. DOI: 10.1016\/j.critrevonc.2018.07.010"},{"key":"i2590-017X-9-4-153-b582","series-title":"N Engl J Med","first-page":"2018","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","unstructured":"Garon EB,Rizvi NA,Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018\u20132028. DOI: 10.1056\/NEJMoa1501824"},{"key":"i2590-017X-9-4-153-b583","series-title":"J Clin Oncol","first-page":"4102","article-title":"Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma","volume":"34","author":"Daud","year":"2016","unstructured":"Daud AI,Wolchok JD,Robert C, et al. Programmed death-ligand 1 expression and response to the anti-programmed death 1 antibody pembrolizumab in melanoma. J Clin Oncol. 2016;34:4102\u20134109. DOI: 10.1200\/JCO.2016.67.2477"},{"key":"i2590-017X-9-4-153-b584","series-title":"Ann Oncol","first-page":"44","article-title":"Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic","volume":"30","author":"Chan","year":"2019","unstructured":"Chan TA,Yarchoan M,Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30:44\u201356. DOI: 10.1093\/annonc\/mdy495"},{"key":"i2590-017X-9-4-153-b585","series-title":"Science (1979)","first-page":"124","article-title":"Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Cancer immunology","volume":"348","author":"Rizvi","year":"2015","unstructured":"Rizvi NA,Hellmann MD,Snyder A, et al. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Cancer immunology. Science (1979). 2015;348:124\u2013128. DOI: 10.1126\/science.aaa1348"},{"key":"i2590-017X-9-4-153-b586","series-title":"Science (1979)","first-page":"409","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","unstructured":"Le DT,Durham JN,Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science (1979). 2017;357:409\u2013413. DOI: 10.1126\/science.aan6733"},{"key":"i2590-017X-9-4-153-b587","series-title":"Front Immunol","first-page":"1816","article-title":"Is there a place for immunotherapy for metastatic microsatellite stable colorectal cancer","volume":"10","author":"Ghiringhelli","year":"2019","unstructured":"Ghiringhelli F,Fumet JD. Is there a place for immunotherapy for metastatic microsatellite stable colorectal cancer? Front Immunol. 2019;10:1816. DOI: 10.3389\/fimmu.2019.01816"},{"key":"i2590-017X-9-4-153-b588","series-title":"Cancer Discov","first-page":"264","article-title":"Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer","volume":"7","author":"Anagnostou","year":"2017","unstructured":"Anagnostou V,Smith KN,Forde PM, et al. Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer. Cancer Discov. 2017;7:264\u2013276. DOI: 10.1158\/2159-8290.CD-16-0828"},{"key":"i2590-017X-9-4-153-b589","series-title":"Cancer Cell","first-page":"462","article-title":"Macrophages and therapeutic resistance in cancer","volume":"27","author":"Ruffell","year":"2015","unstructured":"Ruffell B,Coussens LM. Macrophages and therapeutic resistance in cancer. Cancer Cell. 2015;27:462\u2013472. DOI: 10.1016\/j.ccell.2015.02.015"},{"key":"i2590-017X-9-4-153-b590","series-title":"Cell","first-page":"35","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","unstructured":"Hugo W,Zaretsky JM,Sun L, et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165:35\u201344. DOI: 10.1016\/j.cell.2016.02.065"},{"key":"i2590-017X-9-4-153-b591","series-title":"Cancer Discov","first-page":"188","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","unstructured":"Shin DS,Zaretsky JM,Escuin-Ordinas H, et al. Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations. Cancer Discov. 2017;7:188\u2013201. DOI: 10.1158\/2159-8290.CD-16-1223"},{"key":"i2590-017X-9-4-153-b592","series-title":"J Clin Oncol","first-page":"9028","article-title":"Association of STK11\/LKB1 mutations with primary resistance to PD-1\/PD-L1 axis blockade in PD-L1 positive non-squamous NSCLC","volume":"36","author":"Skoulidis","year":"2018","unstructured":"Skoulidis F,Carter BW,Zhang J, et al. Association of STK11\/LKB1 mutations with primary resistance to PD-1\/PD-L1 axis blockade in PD-L1 positive non-squamous NSCLC. J Clin Oncol. 2018;36:9028. DOI: 10.1200\/JCO.2018.36.15_suppl.9028"},{"key":"i2590-017X-9-4-153-b593","series-title":"Cancer Discov","first-page":"822","article-title":"STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma","volume":"8","author":"Skoulidis","year":"2018","unstructured":"Skoulidis F,Goldberg ME,Greenawalt DM, et al. STK11\/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 2018;8:822\u2013835. DOI: 10.1158\/2159-8290.CD-18-0099"},{"key":"i2590-017X-9-4-153-b594","series-title":"Sci Transl Med","first-page":"279ra41","article-title":"Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma","volume":"7","author":"Hu-Lieskovan","year":"2015","unstructured":"Hu-Lieskovan S,Mok S,Homet Moreno B, et al. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma. Sci Transl Med. 2015;7:279ra41. DOI: 10.1126\/scitranslmed.aaa4691"},{"key":"i2590-017X-9-4-153-b595","series-title":"Cancer Discov","first-page":"202","article-title":"Loss of PTEN promotes resistance to T cell-mediated immunotherapy","volume":"6","author":"Peng","year":"2016","unstructured":"Peng W,Chen JQ,Liu C, et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 2016;6:202\u2013216. DOI: 10.1158\/2159-8290.CD-15-0283"},{"key":"i2590-017X-9-4-153-b596","series-title":"Nature","first-page":"231","article-title":"Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","unstructured":"Spranger S,Bao R,Gajewski TF. Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature. 2015;523:231\u2013235. DOI: 10.1038\/nature14404"},{"key":"i2590-017X-9-4-153-b597","series-title":"JAMA Oncol","first-page":"1504","article-title":"Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types","volume":"5","author":"Wang","year":"2019","unstructured":"Wang F,Zhao Q,Wang YN, et al. Evaluation of POLE and POLD1 mutations as biomarkers for immunotherapy outcomes across multiple cancer types. JAMA Oncol. 2019;5:1504\u20131506. DOI: 10.1001\/jamaoncol.2019.2963"},{"key":"i2590-017X-9-4-153-b598","series-title":"Nat Med","first-page":"1449","article-title":"Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer","volume":"24","author":"Kim","year":"2018","unstructured":"Kim ST,Cristescu R,Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24:1449\u20131458. DOI: 10.1038\/s41591-018-0101-z"},{"key":"i2590-017X-9-4-153-b599","series-title":"Discov Onc","first-page":"213","article-title":"Efficacy of immunotherapy in ARID1A-mutant solid tumors: a single-center retrospective study","volume":"15","author":"Zhou","year":"2024","unstructured":"Zhou H,Sun D,Song S, et al. Efficacy of immunotherapy in ARID1A-mutant solid tumors: a single-center retrospective study. Discov Onc. 2024;15:213. DOI: 10.1007\/s12672-024-01074-1"},{"key":"i2590-017X-9-4-153-b600","series-title":"J Clin Invest","first-page":"2930","article-title":"IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade","volume":"127","author":"Ayers","year":"2017","unstructured":"Ayers M,Lunceford J,Nebozhyn M, et al. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127:2930\u20132940. DOI: 10.1172\/JCI91190"},{"key":"i2590-017X-9-4-153-b601","series-title":"Science (1979)","first-page":"eaar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy","volume":"362","author":"Cristescu","year":"2018","unstructured":"Cristescu R,Mogg R,Ayers M, et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science (1979). 2018;362:eaar3593. DOI: 10.1126\/science.aar3593"},{"key":"i2590-017X-9-4-153-b602","series-title":"Lancet Oncol","first-page":"956","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","unstructured":"Seiwert TY,Burtness B,Mehra R, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17:956\u2013965. DOI: 10.1016\/S1470-2045(16)30066-3"},{"key":"i2590-017X-9-4-153-b603","series-title":"Front Immunol","first-page":"1056144","article-title":"A high interferon gamma signature of CD8(+) T cells predicts response to neoadjuvant immunotherapy plus chemotherapy in gastric cancer","volume":"13","author":"Li","year":"2023","unstructured":"Li S,Li K,Tian F, et al. A high interferon gamma signature of CD8(+) T cells predicts response to neoadjuvant immunotherapy plus chemotherapy in gastric cancer. Front Immunol. 2023;13:1056144. DOI: 10.3389\/fimmu.2022.1056144"},{"key":"i2590-017X-9-4-153-b604","series-title":"Nature","first-page":"568","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","unstructured":"Tumeh PC,Harview CL,Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568\u2013571. DOI: 10.1038\/nature13954"},{"key":"i2590-017X-9-4-153-b605","series-title":"Nature","first-page":"563","article-title":"Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients","volume":"515","author":"Herbst","year":"2014","unstructured":"Herbst RS,Soria J-C,Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515:563\u2013567. DOI: 10.1038\/nature14011"},{"key":"i2590-017X-9-4-153-b606","series-title":"Lung Cancer","first-page":"71","article-title":"Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: a multiplex immunohistochemistry-based single-cell analysis","volume":"174","author":"Isomoto","year":"2022","unstructured":"Isomoto K,Haratani K,Tsujikawa T, et al. Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: a multiplex immunohistochemistry-based single-cell analysis. Lung Cancer. 2022;174:71\u201382. DOI: 10.1016\/j.lungcan.2022.10.012"},{"key":"i2590-017X-9-4-153-b607","series-title":"Mol Cancer","first-page":"306","article-title":"Transcriptional dynamics of CD8(+) T-cell exhaustion in immune checkpoint inhibitor resistance at single-cell resolution","volume":"24","author":"Tseng","year":"2025","unstructured":"Tseng T-Y,Hsieh C-H,Huang H-C, et al. Transcriptional dynamics of CD8(+) T-cell exhaustion in immune checkpoint inhibitor resistance at single-cell resolution. Mol Cancer. 2025;24:306. DOI: 10.1186\/s12943-025-02468-7"},{"key":"i2590-017X-9-4-153-b608","series-title":"Cancer Lett","first-page":"168","article-title":"Treg-mediated acquired resistance to immune checkpoint inhibitors","volume":"457","author":"Saleh","year":"2019","unstructured":"Saleh R,Elkord E. Treg-mediated acquired resistance to immune checkpoint inhibitors. Cancer Lett. 2019;457:168\u2013179. DOI: 10.1016\/j.canlet.2019.05.003"},{"key":"i2590-017X-9-4-153-b609","series-title":"Cancer Immunol Immunother","first-page":"247","article-title":"Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab","volume":"63","author":"Meyer","year":"2014","unstructured":"Meyer C,Cagnon L,Costa-Nunes CM, et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother. 2014;63:247\u2013257. DOI: 10.1007\/s00262-013-1508-5"},{"key":"i2590-017X-9-4-153-b610","series-title":"Nat Rev Immunol","first-page":"253","article-title":"Coordinated regulation of myeloid cells by tumours","volume":"12","author":"Gabrilovich","year":"2012","unstructured":"Gabrilovich DI,Ostrand-Rosenberg S,Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol. 2012;12:253\u2013268. DOI: 10.1038\/nri3175"},{"key":"i2590-017X-9-4-153-b611","series-title":"Nat Med","first-page":"1550","article-title":"Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response","volume":"24","author":"Jiang","year":"2018","unstructured":"Jiang P,Gu S,Pan D, et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018;24:1550\u20131558. DOI: 10.1038\/s41591-018-0136-1"},{"key":"i2590-017X-9-4-153-b612","series-title":"PLoS Med","first-page":"e1002309","article-title":"Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: an exploratory multi-omic analysis","volume":"14","author":"Snyder","year":"2017","unstructured":"Snyder A,Nathanson T,Funt SA, et al. Contribution of systemic and somatic factors to clinical response and resistance to PD-L1 blockade in urothelial cancer: an exploratory multi-omic analysis. PLoS Med. 2017;14:e1002309. DOI: 10.1371\/journal.pmed.1002309"},{"key":"i2590-017X-9-4-153-b613","series-title":"Proc Natl Acad Sci USA","first-page":"11919","article-title":"Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities","volume":"113","author":"Subudhi","year":"2016","unstructured":"Subudhi SK,Aparicio A,Gao J, et al. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. Proc Natl Acad Sci USA. 2016;113:11919\u201311924. DOI: 10.1073\/pnas.1611421113"},{"key":"i2590-017X-9-4-153-b614","series-title":"J Immunotherapy Cancer","first-page":"23","article-title":"Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma","volume":"3","author":"Postow","year":"2015","unstructured":"Postow MA,Manuel M,Wong P, et al. Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma. J Immunotherapy Cancer. 2015;3:23. DOI: 10.1186\/s40425-015-0070-4"},{"key":"i2590-017X-9-4-153-b615","series-title":"Sci Transl Med","first-page":"eaah3560","article-title":"Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance","volume":"9","author":"Roh","year":"2017","unstructured":"Roh W,Chen P-L,Reuben A, et al. Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. Sci Transl Med. 2017;9:eaah3560. DOI: 10.1126\/scitranslmed.aah3560"},{"key":"i2590-017X-9-4-153-b616","series-title":"J Immunother Cancer","first-page":"e008950","article-title":"High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC","volume":"12","author":"Altan","year":"2024","unstructured":"Altan M,Li R,Li Z, et al. High peripheral T cell diversity is associated with lower risk of toxicity and superior response to dual immune checkpoint inhibitor therapy in patients with metastatic NSCLC. J Immunother Cancer. 2024;12:e008950. DOI: 10.1136\/jitc-2024-008950"},{"key":"i2590-017X-9-4-153-b617","series-title":"Cell","first-page":"1259","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","unstructured":"McGranahan N,Rosenthal R,Hiley CT, et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017;171:1259\u20131271 e11. DOI: 10.1016\/j.cell.2017.10.001"},{"key":"i2590-017X-9-4-153-b618","series-title":"Front Immunol","first-page":"952099","article-title":"Association between germ-line HLA and immune-related adverse events","volume":"13","author":"Jiang","year":"2022","unstructured":"Jiang N,Yu Y,Zhang M, et al. Association between germ-line HLA and immune-related adverse events. Front Immunol. 2022;13:952099. DOI: 10.3389\/fimmu.2022.952099"},{"key":"i2590-017X-9-4-153-b619","series-title":"J Immunother Cancer","first-page":"e007236","article-title":"T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy","volume":"11","author":"Stephen","year":"2023","unstructured":"Stephen B,Hajjar J,Sarda S, et al. T-cell receptor beta variable gene polymorphism predicts immune-related adverse events during checkpoint blockade immunotherapy. J Immunother Cancer. 2023;11:e007236. DOI: 10.1136\/jitc-2023-007236"},{"key":"i2590-017X-9-4-153-b620","series-title":"Science (1979)","first-page":"582","article-title":"Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy","volume":"359","author":"Chowell","year":"2018","unstructured":"Chowell D,Morris LGT,Grigg CM, et al. Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy. Science (1979). 2018;359:582\u2013587. DOI: 10.1126\/science.aao4572"},{"key":"i2590-017X-9-4-153-b621","series-title":"Eur J Cancer","first-page":"98","article-title":"Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy","volume":"172","author":"Abed","year":"2022","unstructured":"Abed A,Law N,Calapre L, et al. Human leucocyte antigen genotype association with the development of immune-related adverse events in patients with non-small cell lung cancer treated with single agent immunotherapy. Eur J Cancer. 2022;172:98\u2013106. DOI: 10.1016\/j.ejca.2022.05.021"},{"key":"i2590-017X-9-4-153-b622","series-title":"Science (1979)","first-page":"97","article-title":"Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients","volume":"359","author":"Gopalakrishnan","year":"2018","unstructured":"Gopalakrishnan V,Spencer CN,Nezi L, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science (1979). 2018;359:97\u2013103. DOI: 10.1126\/science.aan4236"},{"key":"i2590-017X-9-4-153-b623","series-title":"Sci Rep","first-page":"5847","article-title":"Associations between the gut microbiome and fatigue in cancer patients","volume":"11","author":"Hajjar","year":"2021","unstructured":"Hajjar J,Mendoza T,Zhang L, et al. Associations between the gut microbiome and fatigue in cancer patients. Sci Rep. 2021;11:5847. DOI: 10.1038\/s41598-021-84783-9"},{"key":"i2590-017X-9-4-153-b624","series-title":"mSystems","first-page":"e0111524","article-title":"Variations in salivary microbiome and metabolites are associated with immunotherapy efficacy in patients with advanced NSCLC","volume":"10","author":"Huang","year":"2025","unstructured":"Huang D,Chen Y,Li C, et al. Variations in salivary microbiome and metabolites are associated with immunotherapy efficacy in patients with advanced NSCLC. mSystems. 2025;10:e0111524. DOI: 10.1128\/msystems.01115-24"},{"key":"i2590-017X-9-4-153-b625","series-title":"J Transl Med","first-page":"180","article-title":"Salivary microbial signature highlighting actinomyces as a predictor of immune-checkpoint inhibitor monotherapy response in advanced non-small cell lung cancer","volume":"24","author":"Cavaliere","year":"2026","unstructured":"Cavaliere S,Fogolari M,Iuliani M, et al. Salivary microbial signature highlighting actinomyces as a predictor of immune-checkpoint inhibitor monotherapy response in advanced non-small cell lung cancer. J Transl Med. 2026;24:180. DOI: 10.1186\/s12967-025-07570-4"},{"key":"i2590-017X-9-4-153-b626","series-title":"Clin Transl Med","first-page":"e70170","article-title":"Lower respiratory tract microbiome dysbiosis impairs clinical responses to immune checkpoint blockade in advanced non-small-cell lung cancer","volume":"15","author":"Zhang","year":"2025","unstructured":"Zhang Y,Chen X,Chen R, et al. Lower respiratory tract microbiome dysbiosis impairs clinical responses to immune checkpoint blockade in advanced non-small-cell lung cancer. Clin Transl Med. 2025;15:e70170. DOI: 10.1002\/ctm2.70170"},{"key":"i2590-017X-9-4-153-b627","series-title":"J Immunother Cancer","first-page":"173","article-title":"Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors","volume":"7","author":"Tamminga","year":"2019","unstructured":"Tamminga M,de Wit S,Hiltermann TJN, et al. Circulating tumor cells in advanced non-small cell lung cancer patients are associated with worse tumor response to checkpoint inhibitors. J Immunother Cancer. 2019;7:173. DOI: 10.1186\/s40425-019-0649-2"},{"key":"i2590-017X-9-4-153-b628","series-title":"Sci Rep","first-page":"31726","article-title":"Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor nivolumab","volume":"6","author":"Nicolazzo","year":"2016","unstructured":"Nicolazzo C,Raimondi C,Mancini M, et al. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor nivolumab. Sci Rep. 2016;6:31726. DOI: 10.1038\/srep31726"},{"key":"i2590-017X-9-4-153-b629","series-title":"Cancers (Basel)","first-page":"835","article-title":"Determination of PD-L1 expression in circulating tumor cells of NSCLC patients and correlation with response to PD-1\/PD-L1 inhibitors","volume":"11","author":"Janning","year":"2019","unstructured":"Janning M,Kobus F,Babayan A, et al. Determination of PD-L1 expression in circulating tumor cells of NSCLC patients and correlation with response to PD-1\/PD-L1 inhibitors. Cancers (Basel). 2019;11:835. DOI: 10.3390\/cancers11060835"},{"key":"i2590-017X-9-4-153-b630","series-title":"Nat Cancer","first-page":"873","article-title":"Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab","volume":"1","author":"Bratman","year":"2020","unstructured":"Bratman SV,Yang SYC,Iafolla MAJ, et al. Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab. Nat Cancer. 2020;1:873\u2013881. DOI: 10.1038\/s43018-020-0096-5"},{"key":"i2590-017X-9-4-153-b631","series-title":"JCO Precis Oncol","first-page":"e2500254","article-title":"Multi-institutional study evaluating the role of early circulating tumor DNA dynamics during treatment with immune checkpoint inhibitors in patients with advanced-stage melanoma","volume":"10","author":"Ma","year":"2026","unstructured":"Ma VT,Zhou AY,Forati A, et al. Multi-institutional study evaluating the role of early circulating tumor DNA dynamics during treatment with immune checkpoint inhibitors in patients with advanced-stage melanoma. JCO Precis Oncol. 2026;10:e2500254. DOI: 10.1200\/PO-26-00740"},{"key":"i2590-017X-9-4-153-b632","series-title":"Cancer Res","first-page":"1214","article-title":"Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer","volume":"79","author":"Anagnostou","year":"2019","unstructured":"Anagnostou V,Forde PM,White JR, et al. Dynamics of tumor and immune responses during immune checkpoint blockade in non-small cell lung cancer. Cancer Res. 2019;79:1214\u20131225. DOI: 10.1158\/0008-5472.CAN-18-1127"},{"key":"i2590-017X-9-4-153-b633","series-title":"J Dermatol Sci","first-page":"71","article-title":"Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-\u03b1 is a biomarker of nivolumab recativity","volume":"86","author":"Tanaka","year":"2017","unstructured":"Tanaka R,Okiyama N,Okune M, et al. Serum level of interleukin-6 is increased in nivolumab-associated psoriasiform dermatitis and tumor necrosis factor-\u03b1 is a biomarker of nivolumab recativity. J Dermatol Sci. 2017;86:71\u201373. DOI: 10.1016\/j.jdermsci.2016.12.019"},{"key":"i2590-017X-9-4-153-b634","series-title":"J Immunother Cancer","first-page":"39","article-title":"Baseline circulating IL-17 predicts toxicity while TGF-\u03b21 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma","volume":"3","author":"Tarhini","year":"2015","unstructured":"Tarhini AA,Zahoor H,Lin Y, et al. Baseline circulating IL-17 predicts toxicity while TGF-\u03b21 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer. 2015;3:39. DOI: 10.1186\/s40425-015-0081-1"},{"key":"i2590-017X-9-4-153-b635","series-title":"Cancers (Basel)","first-page":"5297","article-title":"Focus on the dynamics of neutrophil-to-lymphocyte ratio in cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review","volume":"14","author":"Guo","year":"2022","unstructured":"Guo YS,Xiang DQ,Wan JY,Yang L,Zheng CS. Focus on the dynamics of neutrophil-to-lymphocyte ratio in cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review. Cancers (Basel). 2022;14:5297. DOI: 10.3390\/cancers14215297"},{"key":"i2590-017X-9-4-153-b636","series-title":"Front Immunol","first-page":"234142","article-title":"Neutrophil to lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2023","unstructured":"Zhang W,Tan YF,Li YQ,Liu J. Neutrophil to lymphocyte ratio as a predictor for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis. Front Immunol. 2023;14: 234142. DOI: 10.3389\/fimmu.2023.1234142"},{"key":"i2590-017X-9-4-153-b637","series-title":"ESMO Open","first-page":"105518","article-title":"Autoantibody profiling to predict response to the anti-PD-1 therapy, pembrolizumab, in rare tumors","volume":"10","author":"Derbala","year":"2025","unstructured":"Derbala MH,Hajjar J,Stephen B, et al. Autoantibody profiling to predict response to the anti-PD-1 therapy, pembrolizumab, in rare tumors. ESMO Open. 2025;10:105518. DOI: 10.1016\/j.esmoop.2025.105518"},{"key":"i2590-017X-9-4-153-b638","series-title":"Oncoimmunology","first-page":"2204754","article-title":"Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs)","volume":"12","author":"Daban","year":"2023","unstructured":"Daban A,Gonnin C,Phan L, et al. Preexisting autoantibodies as predictor of immune related adverse events (irAEs) for advanced solid tumors treated with immune checkpoint inhibitors (ICIs). Oncoimmunology. 2023;12:2204754. DOI: 10.1080\/2162402X.2023.2204754"},{"key":"i2590-017X-9-4-153-b639","series-title":"JCO","first-page":"610","article-title":"Early adverse symptoms to predict response to treatment among patients in the I-SPY trial","volume":"43","author":"Basu","year":"2025","unstructured":"Basu A,Umashankar S,Wolf DM, et al. Early adverse symptoms to predict response to treatment among patients in the I-SPY trial. JCO. 2025;43:610. DOI: 10.1200\/JCO.2025.43.16_suppl.610"},{"key":"i2590-017X-9-4-153-b640","series-title":"29th Annual Conference of the International Society for Quality of Life Research","article-title":"Early changes in patient-reported symptoms are predictive of the development of severe immune-related adverse events [abstract]","author":"Mendoza","year":"Nov 1, 2022","unstructured":"Mendoza T,Peterson C,Sheshadri A, et al. Early changes in patient-reported symptoms are predictive of the development of severe immune-related adverse events [abstract]. 29th Annual Conference of the International Society for Quality of Life Research; Prague, Czech Republic, Nov 1, 2022."},{"key":"i2590-017X-9-4-153-b641","series-title":"J Immunother Cancer","article-title":"Artificial intelligence-powered assessment of tumor microenvironment in pre-treatment and on-treatment biopsies informs treatment outcomes to pembrolizumab in patients with rare tumors","volume":"12","author":"Derbala","year":"2024","unstructured":"Derbala MH,McGonagle KE,Batra H, et al. Artificial intelligence-powered assessment of tumor microenvironment in pre-treatment and on-treatment biopsies informs treatment outcomes to pembrolizumab in patients with rare tumors. J Immunother Cancer. 2024;12. DOI: 10.1136\/jitc-2024-SITC2024.1207"},{"key":"i2590-017X-9-4-153-b642","series-title":"JCO","first-page":"9132","article-title":"Artificial intelligence algorithm developed to predict immune checkpoint inhibitors efficacy in non-small-cell lung cancer","volume":"41","author":"Rakaee","year":"2023","unstructured":"Rakaee M,Tafavvoghi M,Adib E, et al. Artificial intelligence algorithm developed to predict immune checkpoint inhibitors efficacy in non-small-cell lung cancer. JCO. 2023;41:9132. DOI: 10.1200\/JCO.2023.41.16_suppl.9132"},{"key":"i2590-017X-9-4-153-b643","series-title":"Lancet Oncol","first-page":"1180","article-title":"A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study","volume":"19","author":"Sun","year":"2018","unstructured":"Sun R,Limkin EJ,Vakalopoulou M, et al. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study. Lancet Oncol. 2018;19:1180\u20131191. DOI: 10.1016\/S1470-2045(18)30413-3"},{"key":"i2590-017X-9-4-153-b644","series-title":"J Immunother Cancer","first-page":"e001752","article-title":"Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers","volume":"9","author":"Colen","year":"2021","unstructured":"Colen RR,Rolfo C,Ak M, et al. Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. J Immunother Cancer. 2021;9:e001752. DOI: 10.1136\/jitc-2020-001752"},{"key":"i2590-017X-9-4-153-b645","series-title":"Invest New Drugs","first-page":"601","article-title":"Radiomics to predict immunotherapy-induced pneumonitis: proof of concept","volume":"36","author":"Colen","year":"2018","unstructured":"Colen RR,Fujii T,Bilen MA, et al. Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. Invest New Drugs. 2018;36:601\u2013607. DOI: 10.1007\/s10637-017-0524-2"},{"key":"i2590-017X-9-4-153-b646","series-title":"Clin Cancer Res","first-page":"4960","article-title":"Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab","volume":"24","author":"Joseph","year":"2018","unstructured":"Joseph RW,Elassaiss-Schaap J,Kefford R, et al. Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab. Clin Cancer Res. 2018;24:4960\u20134967. DOI: 10.1158\/1078-0432.CCR-17-2386"},{"key":"i2590-017X-9-4-153-b647","series-title":"Cancer Treat Res Commun","first-page":"101087","article-title":"Differential predictive value of baseline tumor size according to PD-L1 expression in advanced NSCLC treated with immune checkpoint inhibitors","volume":"46","author":"Ito","year":"2026","unstructured":"Ito H,Shirasawa M,Akazawa Y, et al. Differential predictive value of baseline tumor size according to PD-L1 expression in advanced NSCLC treated with immune checkpoint inhibitors. Cancer Treat Res Commun. 2026;46:101087. DOI: 10.1016\/j.ctarc.2025.101087"},{"key":"i2590-017X-9-4-153-b648","series-title":"Ann Nucl Med","first-page":"968","article-title":"FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer","volume":"34","author":"Seban","year":"2020","unstructured":"Seban R-D,Assie J-B,Giroux-Leprieur E, et al. FDG-PET biomarkers associated with long-term benefit from first-line immunotherapy in patients with advanced non-small cell lung cancer. Ann Nucl Med. 2020;34:968\u2013974. DOI: 10.1007\/s12149-020-01539-7"},{"key":"i2590-017X-9-4-153-b649","series-title":"JCO","first-page":"3098","article-title":"Predicting immunotherapy response in advanced solid tumors using quantitative imaging features from CD8 PET\/CT exams","volume":"43","author":"Postow","year":"2025","unstructured":"Postow MA,Pic\u00f3 Peris A,Estepa-Fern\u00e1ndez A, et al. Predicting immunotherapy response in advanced solid tumors using quantitative imaging features from CD8 PET\/CT exams. JCO. 2025;43:3098. DOI: 10.1200\/JCO.2025.43.16_suppl.3098"},{"key":"i2590-017X-9-4-153-b650","series-title":"Nat Med","first-page":"1655","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","unstructured":"Blank CU,Rozeman EA,Fanchi LF, et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med. 2018;24:1655\u20131661. DOI: 10.1038\/s41591-018-0198-0"},{"key":"i2590-017X-9-4-153-b651","series-title":"Nat Med","first-page":"256","article-title":"Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma","volume":"27","author":"Rozeman","year":"2021","unstructured":"Rozeman EA,Hoefsmit EP,Reijers ILM, et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med. 2021;27:256\u2013263. DOI: 10.1038\/s41591-020-01211-7"},{"key":"i2590-017X-9-4-153-b652","series-title":"Nat Med","first-page":"301","article-title":"Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)","volume":"27","author":"Menzies","year":"2021","unstructured":"Menzies AM,Amaria RN,Rozeman EA, et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med. 2021;27:301\u2013309. DOI: 10.1038\/s41591-020-01188-3"},{"key":"i2590-017X-9-4-153-b653","series-title":"Ann Transl Med","first-page":"34","article-title":"Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases","volume":"9","author":"Qiao","year":"2021","unstructured":"Qiao M,Zhou F,Hou L, et al. Efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer patients with different metastases. Ann Transl Med. 2021;9:34. DOI: 10.21037\/atm-20-1471"},{"key":"i2590-017X-9-4-153-b654","series-title":"Cancer Immunol Res","first-page":"417","article-title":"Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC","volume":"5","author":"Tumeh","year":"2017","unstructured":"Tumeh PC,Hellmann MD,Hamid O, et al. Liver metastasis and treatment outcome with anti-PD-1 monoclonal antibody in patients with melanoma and NSCLC. Cancer Immunol Res. 2017;5:417\u2013424. DOI: 10.1158\/2326-6066.CIR-16-0325"},{"key":"i2590-017X-9-4-153-b655","series-title":"Cancer Immunol Res","first-page":"A114","article-title":"Abstract A114: impact of liver metastases and systemic biomarkers on immunotherapy response and survival outcomes in patients with solid tumors","volume":"13","author":"Stephen","year":"2025","unstructured":"Stephen B,Kwiatkowski E,Anderson MR, et al. Abstract A114: impact of liver metastases and systemic biomarkers on immunotherapy response and survival outcomes in patients with solid tumors. Cancer Immunol Res. 2025;13:A114. DOI: 10.1158\/2326-6074.IO2025-A114"},{"key":"i2590-017X-9-4-153-b656","series-title":"Nat Rev Cancer","first-page":"498","article-title":"Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours","volume":"24","author":"Holder","year":"2024","unstructured":"Holder AM,Dedeilia A,Sierra-Davidson K, et al. Defining clinically useful biomarkers of immune checkpoint inhibitors in solid tumours. Nat Rev Cancer. 2024;24:498\u2013512. DOI: 10.1038\/s41568-024-00705-7"},{"key":"i2590-017X-9-4-153-b657","series-title":"Nat Commun","first-page":"6828","article-title":"Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC","volume":"16","author":"Saad","year":"2025","unstructured":"Saad MB,Al-Tashi Q,Hong L, et al. Machine-learning driven strategies for adapting immunotherapy in metastatic NSCLC. Nat Commun. 2025;16:6828. DOI: 10.1038\/s41467-025-61823-w"},{"key":"i2590-017X-9-4-153-b658","series-title":"Ann Oncol","first-page":"998","article-title":"Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers","volume":"30","author":"Trebeschi","year":"2019","unstructured":"Trebeschi S,Drago SG,Birkbak NJ, et al. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. Ann Oncol. 2019;30:998\u20131004. DOI: 10.1093\/annonc\/mdz108"},{"key":"i2590-017X-9-4-153-b659","series-title":"Mol Oncol","first-page":"783","article-title":"Garbage in, garbage out: a critical evaluation of strategies used for validation of immunohistochemical biomarkers","volume":"8","author":"O\u2019Hurley","year":"2014","unstructured":"O\u2019Hurley G,Sj\u00f6stedt E,Rahman A, et al. Garbage in, garbage out: a critical evaluation of strategies used for validation of immunohistochemical biomarkers. Mol Oncol. 2014;8:783\u2013798. DOI: 10.1016\/j.molonc.2014.03.008"},{"key":"i2590-017X-9-4-153-b660","series-title":"Nat Rev Clin Oncol","first-page":"180","article-title":"Discovery of predictive biomarkers for cancer therapy through computational approaches","volume":"23","author":"Wang","year":"2026","unstructured":"Wang X,Nguyen J,Nader K, et al. Discovery of predictive biomarkers for cancer therapy through computational approaches. Nat Rev Clin Oncol. 2026;23:180\u2013200. DOI: 10.1038\/s41571-025-01109-8"},{"key":"i2590-017X-9-4-153-b661","series-title":"Nat Rev Rheumatol","first-page":"641","article-title":"Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases","volume":"18","author":"Tison","year":"2022","unstructured":"Tison A,Garaud S,Chiche L,Cornec D,Kostine M. Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases. Nat Rev Rheumatol. 2022;18:641\u2013656. DOI: 10.1038\/s41584-022-00841-0"},{"key":"i2590-017X-9-4-153-b662","series-title":"Endocr Pract","first-page":"16","article-title":"Study of the prevalence of autoimmune thyroid disease in women with breast cancer","volume":"22","author":"Freitas","year":"2016","unstructured":"Freitas PA,Vissoci GM,Pinto RM,Lajolo PP,Jorge PT. Study of the prevalence of autoimmune thyroid disease in women with breast cancer. Endocr Pract. 2016;22:16\u201321. DOI: 10.4158\/EP14445.OR"},{"key":"i2590-017X-9-4-153-b663","series-title":"JAMA Oncol","first-page":"1507","article-title":"Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options","volume":"2","author":"Khan","year":"2016","unstructured":"Khan SA,Pruitt SL,Xuan L,Gerber DE. Prevalence of autoimmune disease among patients with lung cancer: implications for immunotherapy treatment options. JAMA Oncol. 2016;2:1507\u20131508. DOI: 10.1001\/jamaoncol.2016.2238"},{"key":"i2590-017X-9-4-153-b664","series-title":"Ann Intern Med","first-page":"149","article-title":"Sorting out the complexities of autoimmunity and checkpoint inhibitors: not so easy","volume":"168","author":"Calabrese","year":"2018","unstructured":"Calabrese LH. Sorting out the complexities of autoimmunity and checkpoint inhibitors: not so easy. Ann Intern Med. 2018;168:149\u2013150. DOI: 10.7326\/M17-3079"},{"key":"i2590-017X-9-4-153-b665","series-title":"Am J Transplant","first-page":"103","article-title":"Cancer screening recommendations for solid organ transplant recipients: a systematic review of clinical practice guidelines","volume":"17","author":"Acuna","year":"2017","unstructured":"Acuna SA,Huang JW,Scott AL, et al. Cancer screening recommendations for solid organ transplant recipients: a systematic review of clinical practice guidelines. Am J Transplant. 2017;17:103\u2013114. DOI: 10.1111\/ajt.13978"},{"key":"i2590-017X-9-4-153-b666","series-title":"Mayo Clin Proc","first-page":"2355","article-title":"Skin cancer in solid organ transplant recipients: a review for the nondermatologist","volume":"97","author":"Berman","year":"2022","unstructured":"Berman H,Shimshak S,Reimer D, et al. Skin cancer in solid organ transplant recipients: a review for the nondermatologist. Mayo Clin Proc. 2022;97:2355\u20132368. DOI: 10.1016\/j.mayocp.2022.07.004"},{"key":"i2590-017X-9-4-153-b666_1","unstructured":"Organ transplants exceeded 48,000 in 2024; a 3.3 percent increase from the transplants performed in 2023. United States Health Resource & Service Administration. Jan 15, 2025. Accessed Feb 6, 2026. www.hrsa.gov\/optn\/news-events\/news\/organ-transplants-exceeded-48000-2024-33-percent-increase-transplants-performed-2023"},{"key":"i2590-017X-9-4-153-b667","series-title":"Semin Perinatol","first-page":"152045","article-title":"Immune checkpoint inhibitors and pregnancy: considerations for treating medically complex patients with the best available therapy","volume":"49","author":"Sharon","year":"2025","unstructured":"Sharon E. Immune checkpoint inhibitors and pregnancy: considerations for treating medically complex patients with the best available therapy. Semin Perinatol. 2025;49:152045. DOI: 10.1016\/j.semperi.2025.152045"},{"key":"i2590-017X-9-4-153-b668","series-title":"J Natl Cancer Inst","first-page":"1200","article-title":"Pre-Existing autoimmune disease and mortality in patients treated with anti-PD-1 and anti-PD-L1 therapy","volume":"114","author":"Tang","year":"2022","unstructured":"Tang K,Tiu BC,Wan G, et al. Pre-Existing autoimmune disease and mortality in patients treated with anti-PD-1 and anti-PD-L1 therapy. J Natl Cancer Inst. 2022;114:1200\u20131202. DOI: 10.1093\/jnci\/djac046"},{"key":"i2590-017X-9-4-153-b669","series-title":"J Immunother Cancer","first-page":"e000356","article-title":"Immunotherapy to treat malignancy in patients with pre-existing autoimmunity","volume":"8","author":"Boland","year":"2020","unstructured":"Boland P,Pavlick AC,Weber J,Sandigursky S. Immunotherapy to treat malignancy in patients with pre-existing autoimmunity. J Immunother Cancer. 2020;8:e000356. DOI: 10.1136\/jitc-2019-000356"},{"key":"i2590-017X-9-4-153-b670","series-title":"J Immunother Cancer","first-page":"e002121","article-title":"Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders","volume":"9","author":"Brown","year":"2021","unstructured":"Brown LJ,Weppler A,Bhave P, et al. Combination anti-PD1 and ipilimumab therapy in patients with advanced melanoma and pre-existing autoimmune disorders. J Immunother Cancer. 2021;9:e002121. DOI: 10.1136\/jitc-2020-002121"},{"key":"i2590-017X-9-4-153-b671","series-title":"Hum Vaccin Immunother","first-page":"2145102","article-title":"Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: a meta-analysis","volume":"18","author":"Cai","year":"2022","unstructured":"Cai Q,Huo GW,Zhu FY, et al. Safety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: a meta-analysis. Hum Vaccin Immunother. 2022;18:2145102. DOI: 10.1080\/21645515.2022.2145102"},{"key":"i2590-017X-9-4-153-b672","series-title":"Cancer Immunol Immunother","first-page":"825","article-title":"Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders","volume":"67","author":"K\u00e4hler","year":"2018","unstructured":"K\u00e4hler KC,Eigentler TK,Gesierich A, et al. Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders. Cancer Immunol Immunother. 2018;67:825\u2013834. DOI: 10.1007\/s00262-018-2134-z29487980"},{"key":"i2590-017X-9-4-153-b672_1","unstructured":"Testing an Immunotherapy Anti-Cancer Drug, Nivolumab, for Advanced Cancers in Patients with Autoimmune Disorders, AIM-NIVO. Accessed Feb 6, 2026. clinicaltrials.gov\/study\/NCT03816345#study-overview"},{"key":"i2590-017X-9-4-153-b673","series-title":"Surg Clin North Am","first-page":"49","article-title":"Posttransplant malignancy","volume":"99","author":"Rossi","year":"2019","unstructured":"Rossi AP,Klein CL. Posttransplant malignancy. Surg Clin North Am. 2019;99:49\u201364. DOI: 10.1016\/j.suc.2018.09.004"},{"key":"i2590-017X-9-4-153-b674","series-title":"N Engl J Med","first-page":"896","article-title":"Tumor regression and allograft rejection after administration of anti-PD-1","volume":"374","author":"Lipson","year":"2016","unstructured":"Lipson EJ,Bagnasco SM,Moore J Jr, et al. Tumor regression and allograft rejection after administration of anti-PD-1. N Engl J Med. 2016;374:896\u2013898. DOI: 10.1056\/NEJMc1509268"},{"key":"i2590-017X-9-4-153-b675","series-title":"J Clin Oncol","first-page":"1011","article-title":"Nivolumab + tacrolimus + prednisone \u00b1 ipilimumab for kidney transplant recipients with advanced cutaneous cancers","volume":"42","author":"Schenk","year":"2024","unstructured":"Schenk KM,Deutsch JS,Chandra S, et al. Nivolumab + tacrolimus + prednisone \u00b1 ipilimumab for kidney transplant recipients with advanced cutaneous cancers. J Clin Oncol. 2024;42:1011\u20131020. DOI: 10.1200\/JCO.23.01497"},{"key":"i2590-017X-9-4-153-b676","series-title":"Blood","first-page":"221","article-title":"PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD","volume":"130","author":"Haverkos","year":"2017","unstructured":"Haverkos BM,Abbott D,Hamadani M, et al. PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. Blood. 2017;130:221\u2013228. DOI: 10.1182\/blood-2017-01-761346"},{"key":"i2590-017X-9-4-153-b677","series-title":"N Engl J Med","first-page":"143","article-title":"Ipilimumab for patients with relapse after allogeneic transplantation","volume":"375","author":"Davids","year":"2016","unstructured":"Davids MS,Kim HT,Bachireddy P, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med. 2016;375:143\u2013153. DOI: 10.1056\/NEJMoa1601202"},{"key":"i2590-017X-9-4-153-b678","series-title":"Blood","first-page":"2182","article-title":"A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation","volume":"135","author":"Davids","year":"2020","unstructured":"Davids MS,Kim HT,Costello C, et al. A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation. Blood. 2020;135:2182\u20132191. DOI: 10.1182\/blood.2019004710"},{"key":"i2590-017X-9-4-153-b679","series-title":"Front Pharmacol","first-page":"619649","article-title":"Graft versus host disease associated with immune checkpoint inhibitors: a pharmacovigilance study and systematic literature review","volume":"11","author":"Nguyen","year":"2021","unstructured":"Nguyen LS,Raia L,Lebrun-Vignes B,Salem JE. Graft versus host disease associated with immune checkpoint inhibitors: a pharmacovigilance study and systematic literature review. Front Pharmacol. 2021;11:619649. DOI: 10.3389\/fphar.2020.619649"},{"key":"i2590-017X-9-4-153-b680","series-title":"Oncologist","first-page":"e1883","article-title":"Outcomes of pregnancy during immunotherapy treatment for cancer: analysis of clinical trials sponsored by the national cancer institute","volume":"26","author":"Mittra","year":"2021","unstructured":"Mittra A,Naqash AR,Murray JH, et al. Outcomes of pregnancy during immunotherapy treatment for cancer: analysis of clinical trials sponsored by the national cancer institute. Oncologist. 2021;26:e1883\u2013e1886. DOI: 10.1002\/onco.13941"},{"key":"i2590-017X-9-4-153-b681","series-title":"Am J Hematol","first-page":"833","article-title":"Checkpoint inhibitor immunotherapy during pregnancy for relapsed-refractory Hodgkin lymphoma","volume":"97","author":"Evens","year":"2022","unstructured":"Evens AM,Brandt JS,Peer CJ, et al. Checkpoint inhibitor immunotherapy during pregnancy for relapsed-refractory Hodgkin lymphoma. Am J Hematol. 2022;97:833\u2013838. DOI: 10.1002\/ajh.26527"},{"key":"i2590-017X-9-4-153-b682","series-title":"JAMA Netw Open","first-page":"e245625","article-title":"Immune checkpoint inhibitor use during pregnancy and outcomes in pregnant individuals and newborns","volume":"7","author":"Gougis","year":"2024","unstructured":"Gougis P,Hamy A-S,Jochum F, et al. Immune checkpoint inhibitor use during pregnancy and outcomes in pregnant individuals and newborns. JAMA Netw Open. 2024;7:e245625. DOI: 10.1001\/jamanetworkopen.2024.5625"},{"key":"i2590-017X-9-4-153-b683","series-title":"N Engl J Med","first-page":"1790","article-title":"Severe immune-related enteritis after in utero exposure to pembrolizumab","volume":"389","author":"Baarslag","year":"2023","unstructured":"Baarslag MA,Heimovaara JH,Borgers JSW, et al. Severe immune-related enteritis after in utero exposure to pembrolizumab. N Engl J Med. 2023;389:1790\u20131796. DOI: 10.1056\/NEJMoa2308135"},{"key":"i2590-017X-9-4-153-b684","series-title":"JAMA Netw Open","first-page":"e2027110","article-title":"Assessment of cancer therapy evaluation program advocacy and inclusion rates of people living with HIV in anti-PD1\/PDL1 clinical trials","volume":"3","author":"Reuss","year":"2020","unstructured":"Reuss JE,Stern D,Foster JC, et al. Assessment of cancer therapy evaluation program advocacy and inclusion rates of people living with HIV in anti-PD1\/PDL1 clinical trials. JAMA Netw Open. 2020;3:e2027110. DOI: 10.1001\/jamanetworkopen.2020.27110"},{"key":"i2590-017X-9-4-153-b685","series-title":"JAMA Oncol","first-page":"1332","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer-A phase 1 study","volume":"5","author":"Uldrick","year":"2019","unstructured":"Uldrick TS,Gon\u00e7alves PH,Abdul-Hay M, et al. Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer-A phase 1 study. JAMA Oncol. 2019;5:1332\u20131339. DOI: 10.1001\/jamaoncol.2019.2244"},{"key":"i2590-017X-9-4-153-b686","series-title":"J Clin Oncol","first-page":"432","article-title":"Cancer immunotherapy trials network 12: pembrolizumab in HIV-associated Kaposi sarcoma","volume":"43","author":"Lurain","year":"2025","unstructured":"Lurain K,Ramaswami R,Ekwede I, et al. Cancer immunotherapy trials network 12: pembrolizumab in HIV-associated Kaposi sarcoma. J Clin Oncol. 2025;43:432\u2013442. DOI: 10.1200\/JCO.24.00640"},{"key":"i2590-017X-9-4-153-b687","series-title":"Cancer","first-page":"985","article-title":"Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS malignancy consortium 095 study","volume":"130","author":"Rajdev","year":"2024","unstructured":"Rajdev L,Jackie Wang C,Joshi H, et al. Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS malignancy consortium 095 study. Cancer. 2024;130:985\u2013994. DOI: 10.1002\/cncr.35110"},{"key":"i2590-017X-9-4-153-b688","series-title":"J Clin Oncol","first-page":"3712","article-title":"Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer: a real-world report from the cancer therapy using checkpoint inhibitors in people living with HIV-International (CATCH-IT) Consortium","volume":"41","author":"El Zarif","year":"2023","unstructured":"El Zarif T,Nassar AH,Adib E, et al. Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer: a real-world report from the cancer therapy using checkpoint inhibitors in people living with HIV-International (CATCH-IT) Consortium. J Clin Oncol. 2023;41:3712\u20133723. DOI: 10.1200\/JCO.22.02459"},{"key":"i2590-017X-9-4-153-b689","series-title":"J Immunother Cancer","first-page":"e009728","article-title":"Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study","volume":"12","author":"Assoumou","year":"2024","unstructured":"Assoumou L,Bald\u00e9 R,Katlama C, et al. Safety and tolerability of immune checkpoint inhibitors in people with HIV infection and cancer: insights from the national prospective real-world OncoVIHAC ANRS CO24 cohort study. J Immunother Cancer. 2024;12:e009728. DOI: 10.1136\/jitc-2024-009728"},{"key":"i2590-017X-9-4-153-b690","series-title":"Sci Transl Med","first-page":"eabl3836","article-title":"Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy","volume":"14","author":"Uldrick","year":"2022","unstructured":"Uldrick TS,Adams SV,Fromentin R, et al. Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy. Sci Transl Med. 2022;14:eabl3836. DOI: 10.1126\/scitranslmed.abl3836"},{"key":"i2590-017X-9-4-153-b691","series-title":"Nat Med","first-page":"505","article-title":"Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy","volume":"32","author":"Talla","year":"2026","unstructured":"Talla A,Azevedo JLLC,Latif MB, et al. Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy. Nat Med. 2026;32:505\u2013517. DOI: 10.1038\/s41591-025-04139-y"},{"key":"i2590-017X-9-4-153-b692","series-title":"J Oncol","first-page":"1","article-title":"Efficacy and safety of immune checkpoint inhibitors in patients with cancer and hepatitis B or C: a systematic review and meta-analysis","volume":"2023","author":"Dong","year":"2023","unstructured":"Dong H,Xue C,Zheng Y, et al. Efficacy and safety of immune checkpoint inhibitors in patients with cancer and hepatitis B or C: a systematic review and meta-analysis. J Oncol. 2023;2023:1\u201313. DOI: 10.1155\/2023\/2525903"},{"key":"i2590-017X-9-4-153-b693","series-title":"Nat Rev Clin Oncol","first-page":"151","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","unstructured":"Llovet JM,Castet F,Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19:151\u2013172. DOI: 10.1038\/s41571-021-00573-2"},{"key":"i2590-017X-9-4-153-b694","series-title":"N Engl J Med","first-page":"1894","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","unstructured":"Finn RS,Qin S,Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u20131905. DOI: 10.1056\/NEJMoa1915745"},{"key":"i2590-017X-9-4-153-b695","series-title":"J Clin Oncol","first-page":"193","article-title":"Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial","volume":"38","author":"Finn","year":"2020","unstructured":"Finn RS,Ryoo B-Y,Merle P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: a randomized, double-blind, phase III trial. J Clin Oncol. 2020;38:193\u2013202. DOI: 10.1200\/JCO.19.01307"},{"key":"i2590-017X-9-4-153-b696","series-title":"Oncologist","first-page":"714","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with cancer and viral hepatitis: the MD Anderson Cancer Center experience","volume":"28","author":"Nardo","year":"2023","unstructured":"Nardo M,Yilmaz B,Nelson BE, et al. Safety and efficacy of immune checkpoint inhibitors in patients with cancer and viral hepatitis: the MD Anderson Cancer Center experience. Oncologist. 2023;28:714\u2013721. DOI: 10.1093\/oncolo\/oyad039"},{"key":"i2590-017X-9-4-153-b697","series-title":"Eur J Cancer","first-page":"119","article-title":"Pharmacokinetic\/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: part 2, immune checkpoint inhibitor antibodies","volume":"128","author":"Desnoyer","year":"2020","unstructured":"Desnoyer A,Broutin S,Delahousse J, et al. Pharmacokinetic\/pharmacodynamic relationship of therapeutic monoclonal antibodies used in oncology: part 2, immune checkpoint inhibitor antibodies. Eur J Cancer. 2020;128:119\u2013128. DOI: 10.1016\/j.ejca.2020.01.003"},{"key":"i2590-017X-9-4-153-b698","series-title":"Clin Pharmacokinet","first-page":"1393","article-title":"Immune checkpoint inhibitors in melanoma: a review of pharmacokinetics and exposure-response relationships","volume":"58","author":"Leven","year":"2019","unstructured":"Leven C,Padelli M,Carre JL,Bellissant E,Misery L. Immune checkpoint inhibitors in melanoma: a review of pharmacokinetics and exposure-response relationships. Clin Pharmacokinet. 2019;58:1393\u20131405. DOI: 10.1007\/s40262-019-00789-7"},{"key":"i2590-017X-9-4-153-b699","series-title":"Clin Pharmacokinet","first-page":"835","article-title":"Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors","volume":"58","author":"Centanni","year":"2019","unstructured":"Centanni M,Moes D,Troconiz IF,Ciccolini J,van Hasselt JGC. Clinical pharmacokinetics and pharmacodynamics of immune checkpoint inhibitors. Clin Pharmacokinet. 2019;58:835\u2013857. DOI: 10.1007\/s40262-019-00748-2"},{"key":"i2590-017X-9-4-153-b700","series-title":"JCM","first-page":"4301","article-title":"Review of the immune checkpoint inhibitors in the context of cancer treatment","volume":"12","author":"Alturki","year":"2023","unstructured":"Alturki NA. Review of the immune checkpoint inhibitors in the context of cancer treatment. JCM. 2023;12:4301. DOI: 10.3390\/jcm12134301"},{"key":"i2590-017X-9-4-153-b701","series-title":"N Engl J Med","first-page":"1767","article-title":"Molecular and biochemical aspects of the PD-1 checkpoint pathway","volume":"375","author":"Boussiotis","year":"2016","unstructured":"Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint pathway. N Engl J Med. 2016;375:1767\u20131778. DOI: 10.1056\/NEJMra151429627806234"},{"key":"i2590-017X-9-4-153-b702","series-title":"J Allergy Clin Immunol","first-page":"1403","article-title":"Immune checkpoint blockade therapy","volume":"142","author":"Wieder","year":"2018","unstructured":"Wieder T,Eigentler T,Brenner E,Rocken M. Immune checkpoint blockade therapy. J Allergy Clin Immunol. 2018;142:1403\u20131414. DOI: 10.1016\/j.jaci.2018.02.042"},{"key":"i2590-017X-9-4-153-b703","series-title":"Clin Pharmacol Ther","first-page":"657","article-title":"Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis","volume":"101","author":"Liu","year":"2017","unstructured":"Liu C,Yu J,Li H, et al. Association of time-varying clearance of nivolumab with disease dynamics and its implications on exposure response analysis. Clin Pharmacol Ther. 2017;101:657\u2013666. DOI: 10.1002\/cpt.656"},{"key":"i2590-017X-9-4-153-b704","series-title":"N Engl J Med","first-page":"2443","article-title":"Safety, activity, and immune correlates of anti-PD-1 antibody in cancer","volume":"366","author":"Topalian","year":"2012","unstructured":"Topalian SL,Hodi FS,Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366:2443\u20132454. DOI: 10.1056\/NEJMoa1200690"},{"key":"i2590-017X-9-4-153-b705","series-title":"J Clin Oncol","first-page":"3167","article-title":"Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","unstructured":"Brahmer JR,Drake CG,Wollner I, et al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010;28:3167\u20133175. DOI: 10.1200\/JCO.2009.26.7609"},{"key":"i2590-017X-9-4-153-b706","series-title":"Int Immunopharmacol","first-page":"114754","article-title":"Pembrolizumab pharmacology for personalized PD-1 inhibitor therapy reveals a critical gap between receptor occupancy and T cell functionality","volume":"157","author":"Verdonk","year":"2025","unstructured":"Verdonk JDJ,Piet B,ter Heine R, et al. Pembrolizumab pharmacology for personalized PD-1 inhibitor therapy reveals a critical gap between receptor occupancy and T cell functionality. Int Immunopharmacol. 2025;157:114754. DOI: 10.1016\/j.intimp.2025.114754"},{"key":"i2590-017X-9-4-153-b707","series-title":"MAbs","first-page":"2156317","article-title":"Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study","volume":"15","author":"Shchelokov","year":"2023","unstructured":"Shchelokov D,Demin O. Jr. Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study. MAbs. 2023;15:2156317. DOI: 10.1080\/19420862.2022.2156317"},{"key":"i2590-017X-9-4-153-b708","series-title":"Cancer Sci","first-page":"752","article-title":"Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit","volume":"115","author":"Hosonuma","year":"2024","unstructured":"Hosonuma M,Hirasawa Y,Kuramasu A, et al. Nivolumab receptor occupancy on effector regulatory T cells predicts clinical benefit. Cancer Sci. 2024;115:752\u2013762. DOI: 10.1111\/cas.16061"},{"key":"i2590-017X-9-4-153-b709","series-title":"Bioanalysis","first-page":"1347","article-title":"Receptor occupancy measurement of anti-PD-1 antibody drugs in support of clinical trials","volume":"11","author":"Fu","year":"2019","unstructured":"Fu J,Wang F,Dong L-H, et al. Receptor occupancy measurement of anti-PD-1 antibody drugs in support of clinical trials. Bioanalysis. 2019;11:1347\u20131358. DOI: 10.4155\/bio-2019-0090"},{"key":"i2590-017X-9-4-153-b710","series-title":"Intl Journal of Cancer","first-page":"2569","article-title":"Early pembrolizumab clearance as prognostic biomarker for non-response in patients with advanced non-small cell lung cancer","volume":"157","author":"de Vries","year":"2025","unstructured":"de Vries F,Otten L,Piet B, et al. Early pembrolizumab clearance as prognostic biomarker for non-response in patients with advanced non-small cell lung cancer. Intl Journal of Cancer. 2025;157:2569\u20132576. DOI: 10.1002\/ijc.70052"},{"key":"i2590-017X-9-4-153-b711","series-title":"Clin Pharmacokinet","first-page":"1749","article-title":"Prognostic value of nivolumab clearance in non-small cell lung cancer patients for survival early in treatment","volume":"62","author":"Otten","year":"2023","unstructured":"Otten LS,Piet B,van den Haak D, et al. Prognostic value of nivolumab clearance in non-small cell lung cancer patients for survival early in treatment. Clin Pharmacokinet. 2023;62:1749\u20131754. DOI: 10.1007\/s40262-023-01316-5"},{"key":"i2590-017X-9-4-153-b712","series-title":"J Pharm Sci","first-page":"692","article-title":"Semimechanistically based modeling of pembrolizumab time-varying clearance using 4 longitudinal covariates in patients with non-small cell lung cancer","volume":"108","author":"Li","year":"2019","unstructured":"Li H,Sun Y,Yu J, et al. Semimechanistically based modeling of pembrolizumab time-varying clearance using 4 longitudinal covariates in patients with non-small cell lung cancer. J Pharm Sci. 2019;108:692\u2013700. DOI: 10.1016\/j.xphs.2018.10.064"},{"key":"i2590-017X-9-4-153-b713","series-title":"Lung Cancer","first-page":"35","article-title":"Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: a population pharmacokinetic analysis in real-world non-small cell lung cancer patients","volume":"173","author":"Ohuchi","year":"2022","unstructured":"Ohuchi M,Yagishita S,Jo H, et al. Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: a population pharmacokinetic analysis in real-world non-small cell lung cancer patients. Lung Cancer. 2022;173:35\u201342. DOI: 10.1016\/j.lungcan.2022.08.018"},{"key":"i2590-017X-9-4-153-b714","series-title":"Clin Pharma and Therapeutics","first-page":"1018","article-title":"Nivolumab clearance is stationary in patients with resected melanoma on adjuvant therapy: implications of disease status on time-varying clearance","volume":"106","author":"Hamuro","year":"2019","unstructured":"Hamuro L,Statkevich P,Bello A, et al. Nivolumab clearance is stationary in patients with resected melanoma on adjuvant therapy: implications of disease status on time-varying clearance. Clin Pharma and Therapeutics. 2019;106:1018\u20131027. DOI: 10.1002\/cpt.1502"},{"key":"i2590-017X-9-4-153-b715","series-title":"Cancer Immunol Immunother","first-page":"317","article-title":"Efficacy and safety of two-year fixed versus continuous immune checkpoint inhibitor therapy in advanced or metastatic non-small cell lung cancer: a systematic review","volume":"74","author":"Pandey","year":"2025","unstructured":"Pandey T,Bhatti SA. Efficacy and safety of two-year fixed versus continuous immune checkpoint inhibitor therapy in advanced or metastatic non-small cell lung cancer: a systematic review. Cancer Immunol Immunother. 2025;74:317. DOI: 10.1007\/s00262-025-04143-8"},{"key":"i2590-017X-9-4-153-b716","series-title":"JAMA Oncol","first-page":"1075","article-title":"Association between duration of immunotherapy and overall survival in advanced non-small cell lung cancer","volume":"9","author":"Sun","year":"2023","unstructured":"Sun L,Bleiberg B,Hwang W-T, et al. Association between duration of immunotherapy and overall survival in advanced non-small cell lung cancer. JAMA Oncol. 2023;9:1075\u20131082. DOI: 10.1001\/jamaoncol.2023.1891"},{"key":"i2590-017X-9-4-153-b717","series-title":"Lancet","first-page":"803","article-title":"New promises and challenges in the treatment of advanced non-small-cell lung cancer","volume":"404","author":"Meyer","year":"2024","unstructured":"Meyer ML,Fitzgerald BG,Paz-Ares L, et al. New promises and challenges in the treatment of advanced non-small-cell lung cancer. Lancet. 2024;404:803\u2013822. DOI: 10.1016\/S0140-6736(24)01029-8"},{"key":"i2590-017X-9-4-153-b718","series-title":"ESMO Open","first-page":"102220","article-title":"Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis","volume":"9","author":"Landr\u00e9","year":"2024","unstructured":"Landr\u00e9 T,Karabou\u00e9 A,Buchwald ZS, et al. Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis. ESMO Open. 2024;9:102220. DOI: 10.1016\/j.esmoop.2023.102220"},{"key":"i2590-017X-9-4-153-b719","series-title":"Lancet Oncol","first-page":"1777","article-title":"Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study","volume":"22","author":"Qian","year":"2021","unstructured":"Qian DC,Kleber T,Brammer B, et al. Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study. Lancet Oncol. 2021;22:1777\u20131786. DOI: 10.1016\/S1470-2045(21)00546-5"},{"key":"i2590-017X-9-4-153-b720","series-title":"Cancers (Basel)","first-page":"896","article-title":"Time-dependent efficacy of checkpoint inhibitor nivolumab: results from a pilot study in patients with metastatic non-small-cell lung cancer","volume":"14","author":"Karabou\u00e9","year":"2022","unstructured":"Karabou\u00e9 A,Collon T,Pavese I, et al. Time-dependent efficacy of checkpoint inhibitor nivolumab: results from a pilot study in patients with metastatic non-small-cell lung cancer. Cancers (Basel). 2022;14:896. DOI: 10.3390\/cancers14040896"},{"key":"i2590-017X-9-4-153-b721","series-title":"J Immunother Cancer","first-page":"e008011","article-title":"Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis","volume":"12","author":"Patel","year":"2024","unstructured":"Patel JS,Woo Y,Draper A, et al. Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis. J Immunother Cancer. 2024;12:e008011. DOI: 10.1136\/jitc-2023-008011"},{"key":"i2590-017X-9-4-153-b722","series-title":"Cell","first-page":"2690","article-title":"Circadian tumor infiltration and function of CD8(+) T cells dictate immunotherapy efficacy","volume":"187","author":"Wang","year":"2024","unstructured":"Wang C,Zeng Q,G\u00fcl ZM, et al. Circadian tumor infiltration and function of CD8(+) T cells dictate immunotherapy efficacy. Cell. 2024;187:2690\u20132702 e17. DOI: 10.1016\/j.cell.2024.04.015"},{"key":"i2590-017X-9-4-153-b723","series-title":"Cancers (Basel)","first-page":"3262","article-title":"Optimizing anti-PD1 immunotherapy: an overview of pharmacokinetics, biomarkers, and therapeutic drug monitoring","volume":"17","author":"Monteiro","year":"2025","unstructured":"Monteiro JF,Fernandes A,Tato DG, et al. Optimizing anti-PD1 immunotherapy: an overview of pharmacokinetics, biomarkers, and therapeutic drug monitoring. Cancers (Basel). 2025;17:3262. DOI: 10.3390\/cancers17193262"},{"key":"i2590-017X-9-4-153-b724","series-title":"Eur J Cancer","first-page":"115564","article-title":"Expanding access to cancer immunotherapy: a systematic review of low-dose PD-(L)1 inhibitor strategies","volume":"225","author":"Jim\u00e9nez-Labaig","year":"2025","unstructured":"Jim\u00e9nez-Labaig P,Mohamed F,Tan NJI, et al. Expanding access to cancer immunotherapy: a systematic review of low-dose PD-(L)1 inhibitor strategies. Eur J Cancer. 2025;225:115564. DOI: 10.1016\/j.ejca.2025.115564"},{"key":"i2590-017X-9-4-153-b725","series-title":"JCO Glob Oncol","first-page":"e2400409","article-title":"Overcoming financial and access barriers in global cancer care with low-dose immunotherapy: a systematic review","volume":"11","author":"Hoyek","year":"2025","unstructured":"Hoyek C,Zheng-Lin B,Bauernfeind JJ, et al. Overcoming financial and access barriers in global cancer care with low-dose immunotherapy: a systematic review. JCO Glob Oncol. 2025;11:e2400409. DOI: 10.1200\/GO-24-00409"},{"key":"i2590-017X-9-4-153-b726","series-title":"Lancet Oncol","first-page":"e171","article-title":"Dose optimisation to improve access to effective cancer medicines","volume":"26","author":"Tannock","year":"2025","unstructured":"Tannock IF,de Vries EGE,Fojo A,Buyse M,Moja L. Dose optimisation to improve access to effective cancer medicines. Lancet Oncol. 2025;26:e171\u2013e180. DOI: 10.1016\/S1470-2045(24)00648-X"},{"key":"i2590-017X-9-4-153-b727","series-title":"Lancet Oncol","first-page":"e552","article-title":"Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab","volume":"23","author":"Malmberg","year":"2022","unstructured":"Malmberg R,Zietse M,Dumoulin DW, et al. Alternative dosing strategies for immune checkpoint inhibitors to improve cost-effectiveness: a special focus on nivolumab and pembrolizumab. Lancet Oncol. 2022;23:e552\u2013e561. DOI: 10.1016\/S1470-2045(22)00554-X"},{"key":"i2590-017X-9-4-153-b728","series-title":"JCO Glob Oncol","first-page":"e2400538","article-title":"Low-dose anti-PD1 immune checkpoint inhibitors in relapsed\/refractory Hodgkin lymphoma: a systematic review","volume":"11","author":"Vaquera-Alfaro","year":"2025","unstructured":"Vaquera-Alfaro HA,Montelongo-Cepeda JE,Vega-Mateos A, et al. Low-dose anti-PD1 immune checkpoint inhibitors in relapsed\/refractory Hodgkin lymphoma: a systematic review. JCO Glob Oncol. 2025;11:e2400538. DOI: 10.1200\/GO-24-00538"},{"key":"i2590-017X-9-4-153-b729","series-title":"J Clin Oncol","first-page":"1526","article-title":"Low-dose anti-PD-(L)1 inhibitor strategies: a systematic review","volume":"43","author":"Labaig","year":"2025","unstructured":"Labaig PJ,Lamin FM,Tan NJI, et al. Low-dose anti-PD-(L)1 inhibitor strategies: a systematic review. J Clin Oncol. 2025;43:1526. DOI: 10.1200\/JCO.2025.43.16_suppl.1526"},{"key":"i2590-017X-9-4-153-b730","series-title":"JCO Glob Oncol","first-page":"e2400122","article-title":"Low-dose anti-PD(L)1 for the treatment of solid malignancies","volume":"10","author":"Souza","year":"2024","unstructured":"Souza IAdA,Dobbert BdM,Sao Jose BG, et al. Low-dose anti-PD(L)1 for the treatment of solid malignancies. JCO Glob Oncol. 2024;10:e2400122. DOI: 10.1200\/GO.24.00122"},{"key":"i2590-017X-9-4-153-b731","series-title":"JCO Glob Oncol","first-page":"e2300312","article-title":"Effectiveness of immune checkpoint inhibitors in various tumor types treated by low, per-weight, and conventional doses at a tertiary care center in Mumbai","volume":"10","author":"Patel","year":"2024","unstructured":"Patel A,Hande V,Mr K, et al. Effectiveness of immune checkpoint inhibitors in various tumor types treated by low, per-weight, and conventional doses at a tertiary care center in Mumbai. JCO Glob Oncol. 2024;10:e2300312. DOI: 10.1200\/GO.23.00312"},{"issue":"16_Suppl","key":"i2590-017X-9-4-153-b732","series-title":"J Clin Oncol","article-title":"Efficacy of low-dose nivolumab in advanced cancers: a retrospective analysis from medical oncology clinic in Eastern India","volume":"43","author":"Lokesh","year":"2025","unstructured":"Lokesh K Sr,Mishra SK. Efficacy of low-dose nivolumab in advanced cancers: a retrospective analysis from medical oncology clinic in Eastern India. J Clin Oncol. 2025;43(16_Suppl). DOI: 10.1200\/JCO.2025"},{"key":"i2590-017X-9-4-153-b733","series-title":"J Immunother Cancer","first-page":"e011622","article-title":"A real-world study on the efficacy and safety of low-dose PD-1 monoclonal antibody alone or in combination as the first-line treatment for advanced non-small cell lung cancer","volume":"13","author":"Sun","year":"2025","unstructured":"Sun J,Hao J,Li X, et al. A real-world study on the efficacy and safety of low-dose PD-1 monoclonal antibody alone or in combination as the first-line treatment for advanced non-small cell lung cancer. J Immunother Cancer. 2025;13:e011622. DOI: 10.1136\/jitc-2025-011622"},{"key":"i2590-017X-9-4-153-b734","series-title":"J Clin Oncol","first-page":"222","article-title":"Low-dose immunotherapy in head and neck cancer: a randomized study","volume":"41","author":"Patil","year":"2023","unstructured":"Patil VM,Noronha V,Menon N, et al. Low-dose immunotherapy in head and neck cancer: a randomized study. J Clin Oncol. 2023;41:222\u2013232. DOI: 10.1200\/JCO.22.01015"},{"key":"i2590-017X-9-4-153-b735","series-title":"Ann Oncol","first-page":"639","article-title":"A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy for localized triple-negative breast cancer (TNBC) (PLANeT trial-Pembrolizumab Low Dose in Addition to NACT in TNBC)","volume":"37","author":"Arora","year":"2026","unstructured":"Arora A,Bhaskarane H,Tansir G, et al. A phase II, randomized, open-label study to evaluate low-dose pembrolizumab plus chemotherapy versus chemotherapy as neoadjuvant therapy for localized triple-negative breast cancer (TNBC) (PLANeT trial-Pembrolizumab Low Dose in Addition to NACT in TNBC). Ann Oncol. 2026;37:639\u2013649. DOI: 10.1016\/j.annonc.2025.12.015"},{"key":"i2590-017X-9-4-153-b736","series-title":"Trials","first-page":"73","article-title":"A phase II, randomized, open-labeled study to evaluate low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer (TNBC)","volume":"26","author":"Arora","year":"2025","unstructured":"Arora A,Seenu V,Parshad R, et al. A phase II, randomized, open-labeled study to evaluate low-dose pembrolizumab in addition to neoadjuvant chemotherapy for triple-negative breast cancer (TNBC). Trials. 2025;26:73. DOI: 10.1186\/s13063-025-08726-9"},{"key":"i2590-017X-9-4-153-b737","series-title":"Cancer","first-page":"778","article-title":"Long-term outcomes in patients with advanced and\/or metastatic non\u2013small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: multicenter, real-world data (KCSG LU20-11)","volume":"128","author":"Kim","year":"2022","unstructured":"Kim H,Kim D,Kim M, et al. Long-term outcomes in patients with advanced and\/or metastatic non\u2013small cell lung cancer who completed 2 years of immune checkpoint inhibitors or achieved a durable response after discontinuation without disease progression: multicenter, real-world data (KCSG LU20-11). Cancer. 2022;128:778\u2013787. DOI: 10.1002\/cncr.33984"},{"key":"i2590-017X-9-4-153-b738","series-title":"Front Immunol","first-page":"1524945","article-title":"Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review and meta-analysis","volume":"16","author":"Lallas","year":"2025","unstructured":"Lallas K,Chatziioannou E,Durak D, et al. Discontinuation of immune checkpoint inhibitors for reasons other than disease progression and the impact on relapse and survival of advanced melanoma patients. A systematic review and meta-analysis. Front Immunol. 2025;16:1524945. DOI: 10.3389\/fimmu.2025.1524945"},{"key":"i2590-017X-9-4-153-b739","series-title":"Lancet Oncol","first-page":"1239","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study","volume":"20","author":"Robert","year":"2019","unstructured":"Robert C,Ribas A,Schachter J, et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol. 2019;20:1239\u20131251. DOI: 10.1016\/S1470-2045(19)30388-2"},{"key":"i2590-017X-9-4-153-b740","series-title":"Cancer Immunol Immunother","first-page":"1719","article-title":"Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study","volume":"71","author":"Bilger","year":"2022","unstructured":"Bilger G,Girard N,Doubre H, et al. Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with advanced non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study. Cancer Immunol Immunother. 2022;71:1719\u20131731. DOI: 10.1007\/s00262-021-03114-z"},{"key":"i2590-017X-9-4-153-b741","series-title":"Lung Cancer","first-page":"107340","article-title":"Immune checkpoint inhibitors in non-small cell lung cancer - When should we dare to stop treatment","volume":"184","author":"Bozorgmehr","year":"2023","unstructured":"Bozorgmehr F,M\u00fcller A,Rawluk J, et al. Immune checkpoint inhibitors in non-small cell lung cancer - When should we dare to stop treatment? Lung Cancer. 2023;184:107340. DOI: 10.1016\/j.lungcan.2023.107340"},{"key":"i2590-017X-9-4-153-b742","series-title":"J Clin Oncol","first-page":"3998","article-title":"Seven-year follow-up of the phase III Keynote-006 study: pembrolizumab versus ipilimumab in advanced melanoma","volume":"41","author":"Robert","year":"2023","unstructured":"Robert C,Carlino MS,McNeil C, et al. Seven-year follow-up of the phase III Keynote-006 study: pembrolizumab versus ipilimumab in advanced melanoma. J Clin Oncol. 2023;41:3998\u20134003. DOI: 10.1200\/JCO.22.01599"}],"container-title":["Journal of Immunotherapy and Precision Oncology"],"original-title":[],"link":[{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/9\/4\/article-p153.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/downloadpdf\/journals\/jipo\/9\/4\/article-p153.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/downloadpdf\/journals\/jipo\/9\/4\/article-p153.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T01:50:35Z","timestamp":1792461035000},"score":1,"resource":{"primary":{"URL":"https:\/\/innovationsjournals-jipo.kglmeridian.com\/view\/journals\/jipo\/9\/4\/article-p153.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":744,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.36401\/jipo-26-12","relation":{},"ISSN":["2590-017X","2666-2345"],"issn-type":[{"value":"2590-017X","type":"electronic"},{"value":"2666-2345","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,29]]}}}